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Abstract 
 
E-selectin, is member of a family of cell-adhesion proteins, which plays a crucial 
role in many physiological processes and diseases [1], and in particular, in the 
early phases of the inflammatory response. Its role is to promote the tethering 
and the rolling of leukocytes along the endothelial surface [2]. These steps are 
then followed by integrin-mediated firm adhesion and final transendothelial 
migration. Therefore, control of the leukocyte-endothelial cell adhesion process 
may be useful in cases, where excessive recruitment of leukocytes can 
contribute to acute or chronic diseases such as stroke, reperfusion injury, 
psoriasis or rheumatoid arthritis [3].  
In this work, efforts to develop in silico-based protocols to study the interaction 
between E-selectin and its ligands, are presented. Hence, different protocols had 
to be developed and validated. In particular, a new procedure for the analysis of 
the conformational preferences of E-selectin antagonists was established and the 
results compared to those obtained with the MC(JBW)/SD approach, which had 
already demonstrated its validity in the past [161,168]. Thus, the comparison 
between the two protocols permitted to recognize a different conformational 
preference of the two methods for the orientation of the sialic acid moiety of sLex 
(3) (torsions Φ3 and Ψ3, Figure A), which reflects the contrasting opinions existing 
for the conformation adopted by sLex (3) in solution [150–168]. A more detailed 
analysis revealed that probably both approaches deliver only a partially correct 
view and that in reality, in solution, sLex (3) exists as a mixture of low energy 
conformers and not as supposed to date [150–154,161–163] as a population of a 
single conformer.  
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Figure A: sLex (3) and the Φ, Ψ convention for the definition of the glycosidic torsions. 
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In addition, a docking routine was established and the impact of different partial-
charge methods and of explicit solvation on the binding mode studied.  
MD simulations enabled to gain an insight into the dynamical character of the 
protein-ligand interactions. In particular, the observations done in an atomic-force 
microscopy study [350], describing the interactions between the carboxylic group 
of sLex and Arg97, and between the 3– and 4–hydroxyls of fucose and the 
calcium ion, as the two main energy barriers for the dissociation process of the 
protein-ligand complex, found confirmation in our MD-investigations. Thus, these 
two contacts always lasted longer than any other in the MD simulation. 
QSAR-models with Quasar [270–272,351] and Raptor [315,316,335] were 
successfully derived and will permit a semi-quantitative in silico estimation of the 
binding affinity for the ligands that will be designed in the future.  
Finally, the developed protocols and models were applied for the development of 
new E-selectin antagonists. Unfortunately, to date, only few biological data is 
available to evaluate our design strategies. However, the impact of the ligand’s 
pre-organization on the binding affinity could be established at least for the Lex-
core of sLex (3). Hence, the importance of the exo-anomeric effect, of the steric 
compression, and of the hydrophobic interaction between the methyl group of 
fucose and the β-face of galactose was clearly demonstrated. 
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1 Introduction 
 
1.1 The choice of the target-protein 
 
E-selectin, an adhesion molecule presently under investigation at the Institute of 
Molecular Pharmacy of the University of Basel, is part of a protein family, which 
plays a crucial role in many physiological processes and diseases [1]. More 
specifically, selectins are a family of carbohydrate-binding proteins expressed at 
the site of inflammation in response to mediators of inflammation liberated by the 
injured tissue. Their key role, early in the inflammatory cascade, is to promote the 
tethering and the rolling of leukocytes along the endothelial surface [2]. These 
steps are then followed by integrin-mediated firm adhesion and final 
transendothelial migration.  
Therefore, control of the leukocyte-endothelial cell adhesion process may be 
useful in cases, where excess recruitment of leukocytes can contribute to acute 
or chronic diseases such as stroke, reperfusion injury, psoriasis or rheumatoid 
arthritis [3].  In addition, it has recently been suggested that cancer may exploit 
the adhesion process after entering the bloodstream to metastasize [4,5].  
Thus, due to its implication in pharmacologically important processes, E-selectin 
has emerged as an interesting therapeutic target for the pharmaceutical industry 
as well as for academic research. 
 
1.2 Inflammation 
 
Inflammation is a complex stereotypical reaction of the organism in response to 
the damage of cells and of vascularized tissues. By studying the details of the 
processes associated with inflammation, a close relationship to the immune 
response has been revealed. 
Already Aulus Cornelius Celsus (ca. 25 B.C.–A.D. 50) has described the basic 
symptoms of inflammation – rubor (redness), tumour (swelling), calor (heat), 
dolor (pain) and functio lesa (deranged function). Such signs are the typical 
consequence of the extravasation of leukocytes from the plasma to the site of 
inflammation [6]. Early investigations considered the inflammatory reaction as a 
primary host defense system [7]. However, it has been showed that an excessive 
response can lead to debilitating diseases e.g. arthritis and gout or even to 
death, as in the case of an anaphylactic shock [8]. 
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1.2.1 The inflammatory cascade 
 
In a healthy person, the invasion of a tissue by pathogens or a tissue injury 
usually triggers the release of inflammatory mediators like chemokines or 
platelet-activating factors [9,10]. This first stimulus initiates a complex response 
that involves the activation and directed migration of leukocytes (neutrophils, 
monocytes and eosinophils) from the venous system to the sites of damage by a 
complex series of steps, referred to as the inflammatory cascade (Figure 1). 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
Figure 1: The inflammatory cascade. 
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The inflammatory cascade can be summarized in five major steps: 
 
Step 1: Stimulus 
After tissue injury or pathogens invasion, the immune system responds with the 
release of a variety of inflammatory mediators. Such substances (e.g. TNF-α,IL-1 
or LPS) stimulate endothelium cells to transiently express E- and P-selectin 
[11,12]. P-selectin, which is stored in the α-granules of platelets and in the 
Waibel-Palade bodies of endothelial cells, is rapidly transported to the cell 
surface and expressed within seconds to minutes after the stimulation occurred 
by pro-inflammatory substances such as histamine or thrombin [13,14]. The 
highest expression level on the cell surface is reached after some five to ten 
minutes. After 30-60 minutes, the protein is internalized again by endocytosis. In 
addition to this fast exposure of P-selectin, a second mechanisms involving the 
activation of E-selectin exists. E-selectin, in contrast to P-selectin, has to be 
synthesized de novo. The production of E-selectin is induced by TNF-α, IL-1 or 
LPS [15,16]. The highest expression levels on the cell surface are reached after 
three to four hours and basal levels can still be detected after 16-24h [17]. As 
observed for P-selectin, also E-selectin starts to be internalized by endocytosis 
few hours later it has reached its highest expression level on the cell surface [18]. 
 
Step 2: Tethering and Rolling 
Next, the presentation of E- and P-selectin at the surface of endothelial cells 
leads to the interaction of these proteins with their natural ligands (ESL-1,  
PSGL-1,…) present on the surface of the leukocytes. The fast association and 
dissociation process (cf. Chapter 1.4.3) of leukocytes to endothelial cells 
produces the well-studied phenomena of tethering (attachment) and rolling of 
white blood cells along the vessel wall [19,20] (Figure 2).  
 
 
 
 
 
 
 
 
Figure 2: Leukocytes rolling on the surface of a blood vessel. 
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L-selectin, which is constitutively expressed on leukocytes, also plays an 
important role in this step: first, it contains carbohydrate structures that can be 
recognized by E-selectin [21], second, its interaction with PSGL-1 [22] of already 
adhering leukocytes [23]. This last mechanism permits to expand the number of 
layers of leukocytes attracted to the site of inflammation. 
The processes of tethering and rolling are prerequisites for the adhesion step 
and are therefore essential to the inflammatory process. Hence, selectins 
became an important therapeutic target (cf. Chapter 1.3.2). 
 
Step 3: Secondary activation 
The rolling of leukocytes along the vessel wall enables the interaction of the 
vascular endothelium with cytokines and leukocytes-activating molecules that 
trigger the activation and upregulation of leukocytes integrins [24,25]. Integrins, 
which are also important drug targets for inflammatory diseases [26–30], form a 
second class of leukocyte adhesion molecules that play an essential role in the 
inflammatory cascade, in particular in the fourth step: the adhesion step. 
 
Step 4: Adhesion 
Integrins, in fact, are needed to immobilize the leukocytes onto the endothelium 
surface. The immobilization or tight adhesion is reached through the interaction 
of the integrins with their endothelial ligands VCAM-1, ICAM-1, and MAdCAM-1 
[24,25].  
 
Step 5: Transendothelial migration 
When the leukocytes are adhered to the endothelium, they can transmigrate 
(extravasation) to the site of inflammation (Figure 3). This process is probably 
facilitated by extracellular proteases, such as matrix metalloproteinases (MMPs). 
 
 
 
 
 
 
 
Figure 3: A leukocyte transmigrating into the site of inflammation. 
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1.3 The pathological role of selectins 
 
1.3.1 Observations in mice 
 
Numerous studies have confirmed the involvement of all three selectins in the 
inflammatory cascade [31–34]. Experiments with gene-deficient mice (knockout 
mice) permitted elucidate the physiological role of the selectins. 
By studying L-selectin knockout mice, significant reduction in lymphocyte homing 
[35,36] and an insufficient immune response was observed [37–39]. P-selectin 
knockout mice showed reduced neutrophil transmigration into the inflamed 
peritoneum [40,41]. In contrast, E-selectin knockout mice didn’t present any 
abnormalities in the inflammatory response [42,43]. However severe defects 
were observed in those mice, when P-selectin was blocked by P-selectin 
antibodies [44] or also mutated. Particularly, the double mutant mice 
demonstrated an increased susceptibility to bacterial infection, a strong reduction 
of the number of rolling leukocytes, and the complete absence of netrophil 
transmigration in first four hours following an inflammatory stimulus [43,45]. 
 
1.3.2 Selectin and human diseases 
 
Excessive leukocyte accumulation in inflamed tissues is the basis for a 
pathological inflammatory reaction, angiogenesis and tumor metastasis. In 
diseases such as atherosclerosis, asthma, organ rejection after transplantation, 
hemorrhagic shock, thrombosis, rheumatoid arthritis, atopic dermatitis, psoriasis, 
diabetes-caused microangiopathies, or myocardial and cerebral ischemia, a 
strong deregulation of the selectin expression and function has been observed 
[46–48].  
In the case of atherosclerosis, accumulation of LDL (low density lipoprotein) in 
blood vessel walls triggers an inflammatory fibroid reaction. As a consequence, 
E- and P-selectins are expressed on the surface of the endothelial cells thereby 
facilitating the invasion of the inflamed tissue by monocytes. The correlation 
between the high expression levels of selectins and the development of a large 
number of atherosclerosis plaques was demonstrated in animal models [49–52].  
The role of selectins in myocardial or cerebral ischemia/reperfusion has been 
studied extensively [53]. When myocardial ischemia occurs, a loss of 
endothelium-derived nitrogen monoxide and a rapid burst of oxygen-derived 
radicals arise. Those provoke an upregulated expression of P-selectin on the 
cells surface and thereby a strong accumulation of neutrophils. This 
accumulation in the already damaged tissue induces a vascular dysfunction and 
further severe damages to the heart muscle cells. The prevention of reperfusion 
injury emerged therefore as an important therapeutic goal. In vivo it was possible 
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to show that the administration of P-selectin antibodies [54] or sLex-related 
oligosaccharides [55] had a protective effect. 
One of most prominent autoimmune diseases, rheumatoid arthritis, is caused by 
a chronic reaction of the immune system. Pathological tissue observations 
demonstrated an inflammation of the synovial membrane of the joints, 
characterized by a massive infiltration of leukocytes. Being pressed against the 
surrounding bones by the presence of the leukocytes, the synovial membrane 
permanently releases inflammatory mediators, leading to a chronic state. 
Although the exact molecular mechanism of the rheumatoid arthritis is not fully 
understood, the role of E-selectin in the pathogenesis and its accumulation in 
rheumatoid tissue has been recognized. Soluble E- and P-selectin serum levels 
are therefore used as the molecular markers of active inflammation in rheumatoid 
arthritis [56–59]. 
Selectins are also involved in asthma [48]. E-selectin, in particular, together with 
the integrin receptors ICAM-1 and VCAM-1 [60] mediates the recruitment of 
eosinophil granulocytes in the lungs.  
In addition to that, increased expression of selectins has been related to the 
rejection of human liver [61], cardial [62,63], bone marrow and renal transplants 
[64], implying therefore a role of these molecules in this complex process. By 
patients, who developed the so-called “graft vs host disease” (GvHD), a 
multiorgan disease caused by immune response against the donated bone 
marrow, increased levels of E-selectin and VCAM-1 were detected [65,66].  
Recent data have given an insight to the fact that inflammation is a critical 
component of tumor progression [67]. Through the years, it has become clear 
that the tumor microenvironment, which is largely populated by inflammatory 
cells, actively participates to tumor proliferation, survival and migration. As a 
matter of fact, it is now known that tumor cells can adhere to the endothelium 
exploiting the mechanism of leukocyte homing [68–72]. Hence, in the case of 
colon and breast carcinoma, a correlation between the metastatic behavior of the 
tumor and the expression of sialidated E-selectin ligands on the tumor cell 
surface has been established [73–76]. Recently, it was even showed that the 
expression level of sLea and a poor prognosis of survey of colon cancer clearly 
correlate [77].  
Selectins are also related to a very rare genetic disease called “type 2 leukocyte 
adhesion deficiency (LAD-2)” [78,79]. Patients affected from LAD-2 lack of 
fucosylated glucoconjugates and can therefore not express functional selectin 
ligands. Clinically, they show mental retardation, short stature and recurrent 
bacterial infection with high leukocyte counts. This medical picture, underscores 
the fundamental role of selectins in the initial recruitment of leukocytes into the 
site of inflammation or infection. In contrast, LAD-1 patients lack of functional 
integrin β2-chains (CD18), essential for neutrophil extravasation and suffer from 
life-threatening infections [80].          
In summary, selectins-related diseases may be classified into five groups: 
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• Acute allergy-related diseases: such as stroke, reperfusion injury during 
myocardial or cerebral ischemia, organ transplantation, and traumatic or 
hemorrhagic shock 
• Chronic allergic diseases: such as asthma, psoriasis, dermatitis and 
rheumatoid arthritis 
• Cardiovascular diseases: such as arteriosclerosis and peripheral vascular 
disease 
• Cancer: Angiogenesis and cancer metastasis 
• Metabolic diseases, such as LAD-2 
 
1.4 The selectin family: a class of versatile proteins 
 
1.4.1 E-, P-, and L-selectin 
 
Lectins are carbohydrate-binding proteins and are typically divided in four groups 
[81]:  
• C-type lectins, which bind one or more calcium-ions in the carbohydrate 
binding site (therefore C-type, C = Calcium) 
• S-lectins or galectins containing free thiol groups (therefore S,                  
S = Sulphur) 
• P-lectins, recognizing phoshorylated mannose residues (therefore P,        
P = Phosphor) and 
• Other lectins not fitting in one of the above categories. 
 
E-selectin, like the high homologous L- and P-selectin, is a C-type lectin. All the 
three selectins present a calcium-binding domain in the carbohydrate recognition 
domain (CRD). Other examples for C-type lectins are the asialo-glycoprotein 
receptor (ASGR) [82] and the mannose binding protein (MBP) [83,84]. The 
selectin family itself consists of just the three proteins named before: E-selectin, 
P-selectin and L-selectin. 
The prefixes (E-, P-, and L-) of the three selectins indicate the cell types where 
the molecules have been identified first: E-selectin on activated endothelial cells, 
L-selectin on leukocytes and P-selectin in the Waibel-Palade bodies of 
endothelial cells and in α-granules of platelets [85]. Selectins belong to type I 
membrane glycoproteins and share a common structural motif including a N-
terminal C-type lectin domain (CRD), an epidermal growth factor-like (EGF-like) 
domain, a variable number of complement regulatory-like repeats, referred to as 
“consensus repeat” or “complement regulatory-like” (CR) domain, a 
transmembrane domain, and a short cytoplasmatic tail [86] (Figure 4). The 
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sequence identity among the different selectin species amounts to 52% in the 
CRD, 47% in the EGF domain, and to 35% in the CR domain. 
 
 
Figure 4: Domains organization of the selectins. 
 
The C-terminal portion of the protein is located intracellular and its functional role, 
which is still not fully elucidated, is supposed to be related to signal transduction 
[87]. The cytoplasmatic tail is rather short, and comprises as few as 17 amino 
acids in L-selectin, 32 in E-selectin, and 35 in P-selectin. After a short 
transmembrane domain, the CR domains are located. These short repetitive 
elements are about 60 amino acids long, contain three disulfides bridges, and its 
numbers differs throughout the selectin family (Figure 4). Humans E-selectin 
contains six, P-selectin nine, and L-selectin only two CR domains. Among other 
species, the number of CRs varies from four to eight. The functional role of the 
CRs is still not fully elucidated but several experiments suggest that the removal 
of several CRs impair the efficiency of the selectins to support leukocyte rolling 
[88–91]. These findings, along with studies that showed that only the CRD and 
the EGF-like domain are needed for specific ligand binding [91], suggest that the 
role of the CRs is to guarantee sufficient distance between the plasma 
membrane and the CRD. Following the CRs is the EGF-like domain. It contains 
six cysteins, located at equivalent positions in the “EGF-repeats” of several 
proteins. Although the carbohydrate binding-site was identified within the CRD for 
all selectins [92], the EGF-domain appears to be necessary for ligand binding. 
The EGF-domain is supposed to either stabilize the conformation of the CRD or 
to directly interact with the ligand [89,93–99]. The N-terminal domain, also 
referred to as CRD, is composed of approximately 120 amino acids and presents 
the typical features of a lectin domain of C-type animal lectin [100]. It bears the 
carbohydrate binding-site [92], conformationally stabilized by a calcium ion. 
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1.4.2 The natural glycoprotein ligands of the selectins and their  
carbohydrate epitopes 
 
Selectins are carbohydrate-binding proteins. Their natural ligands are therefore 
glycoproteins or glycolipids, which presents glycan structures as a binding motif. 
It is generally accepted that to achieve binding to the target protein, selectin-
ligands have to present as an epitope either the trisaccharides Lewisx (Lex) (1) or 
Lewisa (2) or their sialylated derivatives sialyl Lewisx (sLex) (3) or sialyl Lewisa  
(sLea) (4) (Figure 5) [101–103]. In some circumstances, additional sulfation of the 
saccharides is needed to promote binding. 
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Figure 5: Selectin ligands contain the common carbohydrate epitope sLex (3), which was shown 
to interact with all three selectins, albeit with different affinities. 
   
Soluble recombinant forms and IgG fusion protein-constructs of selectins were 
used to identify their natural ligands. As of today, five glycoproteins binding to L-
selectin were discovered: MAdCAM-1 [104,105], Spg200 [106], Gly-CAM-1 [107], 
CD34 [108] and the podocalyxin-like protein [109]. All of them are expressed by 
high endothelial venules in lymph node tissue. MAdCAM-1, which contains both 
a mucin- and an immunoglobulin-like domain, usually binds the lymphocyte 
integrin α4β7. However, one of its subpopulations can also be recognized by L-
selectin. 
Gly-CAM-1 and CD34 are sialomucins presenting large clusters of sialic acid-rich 
O-linked carbohydrate side chains that seem to be essential for L-selectin 
binding. Both proteins are also expressed in tissues other than the lymph nodes 
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but there they lack the required carbohydrate modifications to promote binding. 
Gly-CAM-1 itself is a secretory protein, which is usually stored in cytoplasmic 
granula [110,111]. Its posttranslational modifications have been intensively 
studied and revealed that sulfation, sialidation and fucosylation are essential to 
promote the binding to L-selectin [107,112,113]. 
In 1993 a glycoprotein, referred to as PSGL-1, was identified as a P-selectin 
ligand [114]. PSGL-1 is a 250kDa homodimeric protein linked by two disulfide 
bridges. Like the L-selectin ligands, PSGL-1 also is a sialomucin with a high 
degree of O-linked glycan modifications. Beside the need of sialidation and 
fucosylation to bind P-selectin and probably also L-selectin, PSGL-1 has to be 
sulfated at two of the three N-terminal tyrosine residues (Tyr46 and one of the 
tyrosines Tyr48 or Tyr51) [115–118].  
In the screening for E-selectin ligands, a glycoprotein referred to as ESL-1 was 
identified. ESL-1 was isolated from myeloid cells and neutrophils of mouse origin 
and characterized as a 150kDa glycoprotein [119]. In contrast to the 
glycoproteins discussed above, ESL-1 requires N-linked glycan modifications for 
binding E-selectin. Interesting ESL-1 binds only E- and not P-selectin [120]. 
Three other glycans binding to E-selectin were further identified [121]. All three 
contain the sialyl di-Lex motif on the β-D-GlcNAc-(1–4)-α-D-Man-(1–3)-branch of 
the tetra-antennary N-glycans. The specificity of these ligands was proved in an 
assay with an affinity column charged with soluble E-selectin [122]. E-selectin 
recognizes also PSGL-1 [120,123–127], even when the N-terminal tyrosine of the 
ligand are not sulfated [123,126]. Finally, it has been demonstrated that E-
selectin binds the carbohydrates present on L-selectin on human neutrophils but 
not those located on lymphocytes [21,127]. 
The interactions between the three selectins and their binding partners are 
summarized in Figure 6 [129]. 
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Figure 6: Selectins, integrins and their binding partners. The depicted selectin ligands are those, 
which have been identified by affinity isolation with the respective selectin as affinity probe [129]. 
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1.4.3 Affinities and kinetics of the selectin-ligand interactions 
 
The interactions between the selectins and their ligands are essential to slow 
down the leukocytes streaming in the blood vessels and initiate their rolling. This 
step is fundamental to further permit the leukocytes to adhere to the endothelial 
surface and then extravasate towards the site of inflammation. In the “rolling 
phase” the binding between the selectins and their partners must still be 
reversible. Indeed, the formation of the bond has to be very fast otherwise the 
leukocytes could not be slowed down. On the other hand, the dissociation 
reaction has to be slow enough to facilitate adhesion but also fast enough to 
ensure cellular integrity. Consequently, this special kind of cell-cell interaction 
requires low affinity (KD), fast association (kon) and fast dissociation (koff) rates. In 
addition, this mechanism allows the resistance to the laminar shear stress 
caused by the blood stream. The interaction between the selectins and their 
ligands fulfills all these requirements [25,130,131]. A wealth of investigations has 
shown that the selectins bind synthetic oligosaccharide such as sLex (3) or sLea 
(4) with low affinity (KD ranged between 0.1 to 5 mM) [132–136] and rapid kinetic. 
In a recent study [137], performed using surface plasmon resonance (SPR), the 
binding constance (KD) as well as the kon and koff could be determined for the 
interaction between mouse E-selectin and ESL-1. This data and other coming 
from earlier observations [138,139] are presented in Table 1. 
 
Table 1: Comparison of affinities and kinetics of selectin-ligand interactions. 
Interaction Species Temp (°C) KD (µM) kon (M-1 s-1) koff (s-1) Ref. 
37 62 7.4 x 104 4.6 [137]  
E-selectin / 
ESL-1 
Mouse 
25 56 4.8 x 104 2.7 [137] 
 
L-selectin / 
GlyCAM-1 
Mouse 25 108 > 1 X 105 > 10 [139] 
 
P-selectin / 
PSGL-1 
Human 25 0.32 4.4 x 105 1.4 [138] 
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In general, it can be stated that kon-values of selectin ligands lie in the same 
range as they generally do for protein-carbohydrate interactions [140] and are 
marginally slower than typical protein-protein values (105 to 106 M-1 s-1).  
A closer look at the koff values reveals how fast the whole process is. Hence, the 
lifetime of a selectin-ligand bond is of few seconds. 
It is important to note that there is no significant change in the kinetic values 
when the temperature is changed, which implies that the binding is mostly driven 
by favorable entropic contributions. 
As will be discussed later, the development of effective E-selectin antagonists 
has to take into account the associated kinetics particularity. Thus, with the aim 
to increase the affinity (KD) to low µM or even better nM, kon as well as koff values 
have to be improved. Based on the aforementioned entropic considerations, a 
first approach to increase affinity would be to constrain the ligand in its bioactive 
conformation and/or to simplify the ligand by retaining only the pharmacophoric 
groups. As a consequence of these modifications, unfavorable contributions of 
entropy and desolvation to the ligand-binding energy could possibly be reduced.  
Thus, the kon value would decrease, thereby positively influencing the binding 
affinity. On the other hand, koff values could be increased by adding groups (e.g. 
hydrophobic substituents) that would favorably interact with the protein, resulting 
in higher enthalpic contributions.  
 
1.5 Structure-activity relationship of sLex binding to E-selectin 
 
The development of low-molecular weight, high affinity ligands for E-selectin, 
requires a comprehensive understanding of the 3D structure of sLex, of E-
selectin itself, and of the ligand-protein complex. During the last 20 years, NMR-
spectroscopy, X-ray diffraction studies, molecular simulations as well as binding-
affinity studies with different E-selectin antagonists, have revealed a detailed 
picture of the structure-activity relationship. However, some details are still 
controversially today and some points remain unclear. 
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1.5.1 Pharmacophores 
 
The identification of residues critical for sLex binding to the selectins illustrates an 
interesting aspect of contemporary organic synthesis. In fact, by modifying all 
functional groups of sLex in a systematic fashion, it was possible to determine, 
those essential for binding. Such groups are referred to as pharmacophores. As 
it can be seen from Figure 7, the pharmacophore of sLex is defined by:  
1) the three hydroxyl groups of fucose, 
2) the 4– and the 6–hydroxyl group of galactose, 
3) the carboxylate group of neuraminic acid. 
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Figure 7: Structure/function map of sLex (3). Pharmacophores for binding to E-selectin are 
highlighted. 
 
The role of the hydroxyl groups of fucose was first determined by Gaeta et al. 
[141] and by Hasegawa et al. [142]. They replaced the hydroxyl groups with 
hydrogen atoms and, as a result, binding to E-selectin was no longer observed. 
Correctly, they hypothesized that, as observed in a similar protein (MBP-A) [84], 
fucose was responsible for the binding to a calcium ion. In the case of P-selectin, 
however, only the 3-hydroxyl group turned out to be crucial for binding. 
To investigate the role of the hydroxyl groups of galactose, deoxy- and fluoro-
derivatives of sLex were synthesized [143]. Substitution of the 4– or the 6–
hydroxyl groups showed a decrease in binding affinity, implying that those group 
are essential for binding. 
Investigations of the functional groups of the NeuNAc moiety (the glycerol side 
chain, the 4-hydroxyl group, the amide residue and the carboxylate) lead to the 
Gal 
NeuNAc 
GlcNAc 
Fuc 
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conclusion that only the carboxylate plays a determinant role in the recognition of 
sLex by E-selectin [142,144,145]. 
Several studies [146–148] also discuss the contribution of the GlcNAc moiety to 
the binding affinity. They all agree on the fact that, GlcNAc doesn’t directly 
contribute to the protein-ligand interaction, but serves as a spacer unit to arrange 
the crucial functional groups of fucose and galactose in the required 3D-position 
and orientation. 
 
1.5.2 Conformational studies on sLex 
 
1.5.2.1 The conformation of sLex in solution 
 
Early work in the selectin field was devoted to the study of the conformation of 
sLex in water. NMR studies with labeled and unlabeled compounds, in 
combination with molecular-dynamics simulation, were performed. Initially, three 
independent studies [149] suggested the presence of a single conformation of 
sLex in water. However, this finding was contradicted later [150,151]. A summary 
of the data presents in the literature can be found in Table 2. The convention for 
the definition of the glycosidic torsions, which will be used throughout the thesis, 
is presented in Figure 8. 
 
O
O
O
O
C
O
O
O
OH
HO
O
NHAc
OR
OH
O
OH
HO
HO
HO
NHAc
OH
OH
O
O
H
H
HH
H
H
H
!3
!1
!2"3 "2
"1
 
Figure 8: Φ, Ψ convention for the definition of the glycosidic torsions. 
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Table 2: Summary of the data presents in the literature for the solution conformation of sLex. 
 
Φ1 (°) Ψ1 (°) Φ2 (°) Ψ2 (°) Φ3 (°) Ψ3 (°) %-populated Ref. 
48 25 55 7 163 –57 0% (A) [152] 
    –170 –8 100% (B) [152] 
    –79 7 0% (C) [152] 
    68 –20 0% (D) [152] 
23 30 48 15 167 –63 0% [152] 
24 30 48 16 –171 –6 0% [152] 
        
48 22 50 15 –95 –45 0% [150] 
    –70 5 100%  
    –160 –20 0%  
        
48 24 46 18 - - - [153] 
–23 15 46 18 - - - [153] 
        
65 40 65 15 –95 –60 80% [154] 
    –70 0 10% [154] 
    –160 –25 10% [154] 
 
It is worthwhile to note that there is a general agreement between the different 
studies on the conformation adopted by the so-called core structure formed by 
the Lex-trisaccharide consisting of fucose, GlcNAc, and galactose, whereas 
substantial disagreement reigns regarding the conformation adopted around the 
NeuNAc-Gal linkage. This disagreement arises from whether or not a nuclear 
Overhauser effect (nOe) between the H–3 of Gal and the H–3(ax) of NeuNAc is 
observed (Figure 9). In fact, studies [152,155] observing this nOe suggest that 
the conformation around the NeuNAc-Gal linkage is described by the dihedral 
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angles {Φ3= –180° + 10°, Ψ3 = 0° + 10°}. Those [150,156] not observing the very 
nOe, in contrast suggest {Φ3= –70° + 10°, Ψ3 = 0° + 10°}.  
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Figure 9: The strongly debated nOe. 
 
It is, however, known [150,157] that the glycosidic bond between NeuNAc and 
Gal is highly flexible. Hence, this observation could suggest the presence of 
multiple conformations of sLex in water. As mentioned above, also theoretical 
methods, such as molecular dynamics simulations (MD), were used to determine 
the solution conformation of sLex. MD bases on the fact, that a long enough 
simulation should produce a Boltzmann-weighted ensemble statistically 
representing the conformations of sLex in water. Moreover, through the Karplus 
equations (Figure 10), especially parameterized for carbohydrates by Tvaroska 
[158] (Equation 1) and by Bose [159] (Equation 2), it is possible, to calculate 3JC-H 
and 3JC-C coupling constants and compare them with the experimental data [160]. 
An agreement between theoretical and experimental coupling constants, as 
obtain for example by Kolb and Ernst in their study [161] suggests that the 
structures sampled during a MD correctly display the distribution of 
conformations reigning in water. As a consequence, theoretical methods became 
a powerful tool for the design of E-selectin antagonists (cf. Chapters 1.5.3, 4.7).
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Figure 10: General form of the Karplus equation and correlation to the dihedral angles. 
 
3JC-H = 5.7 cos2(φ) – 0.6 cos(φ) +  0.5 (Eq. 1) 
 
3JC-C = 3.49 cos2(φ) + 0.16   (Eq. 2) 
 
1.5.2.2 The bioactive conformation of sLex 
 
The bioactive conformation of sLex (the conformation adopted upon binding to E-
selectin) has been broadly investigated by NMR through the years. Cooke et al., 
for example, concluded that the bound conformation was not identical as the one 
in solution, by comparing the transfer-nOe of sLex in water and in complex with 
E-selectin [162]. In contrast to these findings, Hensley et al. reported that the two 
conformations were indeed identical [163]. This discrepancy, further discussed 
by Scheffler et al. [164,165], arose from the presence or absence of the NOE 
between the H–3 of Gal and the H–3(ax) of NeuNAc when examining the solution 
conformation of sLex (cf. above). This nOe is, however, absent in the bound 
conformation. In addition to that, in the bound state a nOe between the H–8 of 
NeuNAc and the H–3 of Gal can be observed. By combining this two findings, it 
becomes clear that, in the bound state, the NeuNAc-Gal linkage can only adopt 
the (–)-gauche conformation described by the dihedral angles {Φ = –70° + 10°,  
Ψ = 0° + 10°}. Furthermore, with the exception of Poppe et al. [153], a general 
agreement is also found for the conformation adopted by the Lex-core of sLex 
(Table 3). More recently the suppositions of Scheffler et al. [164,165] were 
confirmed, when the first crystal structure of E-selectin co-crystallized with sLex 
was published [166]. As it is shown in Table 3, the bioactive conformation 
determined by NMR and X-ray are rather similar. The bioactive conformation 
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proposed by Scheffler et al. [164,165] is presented in Figure 11. Particularities of 
this conformation include: the hydrophobic interaction of the methyl group of 
fucose with the β-face of the galactose moiety, the carboxyl function of NeuNAc 
perpendicular to the GlcNAc plane and the GlcNAc moiety playing the role of a 
three dimensional spacer. This particular arrangement permits to sLex to present 
its pharmacophores within a row along one side of the tetrasaccharide, therefore 
facilitating the binding to the relatively shallow hydrophilic cleft of E-selectin. The 
results of Scheffler et al. [164,165] have been the basis for the definition of the 
so-called bioactive window by Kolb and Ernst (see below). 
 
Table 3: Summary of the data presents in the literature for the bioactive conformation of sLex. 
 
Exp. 
Method Φ1 (°) Ψ1 (°) Φ2 (°) Ψ2 (°) Φ3 (°) Ψ3 (°) Ref. 
NMR 70 14 25 33 –58 –20 [153] 
NMR 20 34 52 22 –70 8 [154] 
NMR 38 26 39 12 –76 6 [164,165] 
X-ray 41 22 34 16 –65 –12 [166] 
NMR 29 41 45 19 –43 –12 [167] 
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Figure 11: The bioactive conformation of sLex as determined by Scheffler et al. [164,165]. 
 
1.5.2.3 Comparison of the bioactive conformation of sLex in solution and in  
  the bound state 
 
By comparing the data of solution conformations presented in Table 2 and the 
one of the bioactive conformation in Table 3, it can be concluded how the Lex-
core of sLex undergoes no conformational change upon binding and seems to be 
rather rigid even in the free state. In contrast, different opinions reign for the 
conformation(s) adopted by the NeuNAc-Gal linkage. It seems, however, 
probable that, in solution, a multi-conformational equilibrium exists and that, at 
least a part of the sLex molecules in aqueous solution, have to adapt their 
conformation upon binding to E-selectin [150,162]. Experimental evidence for this 
statement will be presented in Chapter 4.2. The fact, that a multi-conformational 
equilibrium possibly exists, calls for designing conformationally-restrained 
compounds. Thus, an antagonist pre-organized in the bioactive conformation is 
thought to possess a higher affinity due to a more favorable entropic contribution 
than its torsionally less constricted counterpart. 
The theoretical background for this concept is given by the fact shown in Figure 
12, small differences in energy and/or different conformational distributions 
strongly affect the binding affinity of a compound towards its target protein. 
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ΔG° = –RT lnK 
  
Figure 12: Theoretical background for the role played by conformations in drug design. Small 
energy differences between conformations translate in large differences in population. Moreover, 
if the less stable conformer is the bioactive one, affinity is reduced. 
 
1.5.3 The computational model for the investigation of the  
         conformational behavior of E-selectin antagonists 
 
In 1997, Kolb and Ernst [161,168] validated a computational tool for the 
investigation of the conformational behavior of E-selectin antagonists and for 
predicting their affinity towards the target protein. The proposed protocol is based 
on the “Jumping between Wells” (JBW) simulation technique as implemented in 
MacroModel 5.0 [169]. In a first step, local minima conformations of the 
compound of interest are search by applying a systematic pseudo-Monte-Carlo 
(systematic, unbounded multiple minimum search, SUMM) method. The 
energetically most favorable 100 conformations thereby identified, are then used 
as an input for the following “Jumping between Wells” stochastic-dynamics 
simulation (JBW-SD). Thus, a Boltzmann-weighted ensemble of states is 
generated by jumping between different energy wells (the 100 minima retained 
!G° = 0.5 kcal/mol     " 57.6 % preference for minima A  
!G° = 1.0 kcal/mol     " 81.5 % preference for minima A 
!G° = 2.0 kcal/mol     " 96.6 % preference for minima A 
!G° = 3.0 kcal/mol     " 99.4 % preference for minima A 
!G°
Energy
Minima A
Minima B
!G°
Energy
Global energy minimum in solution
Bioactive
Conformation
!G° = 0.5 kcal/mol     " affinity is reduced by a factor 2.3
!G° = 1.0 kcal/mol     "  affinity is reduced by a factor 5.4 
!G° = 2.0 kcal/mol     "  affinity is reduced by a factor 29.3
!G° = 3.0 kcal/mol     "  affinity is reduced by a factor 158.8
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from the SUMM-search) and by then performing stochastic dynamics simulations 
within each well. All calculations were performed with an AMBER force field with 
parameters augmented for carbohydrates [161,168,170] and in conjunction with 
the GB/SA continuum-water model [171]. As a result, a distribution of the 
conformers of the mimic of interest in respect to the whole conformational space 
is obtained. More details on the simulation technique are given in Chapter 
3.2.3.1. 
To facilitate the data analysis of these simulations, Kolb and Ernst [161,168] also 
developed a 2D internal coordinate system (to be use instead of the three 
Φ/Ψ−plots for the three glycosidic bonds) that permits to define the spatial 
orientation of the relevant pharmacophoric groups of E-selectin antagonists 
(Figure 13). The two parameters chosen are the “torsion angles”: Fuc(C4)-
Fuc(C1)-Fuc(O1)-Acid(Cα) and Fuc(C1)-Fuc(O1)-Acid(Cα)-Acid(C=O). The first, 
describes the conformation of the Lex core and is therefore referred to as core 
conformation. The second defines the orientation of the acid group relative to the 
core and is therefore referred to as acid orientation.  
 
 
 
 
 
 
 
 
 
Figure 13: Definition of the acid-core “torsion” angles. 
 
As can be seen in Figure 14, by plotting these two parameters against each 
other, a probabilistic distribution of the conformations of the compound of interest 
in the conformational space can be visualized.  
Acid 
orientation 
Core 
conformation 
O
O
O
O
O
OO
COONa
HO
AcHN
HO
HO
OH
OH
OMe
NHAc
OH
OH
HO
HO
OH
HO
O
O
O
O
O
OO
COONa
HO
AcHN
HO
HO
OH
OH
OMe
NHAc
OH
OH
HO
HO
OH
HO
                                                                                                                                                                                                                          
                                                                23
   
 
Figure 14: Probabilistic distribution of the conformation of a compound. 
 
Moreover, this distribution can be compared to the one obtained with sLex (3) 
and the number of the conformations of compound of interest fitting the bioactive 
window, defined by Kolb and Ernst [161] (Figure 15) upon the results of Scheffler 
et al. [164,165], checked.  
 
 
Figure 15: Definition of the bioactive window (left), based on the NMR of Scheffler et al. 
[164,165], and results obtained for the simulation o fsLex (3). 
 
These two criteria are thought to give sufficient hints about the affinity of the 
compound of interest towards E-selectin. In fact, it was shown [161,168] that a 
compound featuring a strong pre-organization (therefore having a high 
percentage of conformations fitting the bioactive window in the JBW-simulation) 
and a more “concentrated” distribution of conformations compared to sLex, 
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usually has a stronger affinity to the target protein due to the reduced entropy 
costs to pay upon binding. The proof of concept for this approach based on the 
pre-organization of E-selectin antagonists, was given by Kolb and Ernst 
[161,168], who designed a series of compound, thereby showing that the model 
results were able to predict their biological activity (Figure 16). A powerful tool for 
the design of new sLex mimics was since then at disposition. 
 
 
Figure 16: Chemical structure, simulated conformational variability in solution, and biological 
activity of the compounds 5–7. 
 
1.5.4 Hypothetical models for the binding mode of sLex to E-selectin 
 
Different models, predicting the binding mode of sLex to E-selectin, have been 
proposed in the decades before the crystal structure determined [166] gave a 
detailed insight into the molecular recognition of sLex by the protein. It is 
interesting to note, that each model predicted some of the interactions between 
protein and ligand correctly, but that none of them has been able to reproduce 
the binding mode as observed in the crystal structure. In particular, all models 
failed to correctly determine the interaction of fucose with the calcium ion. This 
discrepancy is mainly due to the fact that all models based on the hypothesis that 
the binding of sLex to E-selectin would be analogous to the one of mannose in 
the mannose-binding protein A (MBP-A) but this supposition turned out to be 
incorrect [172]. 
The crystal structure of MBP-A complexed with a mannose-containing 
oligosaccharide was published by Drickamer et al. [84] in 1992. It has been the 
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first structure of a saccharide bound to a C-type lectin domain. The most 
interesting observation was the role played by the 3– and the 4–hydroxyl groups 
of mannose (both equatorial) in the complexation of the calcium ion. Due to the 
high degree of homology between MBP-A and the selectins, this crystal structure 
became unfortunately (see above), the basis for the development of all the 
models aming to describe the interactions between E-selectin and sLex.  
The first model, based on mutagenesis studies, was presented in 1992 by Erbe 
et al. [92]. They hypothesized that sLex bound to E-selectin in a small shallow 
pocket, formed by the amino acids Arg97, Lys111, Lys113, Ser47 and Tyr48. 
The first true insight into the binding site of E-selectin was provided by Graves et 
al. [173], who solved the x-ray crystal structure of the E-selectin CRD/EGF 
domains. This structure presented some differences when compared to MBP-A. 
In particular, in E-selectin the calcium co-ordination sphere contains only four 
amino acid residues instead of the five observed in MBP-A. Further details on the 
binding mode of sLex to E-selectin delivered the crystal structure of sLex co-
crystallized with a selectin-like mutant of MBP-A [172]. Hence, the binding of the 
2– and 3–hydroxyl groups of the fucose to the calcium ion was confirmed but 
surprising, despite earlier finding (e.g. pharmacophore studies), no interactions 
between the carboxylate group of sialic acid and the protein were observed. Two 
theories were therefore put forward: either sLex binds differently to E-selectin 
than to the MBP-A mutant, or the importance of the sialic acid, demonstrated by 
the SAR-studies, is not directly related to protein binding.  
Due to their historic importance the two models, presented by Kogan et al. [174] 
and Ernst et al. [175] respectively, will be briefly discussed. The model proposed 
by Kogan et al. (Figure 17), is based on the bioactive conformation of sLex 
proposed by Cooke [162], which was docked onto E-selectin after having pre-
oriented the fucose moiety of sLex the way it had been found in the mutated 
MBP-A crystal structure [172]. In contrast, the model of Ernst et al. (Figure 17) is 
based on the docking of the bioactive conformation obtained from NMR 
investigations [164,165] onto the crystal structure published by Graves [173].
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Figure 17: The model proposed by Kogan et al. [174] (left) compared with the one of Ernst et al. 
[175] (right). The differences are highlighted in red in the model by Ernst et al. [175] (right). 
 
Both models suggest that the calcium ion is co-ordinated by the 2– and the 3–
hydroxyl groups of fucose, that the 6–OH of the galactose moiety is interacting 
with Tyr94, and that the carboxylate group of the sialic acid residue is in close 
contact with Arg97. Slight differences lie in the amino acids coordinating the 
calcium ion, the contact of the 4–OH of Gal to Asn105 being not predicted by 
Kogan and the interaction of Asn82 with the hydroxyl groups of fucose. Recently, 
however, a directly insight into the molecular recognition of sLex by E-selectin 
was gained through the crystal structure of the E-selectin/sLex complex obtained 
by Somers et al. [166]. This structure will be discussed in Chapter 1.5.5. 
A very different model, proposed first by Ernst et al. (personal communication) 
and further developed in this thesis (cf. Chapter 4.4.3), is based on the so-called 
reverse docking mode. This model may explain the finding of Defrees et al. [176], 
who observed that the introduction of hydrophobic substituents at the 2–position 
of the GlcNAc moiety leaded to higher affinity. In fact, as stated in [176] (”… 
when the synthesized compounds were incorporated into several proposed 
sLex/E-selectin binding models, specific interactions could not be identified …”) 
the reasons for this enhancement were unclear. To possibly identify these 
specific interactions, we screened the surface of E-selectin for hydrophobic 
regions, which lead to the proposition of the reversed binding mode illustrated in 
Figure 18. 
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Figure 18: Schematic representation of the “reverse docking mode”. The calcium ion is 
coordinated by the carboxylate of the sialic acid, whereas the hydrophobic substituents at the 2–
position of the GlcNAc moiety (R) interact with the hydrophobic region of the protein formed by 
Tyr44, Pro46 and Tyr48. 
 
1.5.5 The crystal structure of the sLex/E-selectin complex: an insight  
into the “true” binding mode 
 
Recently, Somers et al. [166] (Figure 19) significantly improved our 
understanding of selectin/carbohydrate binding by determining the crystal 
structures of complexes of sLex with the lectin/EGF domains of P- and E-selectin. 
Their work not only provided new insights, but also a few surprises. In particular, 
the majority of the contacts appear to be electrostatic in nature and the total 
buried surface of the complex is relatively small (only 550 Å2) when compared to 
the size of the free ligand. Moreover, the selectin-bound calcium ion is 
complexed by the 3– and the 4–hydroxyls of Fuc and not, as suggested before 
by the 2–OH and the 3–OH. Further, the 4–OH of Fuc is also involved in 
hydrogen bonds with the residues Asn82 and Glu80, where as the 3–OH 
interacts, even with Asn105. The 2–OH of Fuc is, then again, indirectly bound to 
Asn83 and Glu107 through water-mediated hydrogen bonds. Looking at the Gal 
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moiety, contacts between the 4–OH and Tyr94, as well as between the 6–OH 
and Glu92 could be detected. The carboxylate group of the sialic acid binds the 
amino acids Arg97 and Tyr48.  
The conformation adopted by sLex in the crystal structure is not analyzed in detail 
by Somers et al. [166], but, as it was already discussed above, is very similar to 
the bioactive conformation found by Scheffler et al. [164,165] by NMR and 
corresponds to minina C of the Ichigawa simulation [152] (cf. Table 2). 
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Figure 19: The binding mode of sLex as found in the crystal structure [166]. 
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1.6 Towards the development of sLex mimics as selectin  
      antagonists 
 
After demonstrating that E-selectin plays a key-role in the inflammatory cascade, 
substantial interest arose on developing ligands that could act as anti-
inflammatory agents. The terminal carbohydrate epitope sialyl Lewisx served as a 
lead in the search of new E-selectin antagonists fulfilling two main criteria:  
• modification of the lead structure towards molecules that overcome the 
pharmacokinetic (i.e. fast renal excretion, high polarity leading to low 
bioavailability) and pharmacodymamic disadvantages typical of 
carbohydrates (low affinity), and 
• simplification of the complex structure of sLex. 
 
 Most studies aimed at substitute one or more sugars moieties of sLex with other 
structures, thereby retaining the key pharmacophores. A key aspect in this 
regard is the loss of the conformational pre-organization of pharmacophores, 
caused by the replacement of the relatively rigid Lewisx-core structure by more 
flexible linkers. As it will discussed below, this kind of modifications often lead to 
less affine ligands, because of the high entropic cost associated with binding. 
Another possibility explored to circumvent the problem of the low affinity of sLex 
towards E-selectin, was a polyvalent approach. This showed, at least in part, 
promising results [177–180], but these compounds are not suited for oral drug 
application. Several reviews cover this aspect [181–189].  
This chapter will be dedicated to the most interesting sLex mimics developed to 
date. To facilitate the reading, the overview of the different contributions, is 
composed into sections corresponding to the number of sugar moieties replaced. 
Within each group (one sugar less, two sugars less,…) further strategies such as 
addressing secondary binding sites for additional interactions or pre-organization 
of the pharmacophores in the bioactive conformation by rigidification, will be 
discussed. 
 
1.6.1 Trisaccharide mimics 
 
1.6.1.1 Deletion of sialic acid 
 
It is known from SAR-studies, that only the carboxylic acid of the neuramic-acid 
moiety contributes to E-selectin binding. The first logical step was therefore, to 
replace the costly and synthetic demanding sialic acid by a simple negatively 
charged group. For instance, sulfated Lex trisaccharide (8) does exist in nature, 
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as a natural analog of sLex, and shows even a 20–fold superior binding affinity 
towards E-selectin [190]1. Similar results were achieved by the substitution of the 
sialic acid moiety by a phosphate group (9) [191]. However, the most common 
simplification, is the alkylation of the 3–OH of Gal. The 3–carboxymethyl-
substituted analog (5) shows similar affinity as sLex. A more rigid NeuNAc mimic 
was synthesized by Duthaler et al. [192] (10). This compound, however, showed 
no affinity towards E-selectin. In fact, the acid moiety was fixed in a conformation 
different to the bioactive one. Other NeuNAc replacement will be presented later 
in combination with GlcNAc-substitutions. 
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Figure 20: Mimics containing a negatively charged group replacing NeuNAc. 
 
1.6.1.2 Substitution of the GlcNAc-moiety 
 
As it was confirmed by the crystal structure of the sLex/E-selectin complex [166], 
the GlcNAc-moiety of sLex seems not to be directly involved in any interaction 
with the protein. However, this moiety plays an important role as a three 
dimensional spacer correctly orienting the pharmacophores. Therefore, several 
compounds have been synthesized, where the GlcNAc-moiety has been 
replaced by synthetically less demanding groups and/or by groups with a better 
pharmacokinetic and pharmacodynamic profile. Hannesian [193] for example 
replaced the GlcNAc-moiety by an indolizidinone unit. This structure (11) showed 
no affinity towards E-selectin anymore but bound P-selectin stronger than sLex 
[193]. Substitution of GlcNAc with quinic acid leads to compound 12, which was 
                                                
1 However, these finding could not be reproduced by numerous other groups active in the selectin  
   field. (Beat Ernst, personal communication) 
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equally active as sLex [193]. However, the most successful and, from a 
pharmacokinetic point of view, interesting substitution was obtained by Töpfer 
[194]. He replaced GlcNAc by a (1R,2R)-cyclohexandiol ring. His compound (13) 
was three times more active than sLex. 
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Figure 21: Mimics containing different GlcNAc replacement. 
 
1.6.2 Two-sugar mimics 
 
1.6.2.1 Replacement of NeuNAc and GlcNAc 
 
The next step in the simplification process of sLex was to combine the effects of 
the NeuNAc- and GlcNAc-replacements. The substitution of GlcNAc solely, 
hardly improved binding affinity but lead to mimics easily to be synthesized and 
with improved pharmacokinetic-properties. A variety of GlcNAc-replacements 
have been tested in combination with glycolic acid or alkyl- and aryl lactic acid 
residues mimicking the sialic acid part (Figure 22 and 23). 
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Figure 22: sLex mimics bearing a carboxymethyl group as sialic acid replacement and a variety 
of more or less flexible linker groups substituting the GlcNAc unit. 
 
Wong suggested [182], that a substitution of the GlcNAc-moiety by a (1R,2R)–
cyclohexandiol ring, seems to be energetically neutral when, in parallel, NeuNAc 
is exchanged against a carboxymethyl group (25). Surprisingly, compound 14, 
which contains a much more flexible linker leading to a reduced stability of the 
Lex core structure, was almost as active as 25. In general however, the 
introduction of flexible 1,2 diols as GlcNAc-mimics lead to a reduced affinity of 
the ligands towards E-selectin (15–18) [195]. Further modifications included the 
introduction of a butane- (20), a cis-olefin- (21) or an epoxide-linker (22) between 
Fuc and Gal, but none of these GlcNAc-substitution led to higher affinities. A 
probable explanation for the lost of affinity with this class of compounds lies in 
their lack of a rigid linker between Fuc and Gal, stabilizing the Lex-core structure. 
In addition, the mimics containing quinic acid (23) or indolizidinone (24) as a 
GlcNAc-replacement (even in combination with the positive carboxymethyl 
substitution of NeuNAc) didn’t show any improvement in affinity compared to 
sLex. 
                                                                                                                                                                                                                          
                                                                33
   
Of particular interest for the work performed in this thesis project and at the 
Institute of Molecular Pharmacy in general, are the mimics developed by Ernst et 
al. [161,168,196]. By using a molecular-modeling tool to be described later in 
detail, they identified (2S)–cyclohexyl- and (2S)–phenyl-lactic acid as a plausible 
simplification of the NeuNAc-moiety and further established modifications of the 
(1R,2R)–cyclohexandiol ring initially proposed by Wong [182] as a valuable 
GlcNAc-replacement.  Regarding the sialic acid substitution, they could show that 
the introduction of sterically demanding groups next to the acid function, forces 
the carboxylate to adopt the bioactive conformation observed for sLex. In fact, 
compound 26 that will often be used for reference purposes in this thesis, turned 
out to be ten to twelve times more active than sLex [161,168]. Obviously, the R-
stereoisomer was found to be inactive (27) [161,168]. Even more active 
compounds (28-32) were obtained by combining the NeuNAc-substitution 
through (2S)–cyclohexyl-derivative with the introduction of aliphatic or aromatic 
substituents at the position two of the GlcNAc mimic [196]. The role played by 
these substituents will be part of the investigations performed in this thesis. A 
further improvement in affinity was obtained by serendipity by Thoma et al. [197]. 
Due to an incomplete deprotection of the galactose, compound 36 was obtained 
and turned out to be three times more active than the corresponding mimic with a 
free 2–OH group. A rational explanation for this effect will be hypothesized below 
(cf. Chapter 4.7.2.2).  
Various modifications at the 6-position of Gal of compound 26, as its rigidification 
leading to compound 35 didn’t lead to any improvement in binding affinity [149]. 
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Figure 23: Mimics developed at Novartis AG, Basel. 
 
1.6.2.2 Replacement of the N-acetyl-lactosamine disaccharide 
 
Another approach explored in the search for potent E-selectin antagonists, is the 
replacement of the central N-acetyl-lactosamine disaccharide unit (Figure 24). 
The introduction of unfuctionalized linkers (42–44) [198] instead of the 
disaccharide unit, however delivered only poor results. Reasonable explanations 
for this lack of activity are the high entropic costs resulting from the higher 
flexibility and the lack of functionalities imitating the essential pharmacophores of 
Gal (4–OH and 6–OH). To circumvent this second problem, Töpfer et al.[194] 
proposed a propanediol-cyclohexan linker (39–41), but no breakthrough has yet 
been achieved. Also the use of more complex and rigid linkers like an inflexible 
spiroketal scaffold (47) [199] or a benzenedimethanol (45, 46) [200] didn’t fulfill 
the expectations and led only to poor-affinity ligands. 
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Figure 24: Mimics in which the N-acetyl-lactosamine disaccharide has been substituted. 
 
1.6.3 One sugar mimics 
 
The fucose moiety of sLex, which coordinates the calcium ion in the selectins and 
contains three of the six pharmacophoric groups, is probably the most difficult 
residue to substitute. Therefore, the largest and more “drug-like” group of selectin 
antagonists is based on structure containing only this sugar unit, in some cases 
replaced by mannose or L-galactose. Additional functional groups were then 
attached to this moiety to mimic the omitted pharmacophoric groups of the Gal- 
and NeuNAc-residues. A series of mimics integrating the established linker 
(1R,2R)–cyclohexandiol ring as a GlcNAc replacement had some success 
(Figure 25). For instance, Töpfer et al. [201] used this functionality to prepare a 
series of mimics with malonic acid derivatives (53–62). Bänteli et al. [202] and Liu 
et al. [203] prepared fucose-based mimics featuring different disubstituted aryl 
groups to mimic the NeuNAc-Gal moiety (48–51) but all the substances were 
found to be inactive. The authors suggested that the use of an aromatic spacer 
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instead of Gal probably does not allow the steric pre-organization needed for 
binding. Furthermore the aromatic substitution leads to a completely different 
geometry (the aromatic ring is planar vs. the chair conformation of Gal), making it 
impossible to appropriately position the pharmacophoric groups.  
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Figure 25: Fucose-based sLex-mimics containing a cyclohexanediol spacer combined with a 
variety of linkers to attach the anionic endgroup.  
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Kogan et al. [204,205] developed a library of different glycoaromatics, based on a 
derivatized biphenyl residue attached to the anomeric position of mannose (i–iii 
Figure 26). With the exception of compounds 63-65, the ligands displayed no 
affinity towards E-selectin. However, nine molecules showed a two to twenty fold 
better activity towards P-selectin than sLex. In addition, they studied dimeric 
glycoaromatics to mimic extended sialyl di-Lewisx structures isolated form human 
neutrophils [121]. Dimer 65 was six times more active than sLex against E-
selectin in a cell-based assay. 65 is currently in phase IIa clinical trials conducted 
by Revotar AG [206] for the treatment of asthma and psoriasis. 
The group of Wong [207–212] focused its interest in generating a large library of 
fucose-, mannose-, or galactose-based glycopeptides. Two design elements 
were chosen as variables: “turns” mimicking the GlcNAc unit, and “hydroxyls” 
mimicking the galactose pharmacophores. In general, those compounds showed 
a distinct improvement in affinity for P-selectin and usually only moderate for E-
selectin. It is, however, difficult to derive a SAR-profile for these glycomimics due 
to the substantial differences among the structures and in the range of activity 
(from no activity to µM). Nevertheless, this series contains the most active 
inhibitors known to date. Then again, none of them has ever entered clinical 
trials. A detailed discussion of these compounds can be found in a recent review 
[182]. 
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Figure 26: Biphenyl-based inhibitors investigated by Kogan et al. [204,205]. 
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1.6.4 Groups addressing secondary binding sites 
 
The compounds summarized so far, generally tried to improve binding through 
the simplification of the lead structure sLex. Hence, this approach is based on 
maintaining the pre-organized pharmacophore and on removing of the non-
pharmacophoric functional groups, so that a benefit on the entropic level can be 
achieved. This approach led, in some cases, to more potent ligands, but a real 
breakthrough was not achieved. To further improve the activity of selectin 
antagonists, various attempts have been made to access additional (preferably 
hydrophobic) interactions with the receptor without loosing the key contacts 
described above (cf. Chapter 1.5.1). DeFrees et al. [176] showed that higher 
affinities are obtained when the acetyl group of the GlcNAc moiety of sLex is 
replaced by benzoate (Figure 27, 66) or naphthoate (Figure 26, 67).  
 
66 (R= benzoyl)
67 (R=naphthoyl)
OO
O
O
O
OO
AcHN
HO
HO
OH
OH
COONa
HO
HO
Me
HO
OH
OH
O
OH
OH
NH
O
R
O
OEt
HO
OH
OH
 
 
Figure 27: The compounds identified by DeFrees et al.  [176]. 
 
Ernst et al. [175] also investigated the effect of aliphatic, aromatic and 
heteroaromatic acyl substituents at the GlcNAc-nitrogen. Their findings confirmed 
the results presented by DeFrees and provided even more potent ligands (Figure 
28). It is noteworthy that structure 68j, with an activity 60 times (IC50= 0.013 mM) 
higher than sLex, is one of the most potent inhibitors known to date. However, the 
structural basis for this improvement in activity is not fully understood, despite the 
availability of the crystal structure of the sLex/E-selectin complex [166]. This will 
therefore be analyzed in this thesis. 
Moreover, the introduction of similar hydrophobic substituents to increase the 
affinity towards E-selectin, such as the ones proposed by Ernst et al. [175] for the 
2–position of the GlcNAc moiety, was hypothesized, as a part of this thesis, for 
the 2– and 6–positions of Gal and for the group neighboring the carboxylate 
functionality binding Arg97 and will be discussed in Chapter 4.7.2.  
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Figure 28: Modification of the 2–position of the GlcNAc unity by Ernst et al. [175]. 
 
1.6.5 Non-sugar based mimics 
 
An alternative approach in the search for a high affinity ligand for E-selectin was 
undertook by Kondo et al. [213] and Brandley et al. [214]. They build up a 
pharmacophore model based on the information coming from SAR studies. They 
then screened databases looking for substances fitting to their pharmocophore 
hypohesis. Finally, they identified ligand 69 and 70 (Figure 29) as possible E-
selectin antagonist. 69 showed an activity of 150 µM, 70 of 500 µM. 
A further group of E-selectin inhibitors is formed by the peptidic antagonists. 
However, this class of antagonists will not be discussed in this thesis. For 
additional information please consult reference [215]. 
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Figure 29: The two ligands identified by Kondo et al. [213] and Bradley et al. [214] through 
pharmacophore modeling. 
 
1.7 Introduction to the modeling techniques 
 
This thesis mainly deals with theoretical studies of E-selectin antagonists, 
therefore the following section will be devoted to a brief historic overview of the 
methods used to address the different topics related to the design and 
investigation of E-selectin antagonists. More details over the approaches chosen 
are given in the Chapter 3 and 4. 
 
1.7.1 Conformational analysis 
 
Molecules are not rigid. The thermal energy at 25°C is large enough to let all 
atoms in a molecule move permanently. Therefore, each compound containing 
one or more single bonds exists in many different so-called conformers or 
rotamers. The quantitative and qualitative composition of this mixture is 
permanently changing. Of course, the low-energy conformers contribute most to 
the composition of this mixture. A transformation from one conformation to 
another is usually related to changes in torsion angles around sterically 
unrestricted bonds. The changes in molecular conformations can be understood 
as movements on a multi-dimensional surface describing the potential energy 
and the geometry of a molecule. Each point on this surface represents the 
potential energy of a single state. Stable conformations correspond to the local 
minima on this energy surface. The relative population of a conformation 
depends on its statistical weight, which is both influenced by the potential energy 
and the entropy [216]. As a consequence, the global minimum on the potential 
energy surface is not always the most frequently populated. Conformational 
analyses are of particular interest, because it is assumed that the biological 
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activity of a drug molecule depends on one single unique conformation (the 
bioactive conformation) hidden among all the low-energy conformations [217]. 
The search for the bioactive conformation has therefore become one of the most 
challenging tasks in medicinal chemistry. In fact, as it can be observed in Figure 
12 (cf. Chapter 1.5.2.3), small differences in ΔG° have a substantial influence on 
the conformation population, and in particular case, where the bioactive 
conformation doesn’t coincide with the global minimum, on the binding affinity. 
In the past decades, different theoretical techniques have been developed aimed 
at identifying low-energy conformers on the potential-energy surface [218–225]. 
In this work, only molecular-mechanics concepts will be discussed while QM-
methods remain excluded. 
 
1.7.1.1 Conformational analysis using systematic search procedures 
 
The systematic search [219,220,226] is probably the most intuitive method. It is 
performed by systematically varying each of the torsion angles of a molecule in 
order to generate all possible conformers. Typically a step size of 15° per torsion 
is used. That means, that to sample a single torsion, 24 conformations have to 
be generated. Consequently, the number of conformations to be sample depends 
on the number of torsion (n) and on the step size (s) as given in Equation 3. 
 
Number of conformations = (360/s)n  (Eq. 3) 
 
The disadvantage of this protocol is the huge amount of conformers that have to 
be sampled. If for example a molecule with six rotatable bonds would be 
investigated, by using a step size of 15°, the number of conformers generated, 
would already be of 191’102’976. In the past but even today, the calculation of 
the potential energy for each of this structure would be too time-consuming, and 
therefore ways to reduce the amount of conformations to be evaluated, were 
introduced. The first approach to reduce the data is to perform a van der Waals 
screening or “bump check”. If two atoms are closer than the sum of their van der 
Waals radii the conformer would be rejected prior to the calculation of its energy. 
For the conformers that pass this first filter, the potential energy is computed 
using a molecular force field method. As a second filter, an energy window can 
be defined. The underlying idea for applying an energy window is based on the 
fact that conformations having much higher energy compared to the global 
minimum will be only neglectable populated (see again Figure 12). The value for 
this energy window depends on the size of the molecule studied and on the 
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applied force field. Typical values vary from five to fifteen kcal/mol above the 
global-energy minimum [224–228]2. 
The structures that pass both filters should represent the complete ensemble of 
energetically accessible conformations of a particular molecule. However, in 
many cases the number of structures obtained, is still too large to be reasonable 
handled. Therefore, further techniques like clustering or factor analysis have 
been developed. For a discussion of these methods a detailed review is available 
[229]. 
 
1.7.1.2 Conformational analysis using Monte-Carlo methods 
 
A completely different approach for screening the conformational space is based 
on Monte-Carlo search techniques. Random search techniques are of statistical 
nature [230]. At each step of the simulation, the actual conformation is randomly 
transformed in a new one by changing one or more values of the torsion angles 
(internal space refinement) [224] or by modifying the cartesian coordinates 
(cartesian space refinement) [221,222]. After each step the molecule is 
minimized and compared with the already sampled conformations. Only if it is 
unique, it will be retained. After this check, the randomization process is 
resumed. Potentially, the random methods allow to cover all the regions of the 
conformational space, but this is only true if the simulation runs for a sufficient 
time span. Hence, the probability to sample a unique conformation decreases 
dramatically depending on the growing number of conformers already 
discovered. Therefore, unless the computational time invested is indefinite, a 
residual probability of not having sampled all the conformational space remains. 
Hence, it is important to check the completeness of the analysis by performing 
different parallel runs starting the search protocol with different input 
conformations. The main advantage of a random search method is that, in 
principle, molecules of any size and also including ring systems can be 
successfully treated. In reality, however, highly flexible molecules like the 
carbohydrates investigated in this thesis, often don’t give exhaustive sampled 
results, because the volume of the respective conformational space is too large. 
A slightly modified random method (SUMM searches) was therefore used to 
generate some of the results presented in this thesis. The difference to a 
standard Monte-Carlo approach relies on the fact that this method keeps track of 
the regions of the conformational space already visited, and thereby addresses 
the search towards new regions. A detailed description of this method can be 
found in reference [231]. 
 
                                                
2 If this filter is applied, the actual solutions of the search have to be intermediately saved and 
resorted by energy after each simulation cycle. 
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1.7.1.3 Conformational analysis using Molecular-Dynamics Simulations 
 
The aim of a molecular dynamics simulation approach is to reproduce the time-
dependent motional behavior of a molecule. Basically, it is assumed that the 
atoms of a molecule move according to the Newton’s laws, thereby interacting 
with each other through molecular forces. The simulation starts by applying a 
random velocity (Boltzmann distribution at a defined temperature) to each atom 
of the molecule of interest. At regular time intervals (e.g. 1.5 fs) then, the second 
law of Netwon is solved by integration, thereby yielding a new position and 
velocity of each atom of the system, the result being a new conformation. This 
cycle can then be repeated for a predefined number of steps. The collection of 
the energetically accessible conformations produced by MD is referred to as 
“ensemble”. One of the most interesting features of this method is its ability to 
overcome energy barriers. Hence, by performing an MD, it should be possible to 
find also the minima other than the nearest on the potential energy surface (e.g. 
the global minimum). However, if the energy barriers are high or the number of 
degrees of freedom in the molecule very large, then some of the conformers can 
not be produced during the simulation time. Moreover, in the case of molecules 
with many rotatable bonds, due to huge conformational space that has to be 
sampled, the completeness of the search cannot be reached in a reasonable 
amount of time. To overcome the barrier problem, an often-used tactic is to 
perform the simulations at elevated temperatures, thereby introducing more 
energy to the system and thus facilitating the overcoming of energy barriers. A 
well-established protocol to perform conformational analysis by MD is to integrate 
this philosophy referred to as simulated annealing [232]. Here, the molecule is 
first “warmed up” to an elevated temperature (e.g. 600 K), and then, after 
equilibrating the system for a given period of time (e.g. 150 ps) at the elevated 
temperature, cooled down to the defined sampling temperature (e.g. 300 K) and 
thereby trapped in the nearest local minimum conformation. This conformation is 
then used as starting point for the “next high temperature cycle”. In order to 
obtain a set of low-energy conformations, the heating-, equilibrating-, cooling-, 
and sampling-cycle should be repeated several times. This approach was mainly 
used for this work and will be presented in detail later (cf. Chapter 3.2.3.2). 
 
1.7.1.4 Conformational analysis of carbohydrates 
 
Due to the intrinsic characteristics of carbohydrates, their conformational analysis 
differs in several ways from that of the other organic molecules. The potential 
information content of carbohydrates is several orders of magnitude higher than 
any other biological macromolecule (e.g. peptides). The diversity of carbohydrate 
structures relies on the broad number of different monosaccharides available 
(>100) and on the different ways they are branched. For example, the number of 
all possible linear and branched isomers of a hexasaccharide containing only one 
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type of monosaccharide moiety exceeds 1012, whereas only one hexapeptide is 
possible using always the same amino-acid as a repeated unit [233]. In addition 
to that, carbohydrates are highly flexible and will therefore often populate 
numerous conformations co-existing in solution even at room temperature. 
Furthermore, this floppiness represents a major problem in crystallizing 
carbohydrates, thereby rending the access to experimental data difficult. Finally, 
even though most recent development in NMR-techniques permits a better 
understanding of their structures, carbohydrates generally show only few inter-
residual nOes in contrast to proteins. As a consequence, due to the lack of 
measurable data, it is often difficult to uniquely determine the conformation of an 
oligosaccharide through experimental methods [234]. However, also for 
theoretical methods this task remains difficult. Next to the huge number of 
conformations that has to be sampled, carbohydrates are especially though to 
model because of their highly polar functionality, the role of solvation, and the 
particular electronic effects present only in carbohydrates such as the anomeric-, 
the exo-anomeric- and the gauche-effect. The particularity of carbohydrates 
therefore induced the development of various force fields that may be suited for 
studying carbohydrates. Two extensive reviews on this topic have been 
published [235,236]. 
 
1.7.2 Docking and scoring procedures 
 
1.7.2.1 An insight into the docking procedures 
 
Docking procedures aim to identify the correct orientation/conformation of a small 
molecule in the binding pocket of a protein and to predict its affinity towards the 
target protein. Molecular docking has contributed important proceedings to drug 
discovery for many years and has become an essential tool in structure-based 
drug design. It is widely applied and meets very heterogeneous demands. Of 
course, the major task remains the identification of new active compounds for a 
particular target protein. Docking proved to be a reliable and fast filter in high-
throughput virtual screening [237,238], thereby providing a pool of ideas for novel 
lead structure, and did produce several success stories [239–242]. In addition, 
docking is often used to predict the binding mode of new compound classes for 
which no crystal structure has been determined yet [243–247].   
The setup for a ligand docking approach requires the following components: a 
target protein structure with or without a bound ligand, the molecules of interest 
and a computational framework that allows the implementation of the desired 
docking and scoring procedures. To guarantee a certain accuracy, the three-
dimensional structure of the protein-ligand complex has to be detailed at atomic 
resolution. Most of the docking algorithms assume the protein to be rigid, 
according to the high computational cost that the demand of flexibility implicates 
(in some cases, like in Yeti [248,352], which also allows for dynamic solvation of 
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the binding pocket, flexibility of the amino-acids sidechains is allowed). The 
ligand is mostly regarded as flexible. Docking can be performed by placing rigid 
molecules or fragment into protein’s active site using different approaches like 
the clique-search, geometric hashing or pose clustering. In the clique search 
matches are searched to describe the compatible characteristics (shape or 
interaction pattern) of ligand and protein by means of a distance compatibility 
graph. This approach is implemented for example in DOCK [249]. A geometric 
hashing function is created to describe geometric features like distances in two 
steps, the preprocessing phase and the recognition phase. This approach is 
attractive regarding its time-efficacy and the option of partial matching of the 
ligand in the protein pocket [250,251]. Pose clustering is an algorithm based on 
the matching of triplets of features of the ligand with a triplet of features of the 
protein. This approach is implemented in the program LUDI [252,253]. 
The first method introduced to treat ligand flexibility was to dock a set of 
conformers of the same molecule covering the conformational space in an 
exhaustive way. Unfortunately, different studies [254,255] showed that many 
conformers are needed (up to few hunderts) to exhaustively sample the ligand 
conformational space, thereby the demand of the computer time increases. 
A more sophisticated approach is the implementation of algorithms that simulate 
flexible docking, like incremental fragmentation (FLEXX) [256,257], molecular 
simulation (simulated-annealing in AutoDOCK [258], molecular dynamics [259]) 
or Monte-Carlo based methods (PRODOCK [260–262], Yeti [248,352]). Also 
docking techniques based on genetic algorithms showed impressive results 
(GOLD) [263,264]. 
A critical issue that has to be kept in mind when performing docking, is the multi-
factorial dependence of the docking results. Aside from docking algorithms and 
scoring function, binding-site definition and the use of pharmacophore constraints 
are decisive [265]. Moreover, also the nature of the biological target, the 
properties of the active site, crystallographic resolution, as well as ligand 
flexibility and size were found to influence docking reliability [266]. A study by Wu 
et al. [267], clearly showed that a higher docking success (meaning a root square 
deviation between top ranked docking position and X-ray structure of less than 
2Å) could be obtain with a lower number of rotatable bonds. In an other study by 
Perola et al. [268], docking accuracy was related once again to ligand flexibility, 
but also with the predominant nature of the interaction between protein and 
ligand, and the degree of solvent exposure of the binding pocket. 
 
1.7.2.2 An insight into the scoring procedures 
 
Scoring of docking poses is still regarded as one of the major challenges in the 
field of molecular docking. The purpose of the scoring procedure is the 
identification of the correct binding pose by its lowest energy value, and the 
ranking of protein-ligand complexes according to their binding affinities [269]. 
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Though much effort has been invested in the development of accurate scoring 
functions, still none of them can correctly rank every protein-ligand complex 
today. Two approaches may help to overcome this problem. First, the 
identification of a good scoring function for the specific case of interest or the 
application of a consensus-scoring scheme (combination of several scoring 
functions). Another problem to overcome for a correct scoring arises from the 
occurrence of induced-fit binding mode of ligands. Compared to the flexibility of 
small molecules, the tackling of the flexibility issue in macromolecules is still a 
demanding problem. Hence, the induce-fit protein movements must be regarded 
as a crucial task to develop better docking and scoring algorithms. 
Scoring functions can be divided in empirical scoring functions, scoring functions 
derived from force fields, and knowledge-based scoring functions. Scoring 
functions derived from force fields handle the ligand binding prediction with the 
use of potential energies and sometimes in combination with solvations- and 
entropy-contributions (Yeti [248,352], Quasar [270–272,351]). Knowledge-based 
scoring functions are based on atom pair potentials derived from structural 
databases. Finally, empirical scoring functions are derived by correlating 
experimental binding affinities with docking scores through the use of a training 
set. For exhaustive reviews on the scoring-function problematic see references 
[273–282]. 
Recently an interesting study by Schulz-Gasch and Stahl [265] compared the 
docking results obtained with the programs FRED, GLIDE, and FLEXX in 
combination with different scoring functions for seven relevant pharmaceutical 
targets. They divide the scoring functions in “soft” and “hard”. A “soft” scoring 
function is defined as a function not including directional terms, a “hard” one is 
obviously the contrary. Moreover, they also distinguish between the scoring 
function used by the docking algorithms (they call it “objective”) and for the final 
ranking (for them the real “scoring”). Although other influences, like binding site 
definition, are also crucial, they were able to derive a number of general guideline 
for an easier selection of the best combination of objective- and scoring-function.  
In their opinion, for lipophilic binding sites mulitconformer docking with a soft 
objective and a harder scoring function is particularly suited. If polar groups also 
play a certain role, incremental construction algorithms, which are always 
combined with hard objective functions, should be applied. Very polar sites with a 
dense network of directed interaction require incremental construction and hard 
scoring functions, or alternatively multiconformer docking in combination with a 
hard scoring function.  
It has, however, to be noted, that particular attention has to be paid when 
handling large molecules, very polar ones or molecules presenting themselves 
as tautomers. In fact, practically all scoring-functions overestimate the affinity of 
large molecule, because of taking unspecific interactions with the protein too 
much in account [283,284]. In the case of very polar substances, often they are 
too much taxed by a desolvation- and/or an entropic-term present in the scoring-
function equation.  
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The role of tautomers and of protonation-states in general, has been recently 
highlighted by Pospisil et al. [285]. Thus, molecular-modeling applications usually 
disregards the last two issues. Obviously just the change of the protonation or 
tautomeric state of a molecule can dramatically modify its hydrogen-bonds 
pattern, thereby dramatically influencing the fitting of the ligand in the binding 
site. Hence, it is easy to understand that the choice of the correct tautomeric or 
protonation state for the docking experiment and the following evaluation by a 
scoring function plays a determinant role. 
 
1.7.3 Quantitative structure-activity relationship (QSAR) 
 
Within congeneric series of compounds, quantitative structure-activity 
relationships (QSAR) correlate affinities of ligands to their binding sites, inhibition 
constants, rate constants, and other biological activities, either with certain 
structural features (Free Wilson analysis) or with atomic, group or molecular 
properties, such as lipophilicity or polarizability (Hansch analysis) [286–298]. 
Although the relationship between lipophilicity and biological properties like 
narcotic effect have been known since 150 years, it was only in 1964 that the 
milestone of QSAR was set through the publication of the Free Wilson method 
[299] and of the Hansch analysis [300]. Since then, QSAR equations have been 
used to describe the correlation between biological activity of compounds and 
some of their physico-chemical properties. Only after a very slow development, 
the breakthrough for the application of QSAR methods was achieved. In 1988 
Cramer et al. [301] published the first real 3D QSAR method known as 
comparative molecular field analysis (CoMFA). 
The CoMFA method was developed as a tool to investigate three-dimensional 
structure-activity relationships. A CoMFA analysis starts with traditional 
pharmacophore modeling to suggest a bioactive conformation of each molecule 
and ways to superimpose the molecules under study. This is one of the most 
critical and difficult steps in a CoMFA study [302,303] and has then later leaded 
to the development of 4D-QSAR methods (see below). The underlying idea of 
CoMFA is that differences in a target property like biological activity are often 
closely related to equivalent changes in the shapes and strengths of the non-
covalent interaction field surrounding the molecules. Usually, only two potentials, 
the steric potential, expressed in a Lennard-Jones function, and the electrostatic 
potential, expressed in a simple Coulomb function, are used within a CoMFA 
study. As a result of a CoMFA study, contours map, highlighting regions in space 
favorable or unfavorable for ligand-receptor interactions of steric or electrostatic 
nature, are obtained.  
Due to the problems associated with the functional form of the Lennard-Jones 
potential (more precisely the A/r12 repulsion term) [304] and the difficulty of a 
correct parameter setting in most of the CoMFA methods [305,306], Klebe et al. 
[307] have developed a similarity indices-based CoMFA method, which is named 
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CoMSIA (Comparative Molecular Similarity Indices Analysis). The method uses 
Gaussian-type functions instead of the traditional CoMFA potentials. Three 
different indices related to steric, electrostatic and hydrophobic potential are 
computed. The advantage of this method lies in the function used to describe the 
molecules studied, as well as in the resulting contours maps. In fact, these maps 
are easier to interpret than the ones obtained with the CoMFA approach. 
Moreover the CoMSIA procedure avoids the cutoff values used in CoMFA to 
prevent the potential functions from assuming unacceptably high values (i.e. 
unfavorable). For a more detailed description of the CoMSIA procedure refers to 
[308–310]. 
A further refinement of the original CoMFA technique has been achieved by 
introducing the concept of variable selection and reduction [311,312]. Hence, the 
large number of variables in the descriptor matrix is one of the problems of the 
CoMFA method. This could be partially solved by the introduction of a statistical 
procedure called GOLPE (General Optimal PLS Equation) developed by Barone 
et al. [311]. 
Several other 3D QSAR approaches have been developed during the last few 
years and some of them differs from the CoMFA method by not being based on 
properties calculated within a lattice. In GERM [313], COMPASS [314] and 
Quasar [270–272,351], properties are calculated for discrete locations in the 
space at or near the union surface of the active ligands. The “receptor surface” 
thus generated is intended to simulate the macromolecular binding site. In the 
past, these methods had two major drawbacks associated with the atomistic and 
receptor-surface based on averaged receptor entities: the adaptation of the 
shape of the binding site by means of induced fit and hydrogen-bond adaptation. 
However, these problems have been approached in the meantime. Vedani et al. 
[270–272] developed so-called multidimensional QSAR methods (4D–, 5D–, and 
6D–QSAR). The 4D extension refers to the possibility to allow for more than one 
conformer per molecule or to handle different orientations, protonation or 
tautomeric states of a compound at the same time, letting thereby the genetic 
algorithm select the most suited conformation of each molecule to obtain the best 
possible model. A further extension (5D) was introduced in 2002, when the 
possibility to simultaneously handle different induced-fit scenarios was 
implemented. Finally, the necessity to account also for different solvation models 
was recognized and implemented in the software Quasar [270–272,351], leading 
to the actual 6D version. In 2004 the same group developed also another multi-
dimensional (4D) QSAR approach, implemented in the software Raptor [315, 
316,335]. In this case, the fourth dimension is used to handle anisotropic 
induced-fit of the protein in the presence of different ligands. The binding site is 
therefore, represented by two layers. The inlying layer maps the fields, which a 
substrate would feel, if it were to fit snugly into the binding pocket. Another 
compound, that features additional groups that reach deeper into the protein, 
may experience different fields as a consequence of induced fit. This can be 
modeled by a second, outer layer. For major details refer to [315,316] and to 
Chapter 3.1.2.10. 
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1.7.4 De novo Design 
 
De novo design has the difficult goal to design novel molecular structures with 
the desired pharmacological properties starting practically from scratch. During 
the last two decades a great variety of de novo design software has become 
available. In de novo design, the following questions are addressed: (i) how to 
assemble candidate compounds; (ii) how to evaluate their potential quality 
(pharmaco-dynamic and pharmaco-kinetic properties); and (iii) how to sample the 
search space effectively for new ligands. A summary of the different approaches 
is given in Table 4. 
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Table 4: Selected de novo design programs with their basic properties in chronological order 
(adapted from [317]). 
 
 
At: Atoms; Fr: Fragments; Rc: Receptor; Li: Ligand; DFS; Depth-first search; BFS: Breadth-first 
search; Rnd: Random; MC; Monte-Carlo sampling with Metropolis criterion; EA: Evolutionary 
algorithms; Gr: Grow; Lk: Link; Lat: Lattice; MD: molecular dynamics simulation; Sto: Stochastic 
 
In this chapter, only protein-based methods will be briefly discussed. The first 
step of most of the protein-based de novo design software is to generate the so-
called primary target constrains by generating a grid of points in the binding site, 
and computing the interaction energies by placing different probe atoms or 
fragment at each grid position. An appropriate selection of probes and of the grid 
resolution, leads to the identification of the key interaction sites. This first step 
Name (year)
Building
blocks
Primary target
constraints
Search strategies Structure sampling Scoring function
At Fr Rc Li DFS BFS Rnd MC EA Gr Lk Lat MD Sto
3D Skeletons (1990) X X X X
Steric constraints and
hydrogen bonds
Diamond Lattice (1990) X X X X
Steric constraints and
hydrogen bonds
Legend (1991) X X X X Force field
LUDI (1992) X X X X X Empirical scoring function
NEWLEAD (1993) X X X X X Steric constraints
SPLICE (1993) X X X X
Pharmacophore and steric
constraints
CONCEPTS (1993) X X X X Empirical scoring function
Growmol/Allegrow (1994) X X X X X
Simple empirical scoring
function
MCDNLG (1995) X X X X Potential energy
Chemical Genesis (1995) X X X X X
Combined score and
shape, grid-based and
scalar constraints
PRO_LIGAND (1995) X X X X X X Empirical scoring function
SmoG (1996) X X X
Knowledge-based scoring
function
SkelGen (1997) X X X X X
Geometric, connectivity
and chemical constraints
Topas (2000) X X X X
Molecular similarity based
on topological
pharmacophore and
substructure fingerprints
CoG (2004) X X X X X
Molecular similarity based
on fingerprint descriptors
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results in maps highlighting the pinpoints favorable for positioning a particular 
atom (H-bond donor/acceptor, hydrophobic atom) of the searched ligand. After 
that, the search for a new ligand can start.  Several concepts have been 
developed for the structure sampling: linking, growing, lattice-based sampling, 
random-structure mutation, transition driven by molecular dynamics simulations, 
and graph-based sampling. 
Linking and growing have emerged as the most promising (Figure 30). The 
linking approach starts with the placement of building blocks at key interaction 
sites of the receptor. These building blocks are either positioned by the program 
itself or by the user [317]. The positioned building blocks are then automatically 
connected to each other by so-called linkers to yield a complete molecule that 
satisfies all key interaction sites. Linkers are selected from a library (e.g. amide, 
sulfonamide, indol rings, benzene,…) with the objective of forming favorable 
interaction with the target protein.  
In contrast, the growing procedure starts with a single building block at one of the 
key interaction sites of the receptor. This starting point is set either by the 
program or the user. The structure is then grown from the initial building block in 
an attempt to provide suitable interactions for both the key interaction sites of the 
receptor and region of the receptor between two key interaction sites. The main 
problem for the de novo design algorithms is how tackle the combinatorial 
explosion. In fact, it is easy to imagine how many different structures can be 
generated also in a small binding site by using only few fragments. Therefore, 
methods for a fast evaluation of the partial solutions (e.g. solutions satisfying only 
two key interactions sites) and thereby drive the search were needed.  
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Figure 30: Principle of structure-based ligand design (adapted from [317]). a) determine the 
interaction points; b) place the fragments; c) place the first fragment; d) grow strategy; e) link 
strategy. 
 
Four different approaches to tackle this problem were developed: the breadth-
first strategy, the depth-first strategy, Monte-Carlo methods, and the use of 
evolutionary algorithms. A breadth-first strategy (Figure 31) retains all partial 
solutions at one level of the search space graph and explores, sequentially, other 
levels until each of these paths reaches an end state. During a breadth-first 
search all nodes are systematically examined so that identifying the optimal 
solution is guaranteed. This exhaustive procedure is very time consuming and 
therefore only implemented in software using the linking sampling method of 
already positioned fragments. Thereby it deals with a relatively small 
combinatorial space (only different linkers are available), making this approach 
applicable. In contrast, the depth-first strategy (Figure 31) retains only one of a 
variety of possible partial solutions at each of the search space graph, until an 
end state is reached. The choice of the single retained partial solution can be 
guided by its score, by chance or by a combination of both. The third approach is 
bases on random sampling (Monte-Carlo) usually controlled with the Metropolis 
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criterion. In this procedure, after each structure-modification step, the change is 
evaluated to decide whether it is accepted or rejected. If the modification results 
in an energetically more favorable candidate compound, it is immediately 
accepted. If, on the other hand, the modification yields to a candidate compound 
with higher energy, it can still be accepted with a probability that is based on the 
scoring function difference between the modified and unmodified structure and a 
random number. This approach is for instance implemented in AlleGrow 
[318,319], the de novo design software used for this work and will be presented 
in detail in Chapter 3.1.2.1. The fourth approach to tackle the problem of 
combinatorial explosion is to make use of evolutionary algorithms. Candidate 
compounds are represented as individuals of a population, their suitability is then 
evaluated by a so-called fitness function that determines which structures are 
chosen as parents for the next generation. 
Once the target number of structures required has been generated, the 
candidate compounds are usually sorted by a scoring function and visually 
inspected by the user, which identifies the most promising ones for other runs of 
de novo design or synthesis. The newest software, as for example Skelgen 
[320,321], incorporates not only typical scoring functions to rank the obtained 
compounds, but also the possibility to rank them by their physico-chemical 
properties and/or by their chemical feasibility, thereby simplifying the choice for 
the user. 
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Figure 31: Tree model of search space exploration by an automated structure generation 
method. A binding pocket and predicted key interaction points are given as an input (entry state). 
In this example, key interaction points are pharmacophore points at which light blue circles 
indicate sites for a ligand hydrogen-bond donor, dark blue for hydrogen-bond acceptor, and 
orange for lipophilic ligand parts. Candidate compounds are assembled by growing. In the 
example some partial structure are rejected due to bondary violation (Level 1 and 2) or due to 
Binding pocket
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mismatching interaction type (Level 2). Two partial solution emerge from Level 1. A breadth-first 
search would follow both nodes in the search graph simultaneously, whereas the three shown 
here selects a single node for expansion (depth-first search). The picture is adapted from [317]. 
 
 
2 Aim of the thesis 
 
E-selectin, a member of a family of cell-adhesion proteins, which plays a crucial 
role in many physiological processes and diseases [1], and in particular, in the 
early phases of the inflammatory response. Its role is to promote the tethering 
and the rolling of leukocytes along the endothelial surface [2]. These steps are 
then followed by integrin-mediated firm adhesion and final transendothelial 
migration. Henceforth, control of the leukocyte-endothelial cell adhesion process 
may be useful in cases, where excess recruitment of leukocytes can contribute to 
acute or chronic diseases such as stroke, reperfusion injury, psoriasis or 
rheumatoid arthritis [3]. In this work, our efforts to develop in silico-based 
protocols to study the interaction between E-selectin and its ligands, will be 
presented.  
First, different protocols, established as a part of this work to accomplish this 
task, will be illustrated and discussed. Particular importance will be given to the 
development of protocols for the analysis of the conformational preferences of E-
selectin antagonists, and to the generation of QSAR-models using Quasar [270–
272,351] and Raptor [315,316,335]. Hence, conformational issues seem to play a 
fundamental role to determine the affinity of the ligands towards the target protein 
(cf. Chapters 1.5.2, 1.5.3). Moreover, the derivation of QSAR-models will permit 
to have at disposition an efficient tool for a preliminary in silico affinity estimation 
of new designed ligands.  
Second, the application of the developed protocols to the design of new E-
selectin antagonists will be debated. 
 
 
3 Material and Methods 
 
3.1 Material 
 
During this thesis various computer systems and software were used. Detailed 
are given in Table 5. 
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Table 5: Overview of the computer, operating systems and software used. 
 
Computer 
Model Processor Memory 
Operating 
System 
Modeling 
Software 
Macintosh 
PowerBook G4 
PowerPC G4 
(2.1) 667MHz 512MB 
OSX 10.2.1-
10.3.8 
Yeti 6.0–6.6 
Excel 
Macintosh 
Power Mac G5 
Dual PowerPC 
G5 (2.2) 1.8GHz 1GB OSX 10.3.2 
Yeti 6.0–6.6 
Raptor 1.2 
Quasar 5.0 
AMBER 7.0 
Pymol 0.98 
Macintosh 
Power Mac G4 
PowerPC G4 
(2.1) 400MHz 384MB OS 9 Yeti 6.0 
Dell PrecisionTM 
Workstation 650 
Dual Intel® 
XeonTM 2.8GHz 1GB  Red Hat 8.0 
AMBER 7.0 
MOPAC 6.0 
VMD 1.8.2 
Plotamber 0.55 
Cronos Linux 
Cluster (for 
more details see 
Pic XX) 
76x Intel® 
XeonTM 2.4GHz 
2GB for each 
node Red Hat 8.0 AMBER 7.0 
Silicon Graphics 
Workstation 
Octane 
Dual 250 MHz 
MIPS R 10000 1.2GB IRIX 6.5 
MacroModel 5.0 
Rfitmm 
PrGen 2.1 
AMSOL 5.4.1 
AMBER 7.0 
QXP 
Allegrow 
Dell PrecisionTM 
Workstation 530 
Dual Intel® 
XeonTM 2.4GHz 1GB  Windows XP 
Samoa 0.98 
 
 
3.1.1 Software 
 
In this section all software used in this work will be introduced. The detailed 
protocols applied, are instead presented in Chapter 3.2. 
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3.1.1.1 Allegrow/QXP 
 
Allegrow [318,319] allows to generate hypothetical ligands with topological and 
chemical complementarity to the three-dimensional structure of a host target 
protein, starting from a growing point of a known ligand or of a fragment 
previously docked in the binding site or from an experimentally determined 
structure. The molecules are generated in the host-binding site fragment by 
fragment, atom or functional groups. At each step the position and type of atom 
to be added is randomly selected from a set of possible fragments, which are 
consistent with internal bond lengths and bond angle requirements as well as the 
spatial and chemical properties of the binding site. The selection is achieved 
using Boltzmann statistics to enhance the acceptance towards atoms, which can 
form favorable interactions with the binding site. Atoms, which are less 
complementary to the binding site will also be chosen but with a low probability. 
This allows ligand structures to be formed in which groups of atoms with 
favorable interactions can be connected by atoms, which are less 
complementary, driving however the search towards overall higher 
complementary ligands. Another important feature of Allegrow [318,319] is its 
ability to connect a newly generate atom to a previously grown atom in the 
growing structure. In that way, rings can be obtained by connecting closely 
previously positioned non-bonded atoms. Conformationally restricted molecules 
may thereby be obtained, having a favorable entropic effect on the binding 
energy. The Boltzmann-driven process ensures that a highly diverse set of 
molecules is generated unbiased by previously generated candidate structures. 
After this generation step, the obtained molecules are analyzed automatically to 
avoid duplicates and structure with too high conformational strain energy. Those 
are eliminated and the remained solutions minimized with the QXP force field 
[319], and finally sorted by a means of a scoring function [318,319]. Technical 
details are given in [318,319]. 
 
3.1.1.2 AMBER 7.0 
 
AMBER 7.0 [322] is one of the worldwide most used packages and includes a 
suite of programs (MM, MD, FEP, GIBBS, ptraj,…). In this work, it was 
exclusively used to perform MD simulations in explicit solvent [323]. The 
programs used include: antechamber (ligand preparation) [324], Leap (ligand and 
target preparation) [322], sander (minimization and molecular dynamic 
simulations) [322], and ptraj (analysis) [325]. The description of the protocols 
used to investigate the conformational preferences of E-selectin antagonists and 
the stability of E-selectin complexes are described in the Chapters 3.2.3.2 and 
3.2.6. 
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3.1.1.3 AMSOL 5.4.1 
 
AMSOL 5.4.1 [326] permitted to calculate CM-1 charges [327] and solvation 
energies. The calculations were performed at the Biographics Laboratory 3R 
[328]. 
 
3.1.1.4 Excel 
 
Excel was used to analyze the results of the MD simulations and of the 
conformational studies. 
 
3.1.1.5 MacroModel 6.5 
 
MacroModel 6.5 [169] was used to generate the 3D-structure of all E-selectin 
antagonists studied, to perform conformational searches (CS) and Jumping 
between Wells (JBW) simulations (cf. Chapter 3.2). 
 
3.1.1.6 MOPAC 6.0 
 
MOPAC 6.0 [329] was used to calculate AM1-BCC charges [330] or MNDO-ESP 
charges [331]. The last were kindly generated at the Biografics Laboratories 3R 
[328]. 
 
3.1.1.7 Plotamber 0.55 
 
This program [332] permits to extract the information contained in an AMBER-
output file into a text-file, which can then be imported into Excel and used to plot 
for instance the course of the energy of the system during an MD simulation. 
 
3.1.1.8 PrGen 2.1 
 
PrGen 2.1 (Pseudoreceptor Generator) [333] was mostly used to prepare the 
compounds for receptor modeling studies or docking studies. In particular, for 
performing their alignment and to assign the entropy (TΔS) change upon ligand 
binding of the individual ligands. The preparation included also renaming of the 
ligands, assigning force-field types and adding the experimental binding energies 
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(IC50). Additionally, the software gives the possibility to prepare runfiles for 
AMSOL- [326,327] or MOPAC-calculations [329–331]. PrGen [333] dealt also as 
“converting platform”. The software was often applied to convert files in 
MacroModel format into files in PDB- or PDB-extended-format. 
 
3.1.1.9 Pymol 0.98 
 
Some pictures within this thesis, were generated with Pymol [334]. 
 
3.1.1.10 Raptor 1.2 
 
Raptor [315,316,335] was applied to generate models for the prediction of the 
relative free binding energy of ligands. It is based on a multi-dimensional 
quantitative structure-activity relationship. In addition to the usual 3D structure-
activity relationship, a fourth dimension accomplishing for the induced-fit 
phenomena is introduced. Hence, induced fit is explicitly and anisotropically 
allowed by a dual-shell representation of the receptor surrogate. The scoring 
function treats solvation effects implicitly and is therefore independent from 
partial-charge models. Moreover, Raptor [315,316,335] offers the possibility to 
define a threshold for the weak binders. This function allows gaining valuable 
information from the weak binders ligand molecules about the binding site of the 
protein without punishing the prediction of weaker binding than experimentally 
measured. A scramble test verifies the biological significance of the generated 
model [338]. More information about the software can be found in [315,316,335]. 
 
3.1.1.11 Rfitmm 
 
Rfitmm [336] is a in-house developed software that permits to superimpose the n 
best conformers of a structure obtained from a conformational-search study 
performed with MacroModel [169] and sort them energetically. 
 
3.1.1.12 Samoa 0.98 
 
Samoa [337] is a piece of software developed at the Institute of Molecular 
Pharmacy by Samuel Schmid. A detailed description of the program can be 
found in his thesis [337]. In this work, it was mainly used for analytical purposes 
(Φ/Ψ-plots, 3J-coupling calculations out of MD simulations, tracking of distance or 
angles over the simulation time,…) and to automatically generate the command 
files for the JBW/SD-simulations (cf. Chapter 3.2.3.1). 
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3.1.1.13 Quasar 5.0 
 
The software was used to generate a receptor model for E-selectin. Quasar 
[270–272,351] – a receptor-modeling concept developed at the Biographics 
Laboratory 3R [328] – is based on 6D–QSAR combined with a directional force 
field and explicitly allows for the simulation of induced fit. In generates a family of 
quasi-atomistic receptor-surface models that are optimized by means of a 
genetic algorithm [338, 339]. This evolution is driven by the lack of fit (LoF) 
function. Based on this function, two individuals of the population with the highest 
LoF – considering the number of properties mapped onto the surface, the 
similarity of the models and the specificity of the conformer selection – are 
discarded at the end of every crossover to improve the cross-validated r2 ( q2) 
of the training set. The hypothetical receptor site is characterized by a three 
dimensional surface which surround the ligand molecules at van der Waals 
distance and which is populated with atomistic properties mapped onto it. The 
topology of this surface mimics the three-dimensional shape of the binding site: 
the mapped properties represent other information of interest, such as 
hydrophobicity, electrostatic potential, and hydrogen-bonding propensity. In 
Quasar [270–272,351], the fourth dimension ( 4D–QSAR) refers to the 
possibility of representing each ligand molecule as an ensemble of 
conformations, orientations, and protonation states, thereby reducing the bias in 
identifying the bioactive conformer. Within this ensemble, the contribution of an 
individual entity to the total energy is determined by a normalized Boltzmann 
weight. In contrast to other concepts in the field, Quasar [270–272,351] allows for 
the explicit simulation of induced fit. The algorithm allows simultaneously 
evaluating of different induced-fit scenarios ( 5D–QSAR). Presently, those 
include a linear fit, an adaptation based on the total interaction energy as well as 
four protocols reflecting the steric, electrostatic, hydrogen bond and lipophilic 
potential, respectively. Solvation phenomena – such as ligand desolvation, 
solvent stripping or shielding effects – may jeopardize an otherwise robust 
simulation as they directly (solvation term) or indirectly (induced-fit component) 
contribute to the calculated binding affinity.  
In Quasar [270–272,351], this quantity based on a directional force field 
[248,341] is determined as follow: 
 
Ebinding = E(force field) + Epolarization – E(ligand desolvation) – TΔSbinding – ΔE(internal strain) – E(induced fit) 
(Eq. 4) 
 
Free energies of ligand binding ΔGpred, are then predicted by means of a linear 
regression between ΔGexp and Ebdg using the molecules of the training set:  
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ΔGpred = |a| ∗ Ebinding + b (Eq. 5) 
 
The sixth dimension ( 6D–QSAR) allows for the simultaneously consideration 
of different solvation models (e.g. degree of desolvation, contribution of different 
protonation states). In addition, it may be used to scale the influence of entropy 
to ligand binding and internal strain in an unbiased fashion. 
The correlation coefficients are q2 (cross validated r2) for the training and p2 
(predictive r2) for the test set. Ideally they reach the value of one. Another 
parameter describing the quality is the root mean square deviation (rms), which 
should approach zero. The quality of the prediction is validated using an external 
set of compounds ( test-set). For this purpose experimentally measured 
binding affinity of the ligands are required. Best predictions of the binding 
affinities were obtained with a large set of molecules in combination with a ratio 
of 3:1 for training- and test-set. 
To verify the sensitivity towards the biological data, the experimental binding 
affinities are scrambled and the simulation is repeated otherwise identical. A 
scramble test with comparable results to the predicting test indicates an apparent 
good model worthless [338]. 
The program allows for a functional-group analysis that identifies the individual 
contribution of common functional groups of the compounds to the binding affinity 
— a useful tool for further developing of high-affine ligands. 
As any QSAR study, Quasar [270–272,351] is typically only applicable within a 
series of related structures, which implies that QSAR models are restricted to a 
specific field of research. 
 
3.1.1.14 VMD 1.8.2 
 
VMD (Visual Molecular Dynamics) [341,342] is a molecular graphics program 
designed for the interactive visualization and analysis protein-ligand complexes. 
The software is able to read in different formats of molecular trajectories and to 
visualize MD simulations. It gives thereby the possibility to generate movies or 
still pictures that are useful for the characterization of the ligand and/or protein 
motion. Moreover it can be used to monitor distances, angles or dihedrals over 
the time. 
 
3.1.1.15 Yeti 6.0-6.6 
 
Yeti [248,352] is a molecular-mechanics program developed by Vedani and 
Huhta to optimize metalloproteins complexed with small molecules. Its main 
purpose is the minimization of molecules and complexes. In this work, the Monte-
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Carlo minimization protocol with Boltzmann sampling was used to identify the 
various conformations of the ligand molecules at the binding site and to obtain 
thereby the most feasible docking mode. The energetically most feasible pose 
was then usually submitted to MD or used for receptor-modeling studies. 
 
3.2 Methods 
 
3.2.1 Data Flow, Strategy 
 
The data flow and the strategy adopted during this thesis is presented in Figure 
32. 
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Figure 32: Schematic representation of the strategy adopted in this work and of data flow. 
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3.2.2 Ligand design with MacroModel 
 
The three-dimensional structures of all the ligands studied, was generated using 
MacroModel 6.5 [169] and optimized in aqueous solution [171] on the basis of 
the improved AMBER 4.0 force field for carbohydrates published by Still [170] 
and partially modified by Kolb and Ernst [161,168]. In principle all structures 
should be submitted to an exhaustive conformational search (CS) but that would 
have been too time consuming. It was therefore decided to execute such a 
protocol only with selected molecules (cf. Appendix 1) representing thereby most 
of the structural variety of the E-selectin antagonists possible. All other structures 
were generated taking advantage of structural similarity, by using the output of 
those CS-studies as a starting point for the new molecule instead. After the 
necessary small modifications, the new compound was optimized keeping 
thereby the common scaffold rigid. 
 
3.2.3 Conformational analysis 
 
3.2.3.1 Conformational analysis using MacroModel 
 
The method is based on the “Jumping between Wells/stochastic Dynamics” 
(MC(JBW)/SD) algorithms [161,168] and the systematic pseudo-Monte-Carlo 
(SUMM, systematic, unbounded multiple minimum search) simulation technique 
[231] . A graphic summary of the method is presented in Figure 33.  
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Figure 33: Analysis of the potential energy surface with the (MC(JBW)/SD)-technique.  
 
First, the locations of the most relevant energy minima (conformations) of a 
compound were determined in an internal coordinate systemic pseudo-Monte-
Carlo SUMM simulation [231]. The number of steps performed, were of 2000 for 
each free-rotatable non-terminal bond. At the end of this pseudo-Monte-Carlo 
step, only structures within a 20 kJ/mol from the energy of the global minimum 
were retained. The shape of the potential energy surface was then probed in a 
subsequent MC(JBW)/SD simulation which used the information obtained in the 
SUMM analysis. Thus, a Boltzmannn-weighted ensemble of states was 
generated in a 10ns MC(JBW)/SD simulation by jumping between different 
energy wells, i.e. the energetically best 100 conformations found in the preceding 
SUMM analysis, and performing stochastic dynamics simulations within each 
well. All calculations were performed with an AMBER force field augmented by 
paramters for carbohydrates [161,168,170] and in conjunction with the GB/SA 
continuum water model [171]. As a result, the distribution of the conformers of 
the structure of interest in respect to the whole conformational space was 
obtained. The exact setting of this kind of simulations can be seen in the 
commented command-files of the two steps presented in the Appendix 2. The 
command file for the JBW/SD-step was automatically generated by SAMOA 
[337]. 
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3.2.3.1 Conformational analysis using AMBER 
 
The AMBER-based protocol used to study the conformational behavior of the E-
selectin antagonists is based on the methodology published by Weimar and 
Woods in the chapter “Combining NMR and Simulation Methods in 
Oligosaccharide Conformational Analysis” of the book “NMR Spectroscopy of 
Glycoconjugates” [343]. The flow chart of this method is presented in Figure 34. 
 
Figure 34: Flow chart of the AMBER-based protocol. This procedure bases on [343]. 
 
Preparation of the ligands 
As a starting point of my procedure, a MacroModel-minimized structure of an E-
selectin antagonist was always used. As a first step, the structure of the 
compound of interest was converted to the PDB-format using PrGen [333]. 
Further, the atom-type of the molecule were manually altered to comply with the 
AMBER-convention, the structure processed with Antechamber [324], and 
atomistic partial charges (AM1-BCC) [330] calculated with MOPAC 6.0 [329]. At 
this stage, the atom-types of the glycosidic oxygen atoms, of the oxygen atoms 
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of 1C4 chair systems, and of the anomeric carbon atoms were changed to fulfill 
the GLYCAM 2000 [344] requirements. The obtained structure was then read in 
Leap, where it was checked for consistency. In case of missing force-field 
parameters, those were added to the GLYCAM-parameter file. A list of the 
parameters added to the original GLYCAM-parameter file can be found in the 
Appendix 3. When all the needed parameters were available, the ligand was 
solvated [345], and if appropriate counter-ions added. All the studies were 
performed with the ligand placed into a 20 Å broad pre-equilibrated box of TIP3P 
water molecule. The topology- and the coordinate-files of the solvated ligand 
were saved and used as an input of “real” investigation protocol. 
 
Minimizations and MD (Figure 34) 
First, an AMBER restart file was generated (cf. Appendix 4: getrst.in). This file 
served as a reference structure during the first minimization step (cf. Appendix 5: 
minres.in), where only the position of the pre-equilibrated water molecules was 
optimized. As a second step, a 150 ps simulated annealing protocol (cf. 
Appendix 6: annealingNEW.in), involving once again only the solvent was 
applied. In this step, the temperature of the system was raised during 50 ps from 
100 K to 300 K and then, after 50 ps at this temperature, cooled back to 100 K. 
The obtained system, formed by the molecule of interest, the 20 Å water box, 
and the counter ion, was then further minimized without this time any constraints 
(cf. Appendix 7: minAN.in) and finally submitted to a long simulated annealing 
protocol (cf. Appendix 8: ANallinone.in). This final step consisted of first period of 
50 ps, where the temperature of the system was raised from 100 K to 600 K, a 
second period lasting 200 ps at 600 K, a third one where the system was cooled 
down to 300 K followed by the first sampling phase at 300 K lasting one 
nanosecond, a new warming phase to 600 K of 50 ps, a second period of 200 ps 
at this high temperature, the second short (50 ps) cooling phase and by the final 
sampling period lasting again one nanosecond. In some cases the protocol was 
performed over only 1.3 instead of 2.6 ns. 
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3.2.4 Preparation steps for the Docking-, MD-, and QSAR-studies 
 
3.2.4.1 Protein preparation for the Docking-, MD- and QSAR-studies 
 
The protein structure co-crystallized with sLex (RCSB Protein Data Bank [346] 
code: 1G1T, resolution: 1.5 Å) solved by Somers et al. [166] was retrieved from 
the RCSB Protein Data Bank [346] and intensively investigated (B-Factors, 
protonation states of histidines, analysis of the electron-density map,…). The file 
was then read in PrGen [333] where: 
• The crystallographic water molecules were deleted 
• The polar hydrogen atom added.  
• The complex subsequently saved in pdb_extended format (the atomic 
charges [327] and the solvation energy for the ligand where computed 
with AMSOL [326]) and handle over to the software Yeti [248,352].  
 
Here, a first minimization of all rotatable polar H-atoms, followed by a full 
minimization of the complex was performed. This relaxed structure was then 
used as reference for all the following experiments.  
 
3.2.4.2 Ligand preparation for the Docking-, MD- and QSAR-studies 
 
The steps needed to prepare the ligands for docking-, MD-, or QSAR-studies that 
will be presented here, can be graphically followed on Figure 32.  
The minimized structures in MacroModel-format were read in PrGen [333] and 
aligned with respect to the experimental conformation of sLex bound to E-selectin 
[166] after the minimization described above (cf. Chapter 3.2.4.1), using the three 
O-glycosidic atoms as reference points. The superposition was further improved 
by manually adjusting the hydroxyl groups essential for binding (Gal–6OH, Gal–
4OH, Fuc–4OH, Fuc–3OH) to obtain a common hydrogen-bonding pattern. To 
simplify the analysis of the computational experiments the ligands were renamed 
by applying a three-letter code (cf. Appendix 9). Next PrGen [333] was then used 
to calculated the entropy (TΔS) penalty for each ligand, to assign the atom types 
and to read in the individual experimental binding energies of every ligand. 
Ligand files containing ester and/or nitro groups had to be manually assigned 
special force-field types. In fact, it is known [347], that these atoms behave 
particularly with respect to hydrogen-bond formation. Therefore, the force-field 
atom type of the ester oxygen had to be changed to OX (from OE) and to ON 
(from O2) for both the oxygen atoms of the nitro-group.  Further, runfiles for 
atomic charge calculation with AMSOL [326,327] and MOPAC [329,331] were 
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prepared. The following steps were the charge calculation performed with 
AMSOL [326,327] or MOPAC [329,331] respectively, and the computation of the 
solvation energies done by AMSOL [326,327]. Finally, the ligand files containing 
coordinates, charges and energy terms such as solvation, entropy and 
experimental binding energies was saved and then used for the docking- and the 
QSAR-studies. In contrast, file for MD-studies were saved in standard format 
(PDB). 
The experimental binding energies, which are necessary for any QSAR study 
were calculated according to Equation 6 using the IC50 data available in house 
(cf. Appendix 9). All the concentrations are measured in mM. If no exact IC50 was 
specified, the value was set to 20 mM for >10 and to 7.5 mM for >5. In the case 
of a multiple-entry of the ligand in the database, the averaged IC50 was used. 
 
ΔG = R • T • lnIC50 (Eq. 6) 
 
3.2.5 The docking protocol 
 
3.2.5.1 General procedure 
 
Before running any minimization, the force-field parameter database had to be 
augmented to include all specific parameters for the studied ligands – most 
particularly, 1–4 (torsional) interactions (cf. Appendix 10). Next, the ligands were 
manually docked into the binding site of E-selectin and minimized using 
constraints (corresponding to those in the experimental structures [166]) 
specified in the Appendix 11 to get an ideal starting position for the MC-
minimization. The minimization of the complex was performed over three steps: 
first, only the ligand was minimized (the protein was kept rigid, zone 0.0 Å), then 
the ligand and an eight-angstroms zone surrounding it were optimized and finally 
the whole complex was relaxed. The obtained structure was then used as a 
starting point for the MC-minimization with Boltzmann sapling, which was carried 
out without constraints. The Fuc–4OH was chosen as the center of rotation for 
the MC-sampling to avoid unreasonable starting structures. This atom was 
therefore used as the reference to position and orient the compound during each 
Monte-Carlo round assigning new starting coordinates. The weighting for the 
energy components hydrogen-bond and metal-interaction was set to 1.2, which 
means that they are considered more in the selection process. This value 
resulted to be the more suitable from a series of pre-experiment (data not 
reported here). The criteria to be fulfilled for a structure being accepted for the 
Boltzmann-sampling step was set to a maximal energy difference of 0.6 kcal/mol 
between the starting structure and the actual lowest energy solution. If none of 
the starting structures could fulfill the criteria, the software automatically save the 
structure with the lowest starting energy. The sampled structures were written out 
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at a frequency of ten rounds. Thus, from a MC-minimization of 2,000 rounds 200 
different local minima conformations were saved. More details on the setting of 
MC-minimization with Boltzmann sampling are given in the Appendix 12. This 
procedure was applied to 181 ligands carrying CM-1 charges [327] and to 16 
ligands (out of the 181) carrying ESP-MNDO charges [331] so that also the 
influence of different charges-calculation methods on the MC-protocol could be 
evaluated. 
 
3.2.5.2 Solvation docking 
 
To investigate the effect of solvation on the minima search, 12 minimized 
complexes (result of the general docking procedure, Chapter 3.2.5.1) featuring 
CM-1 [327] charges  (for details on the ligand structures refers to the Appendix 9 
and 13) were solvated and further minimized. Water molecules including single 
hydrogen-bonded waters were therefore generated within a distance of 8 Å 
around the ligands using the standard water-cavity scan implemented in Yeti 
[248,352]. After a first minimization step, where only the water molecules were 
minimized, a full minimization of the complexes followed. The different 
parameters needed for a correct simulation, were set at the same values 
described in the docking general procedure. 
For ligand 82 a different protocol to further study the effect of solvation was 
choose. In this case, the complex was solvated and minimized before applying 
the MC-protocol. 
 
3.2.6 Molecular-dynamics simulations of protein-ligand complexes 
 
The starting structure taken for MD-studies was always the most energetically 
favorable solution obtained from the docking protocol described in Chapter 
3.2.5.1. 
The pdb_ext file of the complex was then manually converted to the AMBER_pdb 
format. The ligand was extracted from this file and submitted to the ligand routine 
described in Chapter 3.2.3.2 with the difference that prior to solvation the ligand 
structure was re-integrated in the file of the E-selectin complex. The whole 
complex was then placed in a 14 Å wide pre-equilibrated TIP3P water box and 
counter-ions were added to the system. The topology- and the coordinates-file of 
the solvated complex were saved and used as an input for a first minimization 
step (cf. Appendix 14 minresCPL.in), where the solute was kept rigid. After 
minimization the complex was submitted to the same protocol described in 
Chapter 3.2.3.2 (Figure 32) to, first, optimize the position of the water molecules, 
and then relax the full system. Finally, instead of being submitted to the 
simulated annealing protocol as it happens for the ligand alone (cf. Chapter 
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3.2.3.2), the complex was heated up from 100 K to 300 K, where a sampling 
period of at least one nanosecond followed (cf. Appendix 15 md.in). 
 
3.2.7 QSAR studies 
 
3.2.7.1. Quasar 
 
Receptor generation with Quasar [270–272,351] was carried out with 181 
ligands, which were divided into a training- and a test-set. Indeed, four different 
set of 181 ligands were independently used for the derivation of a QSAR-model. 
Namely models were derived with: a first set of ligands presenting CM-1 charges 
[327] and coordinates obtained from a pharmacophore-based alignment of the 
ligands on sLex as found in the E-selectin crystal structure [166], a second one 
carrying the same charges but coordinates obtained after the MC-procedure, a 
third and a fourth one presenting ESP-charging [331] and either coordinates from 
the alignment- or MC-procedure.    
After creating the three-dimensional surface, the ligands individual envelopes 
were generated using all of the six different induced-fit scenarios (module 
Envelope). In search of a consistent QSAR-model, which could predict the 
binding affinity towards E-selectin in good agreement with the experimental data, 
the following parameters were varied:  
• Population size 
• Solvation energy and partial-charge equalization 
• Esolv attenuation factor 
• Dynamic surface area 
• H-bond radii 
• Number of cross-overs 
 
The obtained models were rated on the basis of q2, p2, and rms values. The best 
models were also subjected to a scramble test [338] to assess the sensitivity of 
the model towards the biological data. 
 
3.2.7.2 Raptor 
 
 For our best Quasar models (Q15 and Q21) Raptor [315,316,335] was used to 
generate others QSAR-model based on a different technology. In fact, the 
possibility of two different methods to similarly predict the affinities towards E-
selectin of the same set of ligands, would bring us this consensus-scoring that is 
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nowadays emerging as state of the art in QSAR [273–282]. To achieve that, 
Raptor-models were generated using always ten individual models. For both 
ligands-sets the model generation was performed with and without enabling a 
threshold at 10 mM, to punish the prediction of weaker binding of the “non-
binders” (IC50 > 10 mM) differently. Finally, the sensitivity towards the biological 
data was tested with a scramble test [338]. 
 
3.2.8 De novo design 
 
The de novo design software Allegrow [318, 319] was used to develop new E-
selectin antagonists based on the structure of the previous identified potent 
ligand 26 (Figure 35).  
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Figure 35: The chemical structure of compound 26. 
 
After a detailed analysis of the E-selectin binding site, it was decided to extend 
the ligand towards the pocket defined by the Lys111–113, Pro46, Tyr44, Tyr48, 
starting from one of the hydrogen atoms attached to the carbon atom at the 
position six of the galactose moiety of 26 (Figure 36).  
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Figure 36: Compound 26 docked onto the surface of E-Selectin. One of the hydrogen atoms 
attached to the carbon atom at the position six of the galactose moiety was chosen as starting 
point for the generation of new ligands extending in the pocket defined by the amino acids 
Lys111–113, Pro46, Tyr44, and Tyr48. 
 
The starting point for the design was structure 26 docked onto the E-selectin 
surface as obtained from the docking studies. This complex was read in Allegrow 
[318,319] and prepared for the “grow-procedure”. In particular, all protein 
residues, excepted Lys111–113, Pro46, Tyr44, and Tyr48, which were colored 
blue (flexibility of the side chains), were colored red (rigid), whereas all the ligand 
atoms were colored green. The calcium ion was colored yellow and connected by 
so-called bonds of order zero, to its coordination partners (cf. Chapter 1.5.5). The 
atom-type of one of the hydrogen atoms attached to carbon at the position six of 
galactose was changed to X, thereby indicating to the software, which the “grow-
atom” would have been. Finally, all residues located more than 12 Å from the 
ligand were deleted and the new structure saved. Subsequently, the grow-routine 
was started: 3 x 2,000 structures (using the three different fragment libraries at 
disposition: basic, normal, full) with a minimum of 6 atoms more added to a 
maximum of 12 atom added were generated and scored by the post-grow 
scoring-function [318,319]. The more potent ligands were visually inspected. A 
selection of the chemical more feasible compounds was done. In the end, a 
second “grow round” followed and the same analysis performed. Based on the 
                                                                                                                                                                                                                          
                                                                75
   
obtained structures the synthesis of a small library of compounds was planned 
(cf. Chapter 4.7.2.2). 
 
3.2.9 Analysis of the results 
 
The data produced was mostly analyzed with Excel and Samoa [337]. For the 
results generated with AMBER [322] (Conformational searches or MD of E-
selectin complexes) a prior extraction of the data from the trajectory- and/or 
output-files with Plotamber [332] and ptraj [325] was necessary.  
All the Φ/Ψ- and acid/core-plots were generated with Samoa [337], whereas the 
graphics tracking energy-, angles-, torsion, or distance-values over the time were 
obtained with Excel. Moreover, Samoa [337] permitted to calculate the 3J-
coupling constants and to extract important geometrical features (like torsion-
angles values,…) from both (MC)JBW/SD- and MD-simulations. Finally, VMD 
[341,342] and Pymol [334] were used to produce the necessary movies and 
pictures for the analysis of the results. 
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4 Results and Discussion 
 
4.1 Sampling conformational space of E-selectin antagonists:   
      development of a new protocol 
 
The conformational equilibrium state of a molecule in aqueous solution plays a 
determinant role for its affinity towards a target protein. It is assumed that the 
biological activity of a drug molecule depends on one single, unique conformation 
(the bioactive conformation), which is part of the low-energy conformational 
ensemble [217]. Moreover, it is known that compounds pre-organized in their 
bioactive conformation will show a higher affinity towards the target protein due 
the lower entropic cost they have to pay upon binding (cf. Chapter 1.7.1). The 
investigation and design of pre-organized E-selectin antagonists has become 
one of the major tasks at the Institute of Molecular Pharmacy. In 1997, Kolb and 
Ernst [161,168] presented a molecular-modeling concept for the investigation of 
the conformational behavior of E-selectin antagonists. This method, already 
described in Chapters 1.5.3 and 3.2.3.1, permits to semi-quantitatively determine 
the binding affinity of different compounds towards E-selectin by analyzing their 
conformational equilibrium in water: molecules showing a conformational 
distribution concentrated in the region of the known bioactive conformation of 
sLex, have been shown to be more active than less pre-organized ligands. For 
the following reasons, this method might not be perfectly suited for our system: 
 
1) The fact that only 100 structures (out of several thousands as obtained 
from the conformational search) can be used as an input for the JBW-
stochastic dynamics (SD) simulation represents a technical limitation. 
Consequently, the choice of the energy wells that will be investigated in 
the SD is biased (cf. Chapter 3.2.3.1, Figure 33). This restriction may lead 
an uncomplete sampling such as in the case of 71. As can be taken from 
Figure 37(a), 600 conformations of 71 could be identified within 20 kJ/mol 
from the energy of the global minimum by the conformational-search 
protocol. From Figure 37(b) it becomes evident that, after the selection of 
the 100 energetically most favorable conformations, one of the local 
minima (one of the energy wells) has been removed; its environment will 
therefore not be sampled during the (JBW)-SD simulation, leading to 
incomplete or even incorrect results (compare Figure 37(c) with Figure 
37(d), which is the results of a molecular-dynamics simulation with a 
protocol that shall be discussed below). 
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Figure 38: a) 600 conformations obtained from conformational search b) The 100 lowest-
energy conformations chosen for the JBW-SD simulation c) Results of the JBW-SD 
simulation d) Results of the MD-simulation performed with AMBER [322]. 
 
2) An intrinsic solvation model (GBSA) [171] is used. This model is not 
particularly suited to handle charged molecules like E-selectin antagonists, 
which often are. Moreover, the directionality of the hydrogen bonds 
between the ligand and the solvent cannot be treated optimally, which 
often leads to the formation of intra-molecular hydrogen bonds that, in 
solution, are probably less important because of the possibility of 
interacting with the bulk water. 
3) Unfortunately, the development of this technique has been discontinued in 
favor of the implementation of modern molecular-dynamics protocols. 
 
We therefore developed an alternative concept that could integrate the 
MC(JBW)/SD approach in the conformational analysis for the design of new E-
selectin antagonists. To tackle the aforementioned problems, we based the new 
procedure on the molecular-dynamics approach devised by Woods [343]. A 
detailed description of our new protocol is given in Chapter 3.2.3.2. 
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The main differences to the MC(JBW)/SD approach as established by Kolb and 
Ernst [161,168], are the explicit treatment of the solvent, the use of the GLYCAM 
2000 parameter-set [344] specifically designed for molecular-dynamics 
simulations of carbohydrates within the AMBER suite [322], and the overall 
tailoring of the protocol based on molecular dynamics simulations instead of on a 
MC(JBW)/SD approach. The advantages of this technique are thought to be the 
ability to overcome energy barriers by applying a simulated annealing protocol 
[232], the better treatment of the solvation effects and of the electrostatic (the 
addition of counter ions balancing the total charge of the system is possible), and 
the use of a well established parameter set under continuous extension.  
Some problems may still arise. In particular, due to the high number of rotatable 
bonds that are usually present in E-selectin antagonists, the completeness of the 
search cannot be assured in a reasonable amount of time. 
To challenge the capability of the new protocol to reproduce results achieved 
with the MC(JBW)/SD approach and confirmed by the biological testing 
[161,168], the same set of ligands (3, 5, 6, 7, 72, 73),  that was used by Kolb and 
Ernst [161,168] to validate their molecular-modeling tool was submitted to the 
new protocol and the results compared (Figure 38). An excellent agreement of 
the results could be achieved with the exception of the simulation involving sLex. 
This very result will be discussed apart (cf. Chapter 4.2). Hence, it was decided 
to implement this new technique into our research as a standard method for the 
investigation of the conformational behavior of E-selectin in water.  
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Figure 38: Comparison of the results obtained for the simulated conformational preference of the 
ligands 3, 5, 6, 7, 72, and 73 by applying the MC(JBW)/SD- (A) or the AMBER-based-protocol 
(B). 
 
Prior to that, the effects of different parameters on the simulation protocol were 
investigated. In particular, the coupling between the system and the heat bath 
(taupt-parameter) was of interest because it was known to directly affect the 
simulation results. Typically, values for taupt should be in the range of 0.5–5.0 
ps, with a smaller value providing tighter coupling to the heat bath, therefore 
resulting in a less natural trajectory. Two different values of 1.0 and 4.0 were 
tested for both the heating- and the cooling-phase (cf. Chapter 3.2.3.2) on 
several ligands (3, 4, 7, 26, 74). The results obtained for 74 (Figure 39) are 
presented in Figure 40. By comparing the results of the four MD-simulations with 
the acid-core plot obtained by the MC(JBW)/SD simulation, it becomes evident 
that the default value of 1.0 produces the more consistent results. When instead 
a value of 4.0 is applied during the heating phase, the geometry of the 
cyclohexane ring is unrealistically distorted. The default value of 1.0, was 
therefore chosen throughout all of our simulations.  
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Figure 39: Chemical structure of compound 74 
 
 
 
Figure 40: a) Simulation performed with the taupt-parameter set to 4.0 during the heating phase 
and to 1.0 during the cooling phase; b) Simulation performed with the taupt-parameter set to 4.0 
in both phases; c) Simulation performed with the taupt-parameter set to 1.0 during the heating 
phase and to 4.0 during the cooling phase; d) Simulation performed with the taupt-parameter set 
to 1.0 in both phases; e) Simulation performed with MC(JBW)/SD-approach. 
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4.2 Investigation of the conformational space accessible by sLex 
 
In the last two decades the investigation of the conformational properties of sLex 
(3) drew great interest [149–168]. Unfortunately, no consensual agreement has 
been found to date on the conformation of sLex in aqueous solution. As already 
introduced in Chapter 1.5.2.2, the dispute mainly focuses on the orientation of 
the sialic-acid moiety with respect to the Lex-core substructure. While other 
opinions exist [153], most scientists agree on the fact that the Lex-core 
substructure can be described by the following Φ−, Ψ−values (Φ1 = 30° + 10°, Ψ1 
= 30° + 10°; Φ2 = 39° + 10°, Ψ2 = 15° + 10°) (cf. Figure 8) and that it doesn’t alter 
its conformation upon binding. By analyzing more recent literature data [149–
168], three main suggestions on the conformation sLex adopt in water are found. 
They all share a similar adjustment of Lex-core but differ on the orientation of the 
sialic-acid residue:  
1) {Φ3 = –180° + 10°, Ψ3 = 0° + 10°}  
2) {Φ3 = –70° + 10°, Ψ3 = 0° + 10°} 
3) {Φ3 = –100° + 10°, Ψ3 = –45° + 10°} 
 
Having two theoretical tools at disposition that produce consistent and correct 
results when investigating the conformational behavior of various E-selectin 
antagonists (cf. Chapter 4.1), we decided to perform the very investigation for 
sLex. As already discussed in the previous chapter, the MC(JBW)/SD- and the 
AMBER-based protocol, yielded different results (Figure 41).  
 
 
Figure 41: Simulated conformational distribution of sLex in aqueous solution as predicted by the 
MC(JBW)SD-protocol (A) and by AMBER-based simulation (B).  
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By analyzing them in more detail (Figure 42), it can be observed that the 
mismatch relies on a different conformational preference of the two methods for 
the orientation of the sialic-acid moiety. The AMBER-based simulation converges 
to the minima {Φ3 = –180° + 10°, Ψ3 = 0° + 10°}, whereas the MC(JBW)/SD-
protocol tends towards the (-)-gauche minima ({Φ3 = –70° + 10°, Ψ3 = 0° + 10°}). 
 
 
Figure 42: Simulated conformational distribution around the Φ3− and Ψ3-torsion of sLe
x in 
aqueous solution as predicted by the MC(JBW)SD-protocol (A) and by AMBER-based simulation 
(B). 
 
Further investigation revealed that the potential around the torsion (C-EC-OG-
CT, Figure 43), defining the orientation of the carboxyl acid thought to be 
essential for the binding was different.  
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Figure 43: The torsion C-EC-OG-CT (GLYCAM 2000 [344] nomenclature). 
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As can be seen in Figure 44, both protocols yield a similar overall profile of this 
torsional potential but the energy barriers between the three minima ((+)-gauche, 
trans, and (–)-gauche) are quite different. Both methods identify in the (+)-gauche 
the most favorable orientation for the (C-EC-OG-CT) torsion to be assumed. 
However this conformation is never reached in the case of sLex due to steric 
hindrance (Figure 45a). When analyzing the second and third most favorable 
orientation (trans and (–)-gauche respectively), the trans state of the sialic acid is 
clearly favored over the (–)-gauche in the GLYCAM [344] parameter file by a 
factor of ten (ΔE = 1.4 kcal/mol).  
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Figure 44: Energetic profile of the potential around the torsion (C-EC-OG-CT). 
 
Even though this torsional potential is only one of the contribution to the total 
energy influencing the conformational behavior of the sialic-acid moiety, 
overweighting of the trans conformation would seem to be sufficient to explain 
the convergence of AMBER-simulations toward the trans minima. In contrast her 
to, in the AMBER force field [161,168,170] as implemented in MacroModel [169], 
the potential for the very torsion is much flatter, hence less favoring a particular 
minima. The global minima conformation ((–)-gauche conformation) as obtained 
with the MC(JBW)/SD-protocol (Figure 45b), is stabilized by an intramolecular 
hydrogen bond between the Gal–2OH and the Neu–7OH. This stabilization is not 
possible when the sialic acid assumes a trans orientation (Figure 45c) resulting in 
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a 2.0 kcal/mol higher energy. However, this interaction could also be an artefact 
generated by an overestimation of the importance of intramolecular hydrogen 
bonds when using an implicit-solvent approach. This would seem to be mitigated 
by the presence of real water molecules in explicit solvent models. Unfortunately, 
the different minima solutions obtained with our approaches reflect the two 
concepts (cf. above) and both are valid — albeit for different reasons. In fact, has 
already explained in Chapter 1.5.2.1, few and controversial experimental data 
[149-154] is available; a correct parameterization of the Sia-Gal torsions is 
therefore difficult. 
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Figure 45: The three conformations of sLex (3) representing the different minima of the potential 
around the torsion (C-EC-OG-CT). a) (+)-gauche (red = the steric clashes); b) (–)-gauche (green 
= hydrogen bond of the Gal–2OH and the Neu–7OH); c) the trans orientation 
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In 2001, Bose et al. [159] published an extension of the Karplus equation for the 
calculation of 3JC-C coupling constants (cf. Eq. 2) specifically parameterized for 
carbohydrates. We applied this equation as well as the one previously derived by 
Tvaroska et al. [158] (cf. Eq. 1) for the calculation of the 3JC-H coupling constants 
of sLex from the two MD-ensembles and compared the calculated 3J-values with 
the experimental data [167]. The results are given in Table 6.  
 
Table 6:  The 3J-coupling constants calculated from the two MD-ensembles compared with the 
experimental data [167]. Green = good agreement, orange = poor agreement, red = 
disagreement. All values are given in Hz. 
 
 
Both methods yielded 3J-coupling constants in good agreement with the 
experiment, suggesting the validity of both approaches. However, one exception 
must be noted. Particularly with the 3JC-C coupling constant defining the 
orientation the (C-EC-OG-CT)-torsion, there is a disagreement. Interestingly, 
3
JC-H
Experimental
Data
sLe
x
-JBW
(gauche)
sLe
x
-AMBER
(trans)
FucH1-GlcNAcC3 2.8 + 0.5 3.18 2.91
FucC1-GlcNAcH3 5.1 + 0.5 5.03 4.91
GalH1-GlcNAcC4 2.8 + 0.5 2.35 3.02
GalC1-GlcNAcH4 5.0 + 0.5 5.4 4.9
SiaC2-GalH3 5.4 + 0.5 5.51 5.4
3
Jc-c
Experimental
Data
sLe
x
-JBW
(gauche)
sLe
x
-AMBER
(trans)
SiaC1-GalC3 1.9 + 0.5 3.56 0.29
SiaC2-GalC2 1.8 + 0.5 0.75 1.63
SiaC2-GalC4 <1.0 1.43 0.43
GalC2-GlcNAcC4 2.9 + 0.5 3.55 3.55
GalC1-GlcNAcC3 2.3 + 0.5 1.63 1.99
GalC1-GlcNAcC5 <1.0 0.55 0.48
FucC2-GlcNAcC3 3.3 + 0.5 3.24 3.5
FucC1-GlcNAcC2 <1.0 0.37 0.2
FucC1-GlcNAcC4 2.2 + 0.5 2.1 2.01
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both calculated values differ significantly from the experiment — an important 
finding indicating that in water sLex is neither represented by 100% trans 
conformers as suggested by the AMBER-based protocol nor by 100% (–)-gauche 
as proposed by the MC(JBW)/SD-procedure. Even when calculating the 3JSiaC1-
GalC3 for the conformation representing the energy minimum hypothesized to be 
the most frequently populated by Veluraja and Margulis [154] ({Φ3 = –100° + 10°, 
Ψ3 = –45° + 10°}) a value of only 0.26 Hz is obtained. Again, this value differs 
from the experimental one (1.9 Hz + 0.5 Hz). Hence, it may be concluded that it 
is probable that in water sLex exists as a mixture of different conformations and 
not as supposed to date [150–154, 161–163] by populating a single conformer. 
As a consequence, the idea to design mimics with a pre-organized structure, and 
in particular a pre-oriented acid moiety gained importance. 
 
4.3 Comparison of two  approaches of computing partial atomic    
 charges: ESP-MNDO and CM-13  
 
For all ligands studied in this work, two methods, ESP-MNDO [331] and CM-1 
[327] were applied to compute atomic partial charges. The idea behind was to 
analyze the impact of a different atomic charge model:  
1. on the very binding mode to the target and 
2. on the development of a QSAR-model for affinity estimation.  
 
In general, the two methods yielded quite similar atomic partial charges. However 
some distinct differences were observed for certain atom types. As an example, 
Figures 46 show three representative ligands (75–77), where inequalities for the 
partial charge carried by some atoms is observed. Essential differences were 
found for nitrogen atoms (AMBER atom-type: N), chlorine atoms, and for the 
atoms within –C=N-fragments. The charge of chlorine is negative when applying 
the CM-1 [327] methodology and positive when using the ESP-MNDO [331] one. 
Moreover, according to CM-1 theory [327], the nitrogen atom in the C–N bond 
are negatively charged, whereas the carbon atom is positively charged. When 
ESP-MNDO-charges [331] are computed instead, both the nitrogen and carbon 
atoms of the C–N bond are slightly negatively charged. Thus compared to ESP-
MNDO [331], CM-1 [327] calculations led to a more polarized N–C bond. The 
dissimilarities observed probably arise from the different philosophies behind the 
two approaches. Hence, ESP MNDO [329,331] tries to reproduce the 
electrostatic potential whereas CM-1 [326,327] the dipole moment.   
                                                
3 Results of this chapter were obtained as a part of a diploma work (M. Schmid, 2004) under my   
   supervision. 
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Figure 46: The observed differences in partial atomic charges are highlighted for ligands 75–77. 
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4.4 Docking results3 
 
Prior to start our docking simulations a careful evaluation of the available 
software for the planned task was performed. Different studies [265–268,348] 
have shown that each program has its strengths and its weaknesses. At the 
Institute of Molecular Pharmacy, different pieces of software (AutoDOCK [258], 
QXP [329], and Yeti [248,352]4) were at disposition. We selected Yeti [248,352] 
because it had been specifically designed for the modeling of metallo proteins. 
Moreover, as shown by Schulz-Gasch and Stahl [265], when dealing with a 
protein bearing a high polar surface (e.g. E-selectin), software using a hard 
scoring function is needed. Yeti [248, 352], whose force field energy expression 
contains a directional term for hydrogen bonds, would seem to accomplish this 
requirement in a perfect way. Further, in some preliminary studies performed (cf. 
Chapter 4.4.1) prior to the final docking experiments, Yeti [248,352] correctly 
reproduced the binding mode of sLex as observed in the crystal structure [166] 
and showed only little dependence on “external” factors such as atomic partial-
charge models or solvation. Finally, the fact that Yeti [248,352] allows for the 
flexibility of the amino-acids side chains of the protein during the MC-searches 
was considered an advantage against other software. 
 
4.4.1 Docking preliminary studies 
 
4.4.1.1 Reproducing the docking mode sLex 
 
The first test to evaluate the performance of Yeti [248,352] was to dock sLex in its 
binding site to check if the binding mode identified by the crystal structure [166] 
could be reproduced. The protein and the ligands were prepared as described in 
Chapter 3.2.4. The ligand, bearing CM-1 atomic partial charges [327] was 
manually docked onto the E-selectin surface and submitted to the MC-protocol 
designed above (cf. Chapter 3.2.5). The energetically best solution (the ligand-
protein interaction energy was used as a criterium) obtained by this protocol, 
superimposed to the position of sLex as found in the crystal structure [166] is 
given in (Figure 47). As it can be observed only minimal differences are visible. 
An overall rms deviation of only 0.5 Å calculated. 
                                                
3 Results of this chapter were obtained as a part of a diploma work (M. Schmid, 2004) under my  
   supervision. 
4 The use of Yeti [248,352], which was provided by courtesy of the Biographics Laboratory 3R   
  [328], is kindly acknowledged.   
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Figure 47: The docked structure (green) compared to the crystal structure (red). 
 
4.4.1.2 Impact of the different partial-charge models on the docking results 
 
To study possible effects of different partial-charge models on the docking mode, 
16 ligands (cf. Appendix 16) bearing either CM-1 [327] or ESP-MNDO [331] 
charges were manually docked onto E-selectin and submitted to the docking 
protocol (cf. Chapter 3.2.5.1). The solutions are compared in Figure 48, which 
shows the superposition of the binding modes obtained with the two different 
partial-charge methods for ligands 78 and 79. As it can be seen, the binding 
mode of the ligands seems not to be strongly affected by the use of different 
partial-charge methods. A possible explanation could rely on the fact that, in 
general, the partial atomic charge differences observed (cf. Chapter 4.3), 
involves atoms not being part of the pharmacophoric groups determining the 
binding mode. It was therefore decided to perform all further docking experiments 
only with ligands carrying CM-1 charges [327], which are calculated faster. 
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Figure 48: The docking mode obtained with the two partial-charge models: ESP-MNDO [331] 
(blue) and CM-1 [327] (red) for the ligands 78 (a) and 79 (b). 
 
4.4.1.3 Impact of solvation on the docking results 
 
To check the influence of solvation on global minimum obtained from the MC-
protocol (cf. Chapter 3.2.5.1), 12 MC-minimized ligands bearing CM-1 charges 
[327] (cf. Appendix 13) were explicitly solvated as described in Chapter 3.2.5.2. A 
superposition of the minimized conformations before and after solvation provides 
information on the influence of the solvent on the global minimum identified. The 
compounds used in this study vary in lipophilic portions, backbone, as well as on 
their binding affinity to E-selectin and therefore represent a good structural 
subset to study the effect of solvation on all antagonists. In Figure 49, the 
superposition of the ligand conformations from 80 and 81 is depicted. The 
deviation between the ligand structures before and after the solvation is small 
(rms = 0.2 Å). A further investigation on the effect of the solvent on the minima 
search was carried out using 82. This ligand was docked in the binding site but 
this time the MC-protocol was applied only after solvating the protein-ligand 
complex (cf. Chapter 3.2.5.2).  As a result, the obtained conformation and the 
orientation of the ligand showed the flipping of the hydrogen bond of Gal–2OH 
and Gal–6OH and subtle deviations for the cyclohexane puckering and the 
carboxylate compared to the MC-minimized conformation without water (Figure 
50). This result confirms our hypothesis that the influence of the solvent is minor 
and that the optimized protein-ligand interactions for this system seem to be 
superior to the effects of water molecules. 
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Figure 49: Superposition of the global-minimum solution obtained for the ligands 80 (a) and 81 
(b) with (blue) and without (green) explicit solvation. 
 
 
 
Figure 50: Superposition of the global minimum solution obtained for the ligands 82 with (blue) 
and without (green) explicit solvation. 
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4.4.2 General docking results 
 
Our simulation yielded a binding pattern similar for all ligands, showing a binding 
mode similar to the one of sLex as found in the crystal structure [166]. This was 
expected since all compounds are quite similar to sLex (cf. Appendix 9). By 
looking at the superposition of the 200 conformations of each molecule populated 
during the sampling procedure (cf. Chapter 3.2.5.1) only slight differences could 
be observed (Figure 51). They frequently arise from the different orientation of 
side chains or from a slight translation (0.1-0.4 Å) of one of the sugar rings 
(Figure 52). Thus, it appears that E-selectin antagonists prefer a very conserved 
and unique binding mode. In particular, the importance of pharmacophoric 
groups (Fuc–4OH, Fuc–3OH, Gal–4OH, Gal6–OH and the acid moiety of Sia) 
could be confirmed. Hence, the absence of one those groups lead to lower Elig-rec 
(data not presented here).  
As, the Yeti “scoring function”5 [248,352] was not sensitive enough to distinguish 
between ligands having similar affinity towards the protein. It should be noted 
that most of the modifications leading to higher affinity towards the target protein 
(for example the introduction of hydrophobic substituents at the 2 position of the 
GlcNAc moiety) seems rather to be oriented towards the solvent and should 
therefore only have little influence on the affinity on an enthalpic level. Instead, 
their role could be important on an entropic level by liberating a larger amount of 
protein-bound water molecules upon binding and by stabilizing the bioactive 
conformation of the ligand. Hence, for having access to a fast in silico estimation 
of the affinity towards E-selectin, the development of a QSAR-relation taking in 
account also solvation effects became mandatory (cf. Chapter 3.2.7). 
 
 
Figure 51: Graphical representation of the 200 sampled conformations (MC) for the ligands a) 
83, b) 84, c) 85. 
                                                
5 The weighting of the different energy components was changed to the values described in  
 Chapter 3.2.5.1.  
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Figure 52: Superposition of the 181 ligands used for the docking- and QSAR-experiments after 
MC-minimization. Each ligand is represented by the lowest energy confomer. 
 
4.4.3 Reverse docking 
 
It is known from the literature [175,176] that the introduction of hydrophobic 
substituents at the 2 position of the GlcNAc moiety clearly enhances the affinity 
of the ligands towards E-selectin (cf. Chapter 1.6.4), although reason for this 
remains unclear [176]. To date, two hypotheses have been put forward: the first, 
discussed in the Chapters 4.4.2 and 4.7.1 bases on entropic considerations, the 
second on an different docking mode. Both were first proposed within the 
framework of this work.  
One possibility to explain an enhanced activity of a compound towards the target 
protein is that this particular molecule shows additional contacts with the protein, 
when compared to others ligands, thereby giving rise to stronger enthalpic 
contribution to the binding affinity. However, for compounds carrying hydrophobic 
substituents at the 2 position of the GlcNAc moiety, no such evidence is 
detectable. Hence, the docking poses obtained out of the MC-protocol for those 
                                                                                                                                                                                                                          
                                                                96
   
compounds show the hydrophobic substituents rather orientated towards the 
solvent (Figure 53).  
 
 
Figure 53: Compound 74 docked onto E-selectin. The hydrophobic substituent at the 2 position 
of the GlcNAc moiety is orientated towards the solvent. 
 
NMR experiments [349] indicated the presence of NOE-contacts between the 
hydrophobic moiety of ligand 68j and the protein. Therefore, the hypothesis of a 
different docking mode for ligands carrying hydrophobic modification at the 2 
position of the GlcNAc moiety was considered.  
First, the binding region of E-selectin was screened for regions, which could 
interact with the hydrophobic substituents attached at the 2 position of the 
GlcNAc moiety. Three of those regions could be identified:  
a) Tyr44-Pro46-Tyr48  
b) Lys111-Lys112-Lys113 
c) Ala77-Pro78-Met103 
 
It was then attempted to dock the compounds bearing a hydrophobic moiety 
linked at the 2 position of the GlcNAc residue with these rest being in close 
proximity of one of the identified regions on the E-selectin surface. Plausible 
binding modes, that could still explain the calcium-dependent binding of the E-
selectin antagonists to the protein [81,86,92] and the results of the studies 
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investigating the structure-activity relationship of E-selectin antagonists [141–
148], could only be achieved when positioning the hydrophobic moieties next to 
region a). The energetically and geometrically most favorable solution, obtained 
for ligand 74 (a complete list of the ligands studied can be found in the Appendix 
17), is presented in Figure 54. As can be observed, in this different docking mode 
the molecules would bind to E-selectin, in an orientation that can practically be 
obtained by flipping the ligands of 180° about their longitudinal axis compared 
with the previously assumed binding mode. Therefore this new docking mode is 
referred to as “reverse docking mode”.  
 
 
Figure 54: Compound 74 docked in the so-called “reverse docking mode”. 
 
In the reverse docking mode, the coordination to the calcium ion would be 
completed by the carboxyl group of the sialic acid residue (bidentate) of the 
ligand, where as the hydrogen bond to Glu92 would be guaranteed by the Fuc–
3OH (as a donor). In addition, other hydrogen bonds between the Fuc–4OH 
(acceptor) and the lysines 111 and 113, as well as between the Gal–4OH 
(acceptor) and Asn105, and finally between the Gal–6OH (donor) and Glu80, are 
observed (cf. Figure 18). In conclusion, this docking mode fulfills all structural 
requirements and moreover seems to give a suitable explanation (additional 
hydrophobic contacts with the amino-acids Tyr44-Pro46-Tyr48) to the enhanced 
activity of compounds bearing hydrophobic substituents at the 2 position of the 
GlcNAc moiety. It is, however, worth to note, that the “interaction” energy 
between the ligand and the protein (Eprot-lig, Yeti [248,352]) in this “reverse 
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binding mode” is smaller (2.0 to 10.0 kcal/mol) than when assuming a normal 
binding mode. Consequently, even though the “reverse binding mode” would 
seem to plausibly explain the role of the substituents at the position 2 of the 
GlcNAc moiety on both a structural and energetic level, the “normal docking 
mode” is still the more probable for this class of compounds. A definitive insight 
into the true binding mode of such ligands could only be reached through an X-
ray structure of E-selectin co-crystallized with ligand 68a-j or 74. This project is 
part of an ongoing thesis at the Institute of Molecular Pharmacy. 
 
4.5 Molecular-dynamics simulations of protein-ligand complexes 
 
To further explore the interaction between E-selectin and its ligands, different 
molecular-dynamics simulations of protein-ligand complexes were performed. As 
starting point for the MD studies, the corresponding best solution from the MC-
sampling was selected. The ligands for the MD studies were chosen to comprise 
a representative subset of all the 181 E-selectin antagonists previously docked to 
the target protein (cf. Appendix 18). 
MD simulations allow for;  
1) A more dynamic characterization (i.e. time dependent) of the protein-
ligand interactions responsible for ligand binding. The idea was to gain 
more insight into the strength and lifetime of those interactions through the 
analysis of many MD trajectories. The gained information should have 
been implemented in the design strategy of new mimics.  
2) The assumption that complexes of compounds having a higher affinity 
towards E-selectin would dissociate slower during the MD simulation than 
complexes formed by the protein and weak binders. 
3) The possibility to identify the favorable docking mode for ligands bearing 
hydrophobic substituents at the 2 position of the GlcNAc moiety by 
analyzing the lifetime and interaction pattern of the two different docking 
modes. 
The stability of the protein-ligand complexes did not correlate with the activities of 
the E-selectin antagonists but rather with their size. Larger ligands, 
independently from their affinity towards the target protein, displayed a longer 
residence time in the binding site when compared to smaller compounds. This is 
observed as well in the normal as in the reverse docking mode, making thereby 
difficult to identify one of the two docking mode as more probable. The longer 
“stability” of the complex formed between larger ligands and E-selectin might be 
explained with slower diffusion rate of heavier molecules.   
With the MD simulations we gained some insight into the dynamical nature of the 
protein-ligand interactions. In particular, it could be observed that, as already 
postulated by Somers et al. [166], only few contacts, mainly of electrostatic 
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nature exist between the ligands and the protein. Moreover, it could be 
distinguished between long-lasting contacts and transient ones. To the latter 
category belong the hydrogen bonds formed by Gal–4OH and Gal–6OH with the 
side chains of Tyr44 and Glu92. Hence, this hydrogen bonds last for few 
picoseconds but are continuously broken and reformed. Instead, the interaction 
between the fucose moiety and the calcium ion as well as the salt bridge 
between the carboxylic group of the sialic acid moiety and Arg97, generally last 
for longer periods, and are always the last contacts to break upon the 
dissociation of the complex. These findings correlate well with the results of an 
atom-force microscopy experiment [350], which identified in the interactions of 
the sialic acid moiety and of the fucose moiety with the metallo-protein, the two 
main barriers in the dissociation process. This agreement supports the 
importance of these two interactions, giving further evidence in keeping the sialic 
acid and the fucose moieties or mimics thereof as central elements in the design 
of new E-selectin antagonists. 
 
4.6 QSAR-models3,6 
 
One of the more recent goals of the Institute of Molecular Pharmacy was to 
develop a QSAR model able to predict the binding affinity of newly designed E-
selectin antagonists in a fast and reliable way. To date, no such model has been 
developed. The starting point for this project was given by the availability of an in-
house database including some 300 chemical structures and their affinities 
towards E-selectin, and of two pieces of software (Quasar [270–272,351] and 
Raptor [315,316,335])7 based on multidimensional QSAR. 
 
4.6.1 Ligand selection 
 
We decided that all ligands used for the QSAR studies had to satisfy some 
structural and charge criteria. In particular, it was chosen to include only ligands 
with an identical overall charge (e.g –1, as it is the case for sLex). Hence, in 
Quasar [270–272,351], the binding affinity is calculated as follow: 
 
Ebinding = E(force field) + Epolarization – E(ligand desolvation) – TΔSbinding – ΔE(internal strain) – E(induced fit) 
(Eq. 4) 
                                                
3 Results of this chapter were obtained as a part of a diploma work (M. Schmid, 2004) under my  
   supervision. 
6 In this chapter the ligands will be discussed according to their three-letter code (cf. Chapter  
  3.2.4.2 and Appendix)  
7 The use of Quasar [270–272,351] and Raptor [315,316,335|, which was provided by courtesy  
  of the Biographics Laboratory 3R [328], is kindly acknowledged. 
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and large deviation in the solvation energy of the individual molecules, as 
obtained for differently charged species, would have a considerable impact on 
the binding-site model. To avoid such an influence originating from different total 
charges, only structures with a total charge of -1 were taken in consideration.  
Second, ligands, which could form tautomers, were excluded. These molecules 
are able to change their physicochemical properties — essential for their binding 
mode and for the modeling of the binding-site — depending on the tautomeric 
structure. To include this class of compounds supplementary docking 
experiments would have been required. Therefore, the QSAR studies were 
preformed with a smaller selection of ligands (e.g.181 structures).  
 
4.6.2 Ligand-set selection 
 
As the best partial-charge model cannot per se be identified, we decided to use 
both sets of ligands bearing either CM-1 [327] or ESP-MNDO as input for Quasar 
[270-272,351]. In addition, the so-called pharmacophore-based alignment and 
the receptor-based alignment [272,333] (cf. Chapter 4.6.3.2). In summary, the 
search for a predictive QSAR model explaining the structure-activity relationship 
between E-selectin and its ligands, was started with 4 sets of ligands (Table 7). 
 
Table 7: Definition of the four sets used for the derivation of a QSAR model with Quasar [270–
272,351]. 
Set number Set name Partial charge method Alignment 
1 CM-1 align CM-1 Pharmacophore-based 
2 ESP-MNDO align ESP-MNDO Pharmacophore-based 
3 CM-1 MC CM-1 Receptor-mediated 
4 ESP-MNDO MC ESP-MNDO Receptor-mediated 
 
As described, preliminary studies showed that docking was not influenced by 
which charge calculation method was applied. Set 4 was therefore obtained out 
of set 3 by exchanging CM-1 charges [327] against ESP-MNDO [331]. 
 
                                                                                                                                                                                                                          
                                                                101
   
4.6.3 Alignment strategies 
 
4.6.3.1 Pharmacophore-based alignment 
 
The least-square technique for superpositioning of corresponding atom positions 
is the most widely used methods [302]. Two molecules are superimposed by 
minimizing the rms distances between the corresponding atom pairs in the 
molecules. The underlying idea is that by superpositioning three or more atom 
pairs an alignement of the pharmacophoric groups would be obtained. In our 
case, the ligands were superimposed onto the conformation of sLeX as observed 
in the crystal structure of the sLex/E-selectin complex [166] using the three 
glycosidic oxygen atoms of sLex as reference atoms. The alignment was then 
further syncronized by reorienting some hydroxyl groups (cf. Chapter 3.2.4.1), 
thereby improving the directionality of the H-bonds formed between ligands and 
protein. The obtained alignment of the 181 ligands used for the development of 
the QSAR model is presented in Figure 55. 
In general, the ligands show a common hydrogen-bonding pattern and a similar 
orientation of Lex-core, but a wide variability in sidechains of the GlcNAc-moiety 
and in mimics of the NeuAc-moiety. 
To remember is that this kind of alignment, based on the orientation of the 
common pharmacophoric groups, is only position and conformation dependent. 
For this procedure, the protein itself is not considered. 
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Figure 55: Pharmacophore-based alignment of the 181 ligands. 
 
4.6.3.2 Receptor-mediated alignment 
 
All the ligands were manually docked into the protein-binding site in an 
orientation similar to sLex as observed in the crystal structure [166]. The protein-
ligand interactions were optimized through the Monte-Carlo protocol (cf. Chapter 
3.2.5.1) to identify the energetically most favorable binding mode for the E-
selectin antagonists at the receptor. By superpositioning the 200 conformations 
of each molecule obtained during the Boltzmann sampling over 2,000 rounds 
only slight differences were observed (cf. Figure 51). Therefore, it was decided to 
use only the energetically lowest conformation of each compound to establish a 
QSAR. The 3D superposition of the lowest-energy structures of the entire set of 
ligands (cf. Figure 52) showed large deviations between the individual ligands. 
The position of the sugar moieties and the orientation of the sidechains differ 
from each other leading to a large spatial distribution of the functional groups. 
This complicates the precise distribution of the atomistic properties onto the 
three-dimensional surface of the receptor model. However, the receptor-
mediated alignment yields more “realistic” conformations and orientation of the 
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ligands compared to ones obtained from a pharmacophore-based approach, 
because it allows for the induced fit of the protein. 
 
4.6.4 Development of a QSAR model using Quasar 
 
The four ligand sets defined above (CM-1 align, CM-1 MC, ESP align, ESP MC, 
cf. Chapter 4.6.2) were used to generate a binding-site model based on 6D-
QSAR (cf. Chapters 1.7.3 and 3.1.2.13). In this work, however, the fourth 
dimension of Quasar [270–272,351], the multi-representation of the 
conformation, was not used because every ligand of the pharmacophore and of 
the receptor-mediated alignment was represented only by the lowest-energy 
conformation obtained from the docking protocol. The reasons for that choice 
were explained in the previous chapter.  
Different boundary conditions (Table 8) were tested to obtain an optimal model 
(high predictability, low rms deviation). In particular, models with a different 
number of ligands used (the ligand were divided in classes by similarity and each 
group was first added to the model after successful derivation of a QSAR for the 
previous group), different set of ligands (CM-1 align, CM-1 MC, ESP align, ESP 
MC), and different setting for the following parameters (dynamic surface area, 
hydrogen-bond function, population size, Esolv attenuation, number of 
crossovers), were generated. A detailed list of the parameter settings and the 
appertaining q2, p2, rms and the maximal deviation between the calculated and 
the experimental values are given in Table 8. All parameters not specified in this 
table were set as default [351]. The quality of the models was rated based on 
their q2, p2 and rms values. For the best models scramble tests [338] were 
performed to verify their selectivity towards the biological data.  
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Table 8: Variation of the parameters and the resulting values for q2, p2, rms and max. deviations in kcal/mol and in K. Q1–Q11 and Q15–Q17 were 
generated with the ligand set CM-1 align, Q12 and Q18–Q20 with the ligand set CM-1 MC, Q13 and Q21–Q23 with the  ligand set ESP align, and 
Q14 and Q24–Q26 with the ligand set ESP MC. By the simulations Q12–Q14 the parameter “crop selection” [351] was set to “asymmetric 1.0”. In 
addition, in Q14 the cross validation term was set to –2.0. 
 
no. of the 
Quasar 
model 
# total ligands 
(test/training) 
Esolv 
atttenuation 
factor 
Dynamic 
surface area 
H-bond 
radii 
Solv. energy 
and partial-
charge 
equalization 
# cross-
overs 
Population 
size 
q2 p2 Training: rms / 
max. Deviation 
[kcal/mol]     [in 
K] 
Test: rms / 
max. Deviation 
[kcal/mol]     
[in K] 
CM-1/ ESP            
1 97 (38/59) 1.0 none gsm none 10,000 50 0.887 0.096 0.405 / 1.206 1.114 / 2.623 
2 97 (38/59) 1.0 none gsm none 10,000 200 0.763 0.465 0.583 / 1.429 0.843 / 1.639 
3 97 (38/59) 1.0 none gsm none 15,000 500 0.722 0.314 0.621 / 1.521 0.946 / 2.001 
4 103 (32/71) 1.0 solvent std none 20,000 200 0.709 0.530 0.680 / 1.555 0.736 / 1.606 
5 103 (32/71) 1.0 solvent gsm none 25,000 200 0.763 0.533 0.617 / 1.500 0.737 / 2.147 
6 103 (32/71) 1.0 solvent ind none 30,000 200 0.762 0.510 0.618 / 1.417 0.755 / 1.981 
7 103 (32/71) 1.0 none gsm none 10,000 200 0.659 0.519 0.728 / 1.814 0.736 / 1.726 
8 103 (32/71) 1.0 none gsm solvation 10,000 200 0.659 0.519 0.728 / 1.814 0.736 / 1.726 
9 103 (32/71) 1.0 none gsm charge 10,000 200 0.659 0.519 0.728 / 1.814 0.736 / 1.726 
10 103 (32/71) 1.0 none gsm both 10,000 200 0.659 0.519 0.728 / 1.814 0.736 / 1.726 
11 103 (32/71) 1.0 void std none 40,000 200 0.793 0.670 0.572 / 1.647 
1.7 / 15.9 
0.610 / 1.264 
1.9 / 7.8 
12 103 (23/80) 0.3 solvent gsm none 17,000 200 0.786 0.467 0.568 / 1.451 
1.7 / 11.1 
0.744 / 1.627 
2.6 / 15.3 
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13 99 (24/75) 0.3 void gsm none 37,000 200 0.888 0.667 0.384 / 1.115 
0.9 / 5.8 
0.533 / 1.121 
1.5 / 5.9 
14 103 (27/76) 0.2 void gsm none 17,000 200 0.790 0.367 0.511 / 1.131 
1.4 / 6.0 
0.863 / 2.243 
3.4 / 46.1 
15 181 (59/122) 0.3 none std none 19,000 200 0.674 0.483 0.666 / 2.052 
2.1 / 33.0 
0.779 / 1.599 
2.8 / 14.6 
16 181 (59/122) 0.2 solvent std none 15,000 200 0.598 0.396 0.760 / 2.176 
2.7 / 41.0 
0.856 / 1.789 
3.4 / 20.6 
17 181 (59/122) 0.2 void std none 32,000 200 0.699 0.470 0.647 / 2.061 
2.0 / 33.5 
0.791 / 1.709 
2.9 17.8 
18 181 (55/126) 0.27 none gsm none 10,000 200 0.620 0.304 0.717 / 2.688 
2.4 / 100.2 
0.897 / 2.446 
3.7 / 65.8 
19 181 (55/126) 0.23 solvent gsm none 10,000 200 0.570 0.324 0.776 / 2.349 
2.8 / 55.5 
0.888 / 2.049 
3.6 / 32.7 
20 181 (55/126) 0.2 void gsm none 25,000 200 0.638 0.346 0.699 / 2.549 
2.3 / 78.7 
0.865 / 2.003 
3.4 / 30.2 
21 181 (53/128) 0.4 none std none 15,000 200 0.716 0.484 0.626 / 2.194 
1.9 / 42.3 
0.781 / 1.737 
2.8 / 18.7 
22 181 (53/128) 0.4 solvent std none 17,000 200 0.706 0.442 0.637 / 2.262 
2.0 / 47.7 
0.810 / 1.779 
3.0 / 20.2 
23 181 (53/128) 0.3 void std none 5,000 200 0.529 0.350 0.803 / 2.544 
3.0 / 78.1 
0.876 / 2.049 
3.5 / 32.8 
24 181 (55/126) 0.8 none std none 5,000 200 0.414 0.282 0.917 / 2.754 
3.8 / 112.4 
0.926 / 2.462 
3.9 / 67.7 
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25 181 (55/126) 0.7 solvent std none 10,000 200 0.466 0.311 0.872 / 2.747 
3.5 / 111.1 
0.904 / 2.411 
3.7 / 63.1 
26 181 (55/126) 0.6 void std none 5,000 200 0.401 0.309 0.929 / 2.780 
3.9 / 117.6 
0.909 / 2.383 
3.8 / 58.9 
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The impact of the different parameters on the predictability of the models is 
briefly discussed here: 
 
Population size 
To identify the ideal size of the population, binding-site surrogates were 
generated with 50, 200 and 500 models respectively. Population sizes of 200 and 
500 led to comparable results whereas 50 models showed small variabilities and 
led to poor predictions (cf. Table 8, Q1–Q3)8. Thus, for time reasons, it was 
advantageous to carry on with a population size of 200 models.  
 
Esolv attenuation 
One feature of Quasar [270–272,351] includes the possibility to scale the ligand 
desolvation energy (cf. Chapter 3.1.2.13). This option was particularly important 
in our case because the binding site is solvent exposed [166] and therefore the 
ligands may not be desolvated entirely upon binding. For the best models, 
Quasar [270–272,351]  (cf. Table 8, Q15, Q21) attenuated the solvation energy 
by a factor of 70% approximately (cf. Table 8). A similar attenuation of 63% was 
obtained also with the most recent version of Quasar [270–272,351] (version 
5.0), which optimizes this parameter in an unbiased fashion ( 6D-QSAR). 
Interestingly, this reduction tends to have a stronger influence when CM-1 
charges [327] are used. This is possibly related to the more pronounced charge 
separation observed when using the CM-1 method [327] (cf. Chapter 4.3), 
leading thereby to higher and more differentiated desolvation-energy values (cf. 
Appendix 19). 
 
Hydrogen-bond radii 
The variation of the hydrogen-bond radii of the quasi-atomistic particles showed 
comparable results either if this parameter was set to golden-section mean (= 
0.618 • standard + 0.382 • individual) or standard (cf. Table 8, Q4–Q6). Slightly 
lower p2 values were obtained with the parameter set to “individual”. Therefore 
further models were generated with the parameter either set to golden section 
mean or standard. 
 
Dynamic surface area 
Various tests with the dynamic surface area disabled or set to, solvent or void 
showed no apparent trend for this option (cf. Table 8). For all set of ligands 
receptor models were generated with the three settings: none, solvent and void. 
                                                
8 With only 50 models, the genetic pool is not enough broad to capture all the necessary features  
   to describe the ligand set. 
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However, all models other than the “none” one died during the evolutionary 
process. Unfortunately, this could be an artifact produced by Quasar [270-
272,351]. Hence, the current version of the software does not allow the “solvent 
feature” to occupy more than the 30% of the total recetor-model surface, which is 
clearly too small for the E-selectin binding mode. Consequently, such models will 
hardly survive during the simulated evolution. 
 
Number of crossovers 
The evolution of the models is based on the LoF function (cf. Chapter 3.1.2.13). 
To avoid overtraining — the binding-affinity prediction of the training ligands 
improves whereas the difference between the predicted and the experimental 
binding affinity increases for the test ligands — the progression of the p2 and of 
the rms value of the test set were monitored to find the optimal number of 
crossovers. If the p2 and rms values remained stable the simulation was 
dynamically terminated. For our best models Q15 and Q21, the optimal number 
of crossovers was of 19,000 and 15,000 respectively (cf. Figures 57 and 58). 
 
4.6.5 Analysis of the developed models 
 
4.6.5.1 Q11-Q14 
 
In the search for the best predictive model, new ligands were gradually added to 
the previous set of the ligands. The best p2 and rms values of each ligand-set 
(CM-1 aligned, CM-1 MC, ESP aligned, ESP MC) were achieved with ligand-sets 
containing approximately 100 ligands (Q11–Q14, cf. Figure 56 and Table 8). In 
these test–training set arrangements (cf. Appendix 20) the group of the sLex 
mimics with large sidechains were excluded. 
For both partial-charge models the pharmacophore aligned ligands (models: Q11 
and Q13) show a more accurate prediction of the ligands than the receptor-
mediated aligned ligands (Q12 and Q14) (Figure 56) whereas the largest 
difference can be found for the ligands with an IC50 >10 mM, referred to as non-
binders. The predicted binding affinity of these “non-binders” tends to higher 
values than experimentally measured (for a detailed discussion see below). The 
trend of the superior prediction for the pharmacophore-aligned ligands is more 
distinct when using the ESP-MNDO partial-charge method [331]. 
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Figure 56: The results obtained for the model Q11–Q14 (cf. Table 8). 
 
4.6.5.2 Q15-Q26 
 
These models were generated by using all the 181 ligands chosen for QSAR 
studies (cf. Chapter 4.6.1). The results achieved, are somewhat less impressing 
(when comparing the predictive power (p2)) than when handling with only about 
100 ligands (cf. Table 8). This is probably due to the difficulty of the algorithm of 
handling ligands presenting large sidechains contributing only less to the binding 
                                                                                                                                                                                                                          
                                                                110
   
affinity9. However, a QSAR model considered to be good enough for our purpose 
(fast determination of an approximate IC50 of new E-selectin antagonists in silico) 
could also be established when using all the 181 compounds, and even though 
the results were outperformed by the model with about 100 compounds, the 
following models are much more complete (more structural variations are 
included) and with a higher predictive power for new designed ligands.   
The best predictions were achieved using the pharmacophore-aligned ligands 
bearing either CM-1 [327] or ESP-MNDO [331] charges with Q15 and Q21 
respectively (cf. Table 8, Figures 57 and 58).  
                                                
9 Thereby, it is assumed that the hydrophobic chains are orientated towards the solvent and do 
not fold back towards the protein as MD-investigations has shown. 
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Figure 57: Results of the normal simulation, of the scramble-test simulation [355], and “time-
dependent” development of the parameters (p2, q2, rms and maximal deviation) for model Q15. 
                                                                                                                                                                                                                          
                                                                112
   
 
 
 
 
Figure 58: Results of the normal simulation, of the scramble-test simulation [355], and “time-
dependent” development of the parameters (p2, q2, rms and maximal deviation) for model Q21. 
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Figure 59: The best models obtained using the receptor-mediated alignment strategy and the 
partial-charge methods CM-1 [327] (Q20) or ESP-MNDO [331] (Q25) respectively. 
 
On the other hand, the best models, but inferior to those aligned by 
pharmacophore (lower p2, higher rms devations), developed using the receptor-
mediated aligned ligands bearing either CM-1 [327] or ESP-MNDO [331] charges 
were achieved with Q20 and Q25 respectively (cf. Table 8, Figure 59). This 
observation that the pharmacophore aligned ligands yield the best predictions for 
all sets of ligands, might result from a better overlay of the functional groups and 
of the sugar-backbone (Figure 55) that allow a more precise mapping of the 
atomistic properties onto the surface than when the receptor-mediated alignment 
is used (Figure 52). Hence, the more complex alignment of the individual 
receptor-mediated aligned ligands might substantially affect the three-
dimensional surface and the energies for the induced fit between protein and 
ligand. This is supported by the Quasar [270–272,351] study, where the induced 
fit was simulated upon the steric potential, leading to a significant induced fit, i.e. 
a snugly fitting surface. In general, the generation of good predictive receptor-
models was more difficult with the receptor-mediated alignment. 
The overall best model would seem to be Q15 and will be discussed more in 
detail below. 
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4.6.5.3 Prediction of the apparent binding affinity of the weak binders and  
  of ligands presenting particularly hydrophobic moieties   
 
An important point to observe is that in all models the predicted binding affinities 
of the weak binders (IC50 > 5 mM) and of some ligand bearing major hydrophobic 
moieties, tends to be stronger than experimentally measured. The cause of this 
effect may be associated with the fact that the binding-model surfaces of those 
compounds often show a substantial lipophilic fraction where hydrophobic 
sidechains are located (Figure 60). According to the X-ray study [166], those 
sidechains should be exposed to the solvent at the true biological receptor. Thus, 
the tendency of Quasar [270–272,351] to predict higher binding affinities for 
these ligands might result from artificial lipophilic interactions between the 
sidechains and the incorrect atomistic properties on the surface, which are 
probably present due to the limitation of the presence of solvent areas to an 
amount of maximal 30% of the total receptor-model surface, whereas in our case 
the binding site is exposed to the solvent for at least 60% of its surface.  
In the case of weak binders however, the difficulty in predicting their binding 
affinity correctly could also be related to the fact that some IC50 values were not 
exactly determined but rather estimated (cf. Chapter 3.2.4.2). These values could 
lead to fuzzy input-data not really suited for the model generation. By re-
determining the IC50-value of some of these ligands, the range for the binding 
affinity may lead to a better structure-activity correlation. Then, the model would 
have more accurate information (training set) on the structure-activity relationship 
of our E-selectin antagonists. 
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Figure 60: The three dimensional surface of model Q15 with the atomistic properties mapped 
onto it. 
 
4.6.5.4 The best Quasar model: Q15 
 
With a p2 of 0.48±0.04 corresponding to a rms deviation of a factor 2.8 off in IC50, 
Q15 yielded the best correlation with small standard deviations after 19,000 
crossovers (cf. Figures 57 and 60, Table 8). The receptor-model was generated 
without allowance for a dynamic surface area and the H-bond function shift set to 
standard. The solvation energy was attenuated to 30%. 
The prediction of the “non-binding” ligands or ligands bearing long lipophilic 
sidechains tends to be too strong. Ligand A63, a “non-binder” of the training set 
(cf. Appendix 9 and Figure 57), posed the major challenge for the model. Its 
prediction had a rms value of 2.1 kcal/mol (factor of 33 too high in IC50), whereas 
the typical error in biological assays is varies from 0.2 kcal/mol for compounds 
showing an affinity in nanomolar range to 2.0 kcal/mol for compounds showing 
an affinity in millimolar range [215]. This large deviation is possibly resulting from 
the chemical structure because A63 is the only five-membered ring with a 
nitrogen atom (pyrolidine ring) and a large lipophilic group. The same problem 
probably afflicts the ΔG prediction of the test ligands B34 and B37 (cf. Appendix 
9 and Figure 57) with an experimental IC50 of 0.8 mM and 0.5 mM respectively, 
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which were slightly more than a factor of 10 off in IC50. Their ligand structures are 
similar as both molecules contain a six-membered ring with a nitrogen atom 
(GlcNAc mimic) and large lipophilic sidechains. It is the latter that could bias the 
prediction as discussed above. 
There are also two other ligands (B75 and B65) (cf. Appendix 9 and Figure 57) 
with an experimental IC50 of approximately 40 µM that show a deviation of 12 to 
15 (factor off in IC50) in the prediction of the binding affinity. The two structures 
differ only in one N-acetyl group that seems to have no influence on the binding 
affinity10. Their structural backbone is commonly represented in the ligand set but 
the modified sidechains might be poorly distinguished by the binding-site model. 
Moreover both ligands are small in size and therefore the lower binding affinity 
predicted by the model could result from the fewer interactions with the surrogate 
compared to larger compounds. 
 
4.6.6 Development of a QSAR-model using the Raptor technology 
 
More recently the Biographics Laboratory 3R [328] developed another tool for the 
generation of QSAR models: Raptor [315,316,335]. As described in Chapter 
3.1.1.10 section, this software is based on a different approach than Quasar 
[270–272,351]. When comparing results obtained with the two approaches for 
identical set of ligands, consensus scoring can be applied. In particular, Raptor 
[315,316,335] does make not use atomistic charges for model generation. 
Consequently, only models for two of the four set of ligands (based on the 
different alignment strategies: pharmacophore-based or receptor-based 
alignment) had to be evaluated. 
The ligand-sets of Q15 and Q21 were used to perform additional QSAR 
simulations with Raptor [315,316,335] yielding the models R15 and R21 
respectively. With a p2 of 0.46 approximately the plots for R15 and R21 show a 
respectable correlation (Figures 61 and 62) and a relatively large standard 
deviation.  
                                                
10 This statement is based on the results of a functional group analysis performed with Quasar  
 [270-272,351] (data not presented here).  
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Figure 61: Results obtained for R15. On the right the results of the simulation with scrambled 
affinity values [338]. 
 
 
 
Figure 62: Results obtained for R21. On the right the results of the simulation with scrambled 
affinity values [338]. 
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In contrast to Quasar [270–272,351], Raptor [315,316,335], allows for the 
definition a threshold value to less punish the “non-binders”, when their affinity 
prediction is worse than the experimental value. A second model was therefore 
generated making use of this option with the threshold activated for IC50 ≥ 10 mM 
to investigate its effect on the binding-affinity prediction. The plots with the 
predicted values versus the experimental data of these simulations (R15t and 
R21t) are shown in Figure 63. With a p2 of 0.47 and an rmstest of 6.4 off in IC50, 
R21t represents the best model (higher p2 and smaller rms) yielded with Raptor 
[315,316,335].  
 
 
Figure 63: Results obtained for the training/test-set arrangement of R15 and R21 after allowing 
for a threshold (R15t left, R21t right). 
  
The averaged model of R21t is displayed in Figure 64. By comparing the results 
achieved with and without the introduction of a threshold value, it can be noted 
that for the model R15 the prediction from the normal simulation (Figure 61, 
rmstest = 8.9 off in IC50) is comparable to the one from the simulation with 
threshold (Figure 63, rmstest = 8.5 off in IC50), whereas R21 showed a substantial 
improvement (rmstest from 11.4 to 6.4 off in IC50) by enabling the threshold 
(Figures 62 and 63). The prediction of the weak binders became more accurate 
compared to the initial too high values and the predicted binding affinity for the 
ligand B65 improved by a factor of approximately 40 in IC50.  
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Figure 64: Illustration of all ligands with the mean model presenting the main atomistic feature of 
R21t. The model surface is colored as follow: hydrophobic field, beige; hydrogen-bond-donating 
propensity, blue; hydrogen-bond-accepting propensity, red; hydrogen-bond flip-flop, green. 
 
4.6.7 Comparing models generated by Quasar and Raptor 
 
Good models to predict the binding affinities of new E-selectin antagonists could 
be generated with both approaches, Quasar [270–272,351] (p2 = 0.48, cf. Figure 
57) and Raptor [315,316,335] (p2 = 0.47, Figure 63). Hence, the relatively low p2-
values suffer only from the imprecise prediction of weak binders, which are not of 
fundamental importance for the further development of high affinity E-selectin 
antagonists. Quasar [270–272,351] required different test-training arrangements 
for CM-1 [327] and ESP-MNDO [331] because the calculation of the protein-
ligand interaction energy considers the atomistic partial charges. In contrast here 
to, Raptor [315,316,335] neglect atomistic partial charges but instead uses the 
concept of hydrophobicity and calculates the ligand-receptor interactions based 
on hydrogen bonds, hydrophobic interactions and treats solvation effects 
implicitly. Therefore this approach is independent from the partial-charges 
models and the quality of the model depends mainly on the test training set 
arrangement. 
Comparing the best model of each approach, Q15 achieved better rms values for 
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the training and the test ligands (cf. Figure 57), but the predicted binding affinity 
for the non-binders was too high (max. factor of 33.0 off in IC50) favoring R21t. 
Regarding the maximal deviation for the test ligands, Quasar [270–272,351] 
performed well with a maximal deviation of 14.6 off in IC50 (ligand B34) compared 
to Raptor [315,316,335] with 39.6 off in IC50 (ligand B65). 
In general, Raptor [315,316,335] predicts the weak-binders well but shows larger 
standard deviations and Quasar [270–272,351] achieves a high correlation with 
small standard deviations except for some of the weak binders. 
 
4.6.8 Conclusions on the QSAR studies 
 
The aim of these studies was to establish a structure-activity relationship based 
on quasi-atomistic models and using two distinct approaches (software Quasar 
[270–272,351] and Raptor [315,316,335]) to estimate the binding affinity of novel 
E-selectin antagonists. Models were derived using a total of 181 compounds for 
which experimental binding data (IC50) are available. The best models obtained 
— Q15 (p2 = 0.48, Figures 57 and 60) and R21t (p2 = 0.47, Figures 63 and 64) — 
suggest that the surrogates may be used to semi-quantitative predict the binding 
affinity of novel compounds in silico. 
The influence of different partial-charge models (CM–1 [327] or ESP [331]) as 
well as of different alignments (pharmacophore-based or receptor-mediated) on 
the binding-site model was studied. Quasar [270–272,351] yielded a model (Q15) 
that explained the structure-activity relationship of E-selectin antagonists with an 
acceptable correlation (q2 = 0.67±0.01, p2 = 0.48±0.04 corresponding to a factor 
2.1 and 2.8 off in IC50) and small standard deviations whereas the non-binding 
ligands posed some problems in their prediction of the binding affinity. Receptor 
models generated with Raptor [315,316,335] yielded a q2 = 0.64, p2 = 0.47 
corresponding to a factor 2.4 and 6.4 off in IC50 (R21t) that could correctly identify 
the weak binders. 
By using Quasar [270–272,351] and Raptor [315,316,335] (consensus scoring) 
on a large data set, the resulting receptor models are expected to predict novel 
E-selectin antagonists at moderate accuracy. Hence, the models derived could 
be used as a pre-selection tool for an in silico identification of high-affine E-
selectin antagonists for compound synthesis, thereby reducing development time 
and costs as well as contributing to environmental benefits by reducing the 
amount of chemical waste. 
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4.7 Design of new ligands 
 
Two different strategies were employed to improve the affinity of our E-selectin 
antagonists towards the target protein. The first one, introduced in Chapters 1.5.2 
and 1.5.3, bases on the idea that a more rigid and/or pre-organized compound 
will have to pay a less entropic costs upon binding than a more flexible ligand, 
resulting in more affine molecule. Different studies [161,168,175] demonstrated 
the validity of this approach for the optimization of E-selectin antagonists. The 
other strategy adopted, based on the fact that by adding new functional groups to 
the lead compound or by replacing part of the molecule with new functional 
groups more complementary to the target protein, a significant increase in affinity 
can be reached due to a stronger ligand-protein interaction. In the next 
paragraphs it will be outlined how those strategies were applied to the design of 
novel E-selectin antagonists. 
 
4.7.1 Gaining affinity through pre-organization of the ligand structure 
 
Different studies [150–168] and the results achieved in this thesis (cf. Chapter 
4.2), suggest that the conformation of sLex in water could be defined by a quite 
rigid Lex core and a flexible neuraminic acid moiety. Starting from sLex (3) itself 
or from one of the most promising sLex-mimic developed so far (26) (Figure 65), 
series of compounds were designed to study the reasons of the core stability and 
to enhance the pre-organization of the acid moiety. 
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Figure 65: Chemical structure of sLex (3) and of compound 26. 
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4.7.1.1 Investigation regarding the conformational stability of the Lex-core 
 
It is assumed that the exo-anomeric effect (1), the steric compression of the 
fucose under the β-face of the galactose moiety due to the presence of a 
substituent at the position 2 of the GlcNac moiety (2), and the hydrophobic 
interaction between the methyl group of the fucose and the β-face of the 
galactose moiety (3) would be responsible for the stabilization of the 
conformation of the Lex-core (Figure 66) [353].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: The three factors assumed to be responsible for the stability of the Lex-substructure of 
sLex (3). 
 
To investigate this hypothesis, three series of compounds were designed: 
a) C-Glycosides 
b) modified Fucose residues 
c) modified GlcNAc moiety 
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a) The C-Glycosides series 
Within the series of the C-Glycosides, it could be showed that, as assumed, that 
the exo-anomeric effect plays a determinant role in the pre-organization of the 
Lex core of sLex [353]. Hence, the C-glycoside analog of compound 26 (cf. Figure 
65) resulted to be inactive, whereas 26 shows an affinity of 0.08 mM towards E-
selectin. These compounds were detailed described in a recent PhD-thesis [354] 
and will therefore not be further discussed here. 
 
b) The modified Fucose residues series 
With the intention of studying the effect of the hydrophobic interaction between 
the methyl group of the fucose moiety and the β-Face of the galactose residue, 
compounds 77–80 were designed (Figure 67).  
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Figure 67: Chemical structure of the compounds 77–80. 
 
The four molecules were subjected to the AMBER-based protocol (cf. Chapter 
3.2.3.2) to investigate their conformational behavior in water. As showed in 
Figure 68, compound 77 clearly the most stringent conformation distribution 
around the Φ1− and Ψ1-angles closely followed then by 78 and 79. Compound 80, 
instead, which has no substituent at the 5–equatorial position of the arabinose 
ring and therefore no possibility to establish a hydrophobic interaction with the β-
face of the galactose moiety, occupies a much larger part of the conformational 
space.  
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Figure 68: Conformational preferences around the Φ1− and Ψ1-torsion for the compounds 77–80. 
 
Out of those results, we predicted that, due to the different substituents at the 
equatorial five position of arabinose ring, which influence the strength of the 
hydrophobic interaction with the β-face of the galactose moiety, compounds 77–
80 would have shown different affinities towards E-selectin. In particular, it was 
supposed that 77 would have been the most active one (in the same range of 
affinity as sLex (3)), followed by 78 and 79 and finally by 80. These assumptions, 
based upon the results obtained by the application of one of our molecular 
modeling protocols, were nicely confirmed. Hence, the experimentally 
determined IC50 of the compounds in vitro, when relative to compound sLex (3) 
are of the following factors higher: 1.6 for compound 78, 2.8 for compound 79, 
and higher than ten for compound 80. 
These results suggest the importance of the hydrophobic interaction between the 
equatorial substituent placed at the position five of the arabinose ring and the β-
face of the galactose moiety. In fact, this interaction seems to be important to 
pre-organize the Lex-core of sLex in the bioactive conformation leading thereby to 
ligands (77–79) with a higher affinity towards E-selectin than the one observed 
for their more freely rotating counterpart (80). 
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c) The modified GlcNAc mimics series 
Since 1996 [175,176], it is known that the introduction of steric demanding 
substituents at the 2 position of the GlcNAc moiety or of mimics thereof led to an 
increased affinity of the compounds towards E-selectin. To explain this effect two 
different hypotheses were put forward. One, described in Chapter 4.4.3, bases 
on the possibility of a reverse docking mode. The second, on the fact, that the 
introduction of a substituent at the 2 position of the GlcNAc moiety would 
stabilize the Lex-core of sLex or of the sLex-mimics in the bioactive conformation. 
In addition, the presence of a substituent at that position could also generating a 
benefit by liberating a larger amount of protein-bound water molecules upon 
binding and thereby enhancing the affinity of the ligands towards E-selectin even 
more. To proof this concept four compounds were designed (Figure 69) and 
submitted to the MC(JBW)/SD-protocol.  
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Figure 69: Chemical structure of the investigated compounds. 
 
As it can be taken from Figure 70, the distribution of the conformations along the 
core coordinate is clearly narrowed for the compounds presenting a methyl group 
at the position 2 of the GlcNAc-mimic moiety when compared with the ligands 
missing that group. Relying on those results, we predicted that the compounds 
lacking a methyl group, and therefore incapable of pre-organization, would have 
resulted in a lower affinity towards E-selectin. Moreover, we decided to study the 
influence of the substitution of the ring oxygen atom in the GlcNAc-mimic moiety 
with a CH2-group. Hence, we supposed that, by eliminating the ring oxygen 
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atom, we could gain even more affinity towards the target-protein due to a 
reduced desolvation penalty and a rigidification of the ring.  
 
 
Figure 70: Conformational distribution for compounds 26, 81, 82, and 83 as predicted by the 
MC(JBW)/SD protocol. The presence of a methyl group at the position two of the cyclohexane-
ring reduces the core flexibility.   
 
                                                                                                                                                                                                                          
                                                                127
   
O
O
O
O
O
COONa
HO
HO
OH
HO
OH
OH
H
O
O
O
O
O
COONa
HO
HO
OH
HO
OH
OH
H
CH3
O
O
O
O
O
O
COONa
HO
HO
OH
HO
OH
OH
H
CH3
O
O
O
O
O
O
COONa
HO
HO
OH
HO
OH
OH
H
26 IC50 = 0.08 mM 81 IC50 = 0.018 mM
82 IC50 = 0.23 mM 83 IC50 = 0.04 mM  
Figure 71: Chemical structure and biological activity of the investigated compounds. 
 
As it appears from the measured IC50 (Figure 71), it is interesting to conclude that 
all our assumption turned out to be correct. Thus, even though we cannot 
exclude the possibility of a reverse docking mode when more demanding 
substituents are attached at the 2 position of the GlcNAc- or GlcNAc mimic-
moiety (cf. Chapter 4.4.3), we think to have identified the reason of the enhanced 
activity into a stabilization and pre-organization of the core conformation. This is 
probably due to the steric compression exercised by the substituents attached at 
the 2 position of the GlcNAc- or GlcNAc-mimic-moiety on the fucose residue, 
which is thereby fixed in its bioactive orientation under the β-face of the galactose 
unit. This consideration is supported by the molecular-modeling results, which 
show a distinct more stringent conformational freedom along the core coordinate 
for the compounds presenting a methyl group.  
To conclude, it may be stated that the role and importance of all the three 
hypothesized effects (exo-anomeric effect, steric compression and hydrophobic 
interaction), leading to a stabilization of the core conformation of sLex or sLex-
mimics could be demonstrated with the synthesis of the compounds described 
above. Thus, the pre-organization of the core of sLex or sLex-mimics is 
mandatory for achieving high affinity towards E-selectin.  
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4.7.1.2 Pre-organization of the acid moiety 
 
As introduced in Chapter 1.5.1, one of the fundamental pharmacophoric group 
promoting the binding to E-selectin is the carboxylic group of the NeuNAc moiety 
of sLex. From the results presented in this thesis (cf. Chapter 4.2) and from what 
is known from the literature (cf. Chapter 1.5.2), it is quite evident that in solution, 
this functional group is not pre-oriented in the bioactive conformation. It is rather 
supposed that a multi-conformational equilibrium exists around the NeuNAc-Gal 
linkage. Hence, the possibility to gain affinity towards E-selectin by pre-
organizing the carboxylic group in the bioactive conformation was studied. 
Already in 1997, Kolb and Ernst [161,168] presented two simplified sLex-mimics 
that showed a clear higher affinity towards E-selectin than sLex itself (Figure 72).  
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Figure 72: Chemical structure of the compounds developed by Kolb and Ernst [161,168] with the 
intent to pre-orient the acid moiety. 
 
They explained this enhancement by the simplification of the ligand and by the 
pre-organization of the carboxylic group in the bioactive conformation. Ligand 26 
served as a starting point for the design of new mimics. The underlying idea of 
our new development step was the introduction of steric more demanding 
substituents instead of the cyclohexyl-lactic acid residue of compound 26. Thus, 
we supposed that this replacement would lead to another enhancement of the 
affinity towards E-selectin by a stronger stabilization of the bioactive 
conformation of the NeuNAc-mimic due to the reduced rotational freedom of 
bulkier substituents. Nonetheless, compound 26 still shows a relatively flexibility 
around the torsion defining the Φ3− and Ψ3-angles (Figure 73), which was 
hypothesized to be reduced by the introduction of more steric demanding 
substituents.  
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Figure 73: Conformational distribution of 26 in water as obtained with the protocols. 
 
To support this concept, compounds 84 and 85 were designed (Figure 74).  
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Figure 74: Chemical structure of the designed compounds. 
 
As a NeuNAc mimic, they both present groups (the adamantyl- and the tert-butyl-
substituent) known to stabilize the Φ3−torsion in the (-)-gauche conformation (the 
bioactive structure) and to be steric more demanding than the cyclohexyl-lactic 
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acid derivative. Compounds 84 and 85 were submitted to both the protocols for 
the analysis of the conformational preferences in water and their results 
compared with those for compound 26. As it can be seen in Figure 75, both 
compounds show a more stringent conformational variability, which should 
results in a higher affinity towards E-selectin. The synthesis of the compounds 
was performed by Alexander Titz [355] and we are awaiting their biological 
evaluation. 
 
 
Figure 75: Simulated conformational distribution of 84 and 85 in aqueous solution as predicted 
by the MC(JBW)SD-protocol (A) and by AMBER-based simulation (B). For 84 the AMBER-based 
simulation lasted only 1.3 ns, whereas for 85, 5 ns. The MC(JBW)SD-protocol was instead run for 
10 ns for each compound. 
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4.7.2 Gaining affinity through additional enthalpic contributions 
 
A more widely used method to enhance the affinity of a lead compound towards 
its target-protein is its modification with the replacement or addition of functional 
groups that increase its complementarity with the binding pocket. This strategy 
has gained its validity through the years [356,357] and bases on the fact that a 
higher complemetarity leads to higher affinity to the target-protein due to a more 
consistent enthalpic contribution.  
In this section, our efforts directed towards the gain of affinity through new 
enthalpic contribution using compounds 26 as lead structure will be presented. 
 
4.7.2.1 Modification of the sialic acid moiety 
 
It is known that the carboxylic functionality of the NeuNAc-moiety of sLex plays a 
determinant role for the binding of the ligand to E-selectin, whereas the rest of 
the NeuNAc-moiety shows no further contacts with the protein [142,144,145]. As 
can be seen in Figure 76, also the more promising compound 26, displays the 
same problem: the cyclohexyl-lactic acid moiety only stabilizes the carboxylic 
acid in the correct orientation but does not contribute significantly to the binding 
on an enthalpic level.  
 
 
Figure 76: Binding mode of 86 as obtained from the MC-protocol (cf. Chapter 3.2.5. The 
cyclohexyl-lactic acid moiety is oriented toward the solvent. 
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Thus, it was decided to design a new series of compounds bearing functional 
groups introduced at the β-position with respect to the acid that would maintain 
the pre-organization of the acid moiety but also interact with the protein. From a 
synthetic point of view, a very attractive strategy would considered to be the 
possibility to introduce an azide in the β-position with respect to the acid giving 
rise to compound 86. Hence, this is likely to lead to a triazol-based library of 
NeuNAc-moiety mimics over the 1,3-cycloaddition of acetylenes to 86 (Scheme 
1).  
 
Scheme 1: Chemical structure of 86 and of the resulting triazol-based library after 1,3-
cycloaddition of acetylenes. 
 
By looking at the feature most present (H-Bond donors, H-acceptor, hydrophobic 
side chains,…) in the region binding the acid moiety of the sLex-mimics, the 
presence of many hydrophobic amino acids was noticed (Figure 77). Hence, a 
small library of hydrophobic substituted acetylenes to be added to compound 86 
was planned for synthesis. The resulting compounds are expected to show an 
increased the affinity towards E-selectin because of new hydrophobic contacts 
with the protein.  
O
O
O
O
HO
OH
OH
OH
HO
HO
O
NaO2C
N
NN
R
O
O
O
O
HO
OH
OH
OH
HO
HO
O
NaO2C
N3
86
                                                                                                                                                                                                                          
                                                                133
   
 
Figure 77: Hypothetical binding mode of the triazol-based compound library. R = triazol-based 
library.  
 
Due to the fact that the pre-orientation of the acid functionality in the bioactive 
conformation remains an important issue, it became necessary to investigate the 
conformational behavior of compound 87 in solution to prove that the substitution 
of the cyclohexyl-rest with a triazol-based substituent would not lead to inactive 
compounds. The choice of ligand 87 for the conformational study was driven by 
the consideration that this compound would probably correctly represent the 
conformational preferences of the whole planned library. As it is shown in Figure 
78, the conformational distribution obtained with both protocols observed for 87 is 
very similar to the one observed for 26 (cf. Figure 73) implying that the two 
compounds should show also comparable affinity towards E-selectin and 
suggesting higher affinities for the library compounds.  
The synthesis of the compounds was performed by Alexander Titz [355] and their 
biological evaluation is ongoing. 
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Figure 78: Simulated conformational variability of compound 87 in solution. 
 
4.7.2.2 Modification of the galactose unity of compound 26 
 
Only little success was achieved when it was tried to substitute or modify the 
galactose unity of sLex in the search for more potent ligands (cf. Chapter 1.6.2). 
In fact, this unit is known to play a determinant role for the interaction between 
sLex and E-Selectin [143]. Thus, the galactose unity contributes directly to the 
binding over two H-bonds between 4–OH of Gal and Tyr94, and between 6–OH 
of Gal and Glu92, but also indirectly by functioning like a three dimensional linker 
between the NeuNAc- and the fucose-moieties. A complete substitution of the 
moiety is therefore difficult. However, by analyzing the protein surface contouring 
the galactose moiety (Figure 79), it appears that this moiety can still be 
optimized. Hence, two hydrophobic pockets located in front of the position 2 and 
6 of the galactose unit, but are actually not unoccupied by the ligand. The design 
of new ligands based on compound 26 but reaching these two pockets, was 
therefore planned. To achieve this goal it was decided to elongate the chains at 
the position 2 or 6 of the galactose unity. 
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Figure 79: sLex (3) bounded to E-selectin [166]. Two hydrophobic pockets are visible and are 
here highlighted as Region 1 and Region 2.  
 
a) Modification of the position 2 of the Galactose unity of compound 26 
This project was developed together with Lionel Tschopp [358], who synthesized 
the compounds presented in the following. The strategy, chosen for reaching the 
region referred as two in Figure 79, was, as it was already the case for the 
modification of the acid moiety (cf. Chapter 4.7.2), the introduction of an azide. 
This time it was decided to substitute the hydroxyl group at the 2 position of the 
galactose ring. The azide moiety introduced, would then be coupled over a 1,3-
cycloaddition reaction with a library of acetylenes (Scheme 2) in the last step of 
the synthesis, thereby giving rise to several compounds bearing different 
substiutents at the position 2 of the galactose unit.  
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Scheme 2: Last step of the synthesis of the compounds bearing a triazol-based substituent at the 
position 2 of the galactose moiety. 
 
Due to the characteristics of the binding site (cf. Figure 79, Region 2), particularly 
long and hydrophobic substituted acetylenes were chosen. The synthesized 
compounds, presently under biological evaluation, are presented in Figure 80. 
The predicted binding mode of compound 88 is shown in Figure 81. The 
orientation, which the substituent at the position 2 of the galactose unity adopts 
relative to the cyclohexan ring, is interesting. As it can be observed from Figure 
81 for molecule 88, the two groups are found to stand parallel to each other with 
a distance between them of about Ångstroms four. Hence, this finding suggests 
the presence of an intramolecular interaction between the atoms of the 
cyclohexan ring and of the triazol ring at the position 2 of the galactose unit, 
stabilizing the molecule in the bioactive conformation. A similar arrangement was 
found also for compound 74 (cf. Figure 53) in the docking experiments. In this 
case however, the benzyl moiety is too short-reaching to be able to interact with 
the hydrophobic binding pocket present on the surface of E-selectin. Though, its 
affinity towards E-selectin is ten times higher than for its debenzylated 
counterpart, thereby partially confirming the possibility of a stabilization effect of 
the bioactive conformation of the mimic. In conclusion, the designed compounds 
could raise the affinity towards E-selectin to another level by combining the 
stabilization of the bioactive conformation with new enthalpic contributions 
obtained by the newly introduced substituent at the position 2 of the galactose 
moiety.  
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Figure 80: The compounds synthesized so far bearing a modified substituent at the 2 position of 
the galactose unit. 
 
 
Figure 81: Compound 88 docked in the E-selectin binding site. A possible stabilization of the acid 
moiety in the bioactive conformation may be possible through the interaction between the atoms 
of the triazol- and the cyclohexane-ring.  
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b) Modification of the position 6 of the Galactose unity of compound 26 
A shallow hydrophobic pocket (cf. Figure 79: Region 1) opens itself in front of 
position 6 of the galactose unity of sLex. Unfortunately, a substitution of the 
hydroxyl with an azide is not possible because, as it was shown by the 
experiments of Bänteli and Ernst [359], that any modification of the hydroxyl 
group leads to inactive compounds. Therefore, it was decided to keep the 
hydroxyl group but to elongate the chain by modifying the galactose to a heptose. 
The adjacent carbon atom should then serve as a starting point for the 
development of modified mimics that could fill the hydrophobic pocket formed by 
the amino acids Lys111-113, Pro46, Tyr44. At this occasion we made use of the 
de novo design software Allegrow [318,319] to obtain insight on the substitution 
pattern that could be added to the heptose moiety. The technical details are 
described in the methods section (cf. Chapter 3.2.8). Between the several 
thousand compounds that were generated by the first “Allegrow-round”, some 
recurrent patterns were identified. In particular, indols and byphenyl moieties 
were frequently found to be connected over an amide bond to the heptose. After 
few more rounds of compounds generation by Allegrow [318,319] and 
optimization of the output towards chemical more feasible molecules by the user, 
the ligands presented in Figure 82 were chosen for synthesis and biological 
evaluation. All the designed ligands, with the exception of compound 92, which 
has already been synthesized and biologically tested, are still under 
development. Also because the results obtained so far are controversial (an IC50 
could not be determined) and need to be further elucidated, a discussion on 
these compounds is not possible at the moment. Details will be discussed in the 
thesis of Daniel Schwizer [360], in which a detailed description of these new 
ligands, their synthesis and biological evaluation will be found. 
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Figure 82: The compounds selected from the de novo design approach. 
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4.7.2.3 Conclusion on gaining affinity through new enthalpic contributions 
 
Three different approaches to obtain higher affinity through new enthalpic 
contributions have been presented. Unfortunately, to date no biological 
evaluation of the compounds has been performed (with the exception of 
compound 92) and it is therefore difficult to make any conclusion on the real 
benefit of the planned modifications. In principle, all the designed compounds 
should show an increased affinity towards E-selectin due to hydrophobic 
interactions with the protein surface. It is known [361] that this kind of interactions 
is of particular importance for a strong binding of ligands to protein. Those are, 
however, completely missing in the case of sugar-lectin contacts. Hence, in our 
opinion, the introduction of hydrophobic moieties should bring a strong 
enhancement (at least a factor 100) of the ligand’s affinity towards E-selctin. Next 
to the enthalpic considerations, their introduction could also have an effect on the 
entropic level by reducing the desolvation costs to be paid upon binding and by 
the augmented quantity of water molecules liberated from the protein surface 
after ligand binding. 
 
 
5 Conclusions and Outlook 
 
The main goal of this work that was to establish a set of tools that would permit 
the analysis, the design and the evaluation of E-selectin antagonists in silico was 
achieved. Hence, different protocols were developed and validated (cf. Chapters 
3.2 and 4). In particular, a new procedure for the analysis of the conformational 
preferences of E-selectin antagonists was established (cf. Chapter 4.1) and the 
results compared to the ones obtained with the MC(JBW)/SD approach, which 
had already demonstrated its validity in the past [161,168]. Thus, the comparison 
between the two protocols shows that the two methods predict different 
conformational preferences for the orientation of the sialic acid moiety of sLex 
(torsions Φ3 and Ψ3 in Figure 83). This result reflects the contrasting opinions 
existing on the conformation adopted by sLex in solution [150–168].  
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Figure 83: sLex (3) and the Φ, Ψ convention for the definition of the glycosidic torsions.  
 
A more detailed analysis (3J-coupling calculations, cf. Chapter 4.2) revealed that 
probably, both approaches deliver only a partially correct solution and that in 
reality, in solution, sLex (3) exists as a mixture of low energy conformers and not 
as supposed to date [150–154,161–163] as a population of a single confomer. 
Obviously, this finding is important. Hence, as a consequence, the idea to design 
mimics with a pre-organized structure, and in particular a pre-oriented acid 
moiety gains more importance. Thus, as seen in Chapter 1.7.1 (Figure 12), small 
differences in ΔG° have a substantial influence on the population of conformers. 
In our particular case, where the bioactive conformation doesn’t coincide with the 
global energy minimum in solution, this leads to important consequences in 
respect to the binding affinity. 
Furthermore, a docking routine was established and the impact of different 
partial-charge methods and of explicit solvation on the binding mode was studied 
(cf. Chapter 4.3 and 4.4). The obtained results, served as an input for molecular-
dynamics simulations and QSAR-studies.  
The MD simulations gave an insight into the dynamic character of the protein-
ligand interactions. In particular, the observations done in an atomic-force 
microscopy study [350], describing the interactions between the carboxylic group 
of sLex and Arg97, and between the 3– and 4–hydroxyls of Fuc and the calcium 
ion as the two main energy barriers for the dissociation process of the protein-
carbohydrate complex, could be confirmed by our MD-investigations. Thus, these 
two contacts always lasted longer than any other in the MD simulation. 
The successful derivation of QSAR-models with Quasar [270–272,351] and 
Raptor [315,316,335] (cf. Chapter 4.6) gives us the possibility of a semi-
quantitative in silico estimation of the binding affinity for the ligands that will be 
designed in the future.  
In addition, the developed protocols and models were applied for the 
development of new ligands. Unfortunately, to date, only few biological data is 
available to evaluate our design strategies. However, the impact of the ligand’s 
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pre-organization on the binding affinity could be established at least for the Lex-
substructure of sLex. Hence, the importance of the exo-anomeric effect, of the 
steric compression, and of the hydrophobic interaction between the methyl group 
of fucose and the β-face of galactose was clearly demonstrated (cf. Chapter 
4.7.1).  
In my opinion, in the future, our efforts should be directed towards the synthesis 
of compounds featuring more than one of the modifications demonstrating to 
positively influence the binding activity and of more drug-like compounds. In fact, 
all ligands synthesized so far do neither respect the Lipinski rule of five [362] nor 
have the characteristics of a drug [363]. Moreover, it would be interesting to 
design conformationally restricted compounds to study the entropic aspects 
deriving from the flexibility of the Φ3- and Ψ3-torsions.  
Regarding the molecular-modeling protocols developed, further improvements 
are possible. Thus, a newer set of GLYCAM parameters [344] that could be used 
in conjunction with the AMBER-based approach to study the conformational 
preference of the E-selectin antagonists has been released. Furthermore, once 
the biological data of the newly designed ligands would be available, it should be 
integrated in the QSAR-models to ameliorate their predictability. Finally, further 
MD-studies would be necessary to investigate in detail the role played by the 
solvent in the carbohydrate-lectin interactions.  
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6 Appendix 
 
Appendix 1: Listing of the ligands that were submitted to a conformational search. 
 
3 4 5 6 7 26 27 36 
65 (monomer) 72 73 74 77 78 79 80 
81 82 83 84 85 87 A41 A77 
A83 B45 B57 B68 B71    
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Appendix 2: Command-files for the MC(JBW)/SD protocol (cf. Chapters 1.5.3 and 3.2.3.1). The 
first one refers to the CS-step, the second one to the JBW/SD-step. 
 
Command file for the conformational search 
 
 
ligand.dat
ligand.out
MMOD 0 1
SOLV 3 1 0 0 0 0 0 0
EXNB 0 0 0 0 0 0 0 0
FFLD 3 1 0 0 1 0 0 0
SPMC 52000 0 24 0 0 0
MCNV 2 26 0 0
MCSS 2 0 1 0 100
MCOP 1 1
DEMX 0 200 0 0 20 40
COMP 1 2 3 4
COMP 5 7 8 10
COMP 12 15 16 18
COMP 22 23 25 26
COMP 27 30 31 32
COMP 33 34 35 36
COMP 37 39 43 46
COMP 47 48 49 50
COMP 52 56 57 58
COMP 59 60 61 62
COMP 68 72 73 74
COMP 75 76 77 78
COMP 80 81 82 83
COMP 84 85 86 87
COMP 88 89 90 91
COMP 92 93 94 95
COMP 97 98 99 110
COMP 111 0 0 0
READ
CHIG 1 2 4 5
CHIG 22 33 34 35
CHIG 37 57 59 60
CHIG 61 62 78 82
CHIG 83 84 85 86
CHIG 95 0 0 0
TORC 16 15 10 5 0 90
TORC 32 31 110 111 0 90
TORC 50 49 39 34 0 90
TORS 1 7 2 8 0 180
TORS 2 31 4 22 0 180
TORS 5 10 8 84 0 180
TORS 22 23 22 78 0 180
TORS 26 78 26 27 0 180
TORS 33 56 34 39 0 180
TORS 35 48 37 43 0 180
TORS 43 46 56 57 0 180
TORS 60 72 61 74 0 180
TORS 62 76 78 80 0 180
TORS 82 94 83 88 0 180
TORS 85 89 86 90 0 180
TORS 90 91 94 95 0 180
EXNB 0 0 0 0 0 0 0 0
CONV 2 0 0 0 0.1 0 0 0
MINI 9 0 500 0 0 0 0 0
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Command file for the JBW-stochastic dynamics 
 
ligandJBW.dat
ligandJBW.out
MMOD 0 1
SOLV 3 1 0 0 0 0 0 0
EXNB 0 0 0 0 0 0 0 0
FFLD 3 1 0 0 1 0 0 0
MCNV 2 25
MCSD 1 0 0 1 300
READ
#JBW/SD-body
ITOR 12 1 7
ITOR 8 2 31
ITOR 3 4 22
ITOR 1 5 10
ITOR 1 7 97
ITOR 2 8 84
ITOR 5 10 15
ITOR 5 10 17
ITOR 10 15 16
ITOR 10 15 18
ITOR 4 22 23
ITOR 22 23 25
ITOR 78 26 27
ITOR 26 27 30
ITOR 2 31 32
ITOR 2 31 110
ITOR 95 33 56
ITOR 33 34 39
ITOR 34 35 48
ITOR 36 37 43
ITOR 34 39 49
ITOR 34 39 51
ITOR 37 43 46
ITOR 43 46 47
ITOR 35 48 99
ITOR 39 49 50
ITOR 39 49 52
ITOR 33 56 57
ITOR 58 57 56
ITOR 58 59 68
ITOR 59 60 72
ITOR 60 61 74
ITOR 57 62 76
ITOR 60 72 73
ITOR 61 74 75
ITOR 62 76 77
ITOR 22 78 26
ITOR 22 78 80
ITOR 78 80 81
ITOR 83 82 94
ITOR 82 83 88
ITOR 83 84 8
ITOR 84 85 89
ITOR 85 86 90
ITOR 83 88 92
ITOR 85 89 98
ITOR 86 90 91
ITOR 90 91 93
ITOR 82 94 95
ITOR 33 95 94
#total nr of var. bond angles = 50
ITOR 97 7 1 5 0 180
ITOR 84 8 2 31 0 180
ITOR 2 8 84 85 0 180
ITOR 15 10 5 4 0 180
ITOR 78 22 4 5 0 180
ITOR 78 22 23 25 0 180
ITOR 23 22 78 80 0 180
ITOR 27 26 78 80 0 180
ITOR 78 26 27 30 0 180
ITOR 110 31 2 8 0 180
ITOR 49 39 34 35 0 180
ITOR 46 43 37 95 0 180
ITOR 37 43 46 47 0 180
ITOR 99 48 35 36 0 180
ITOR 57 56 33 34 0 180
ITOR 33 56 57 62 0 180
ITOR 73 72 60 61 0 180
ITOR 75 74 61 62 0 180
ITOR 77 76 62 61 0 180
ITOR 26 78 80 81 0 180
ITOR 92 88 83 84 0 180
ITOR 98 89 85 86 0 180
ITOR 91 90 86 87 0 180
ITOR 86 90 91 93 0 180
ITOR 95 94 82 87 0 180
ITOR 82 94 95 37 0 180
#total nr of var. bond torsion = 26
#JBW/SD-tail
IMPS 1 0 0 0 3
IMPO 1 1 0 0 20 60 0.05
MINI 9 0 100 0 0 0 0 0
MDIT 0 0 0 0 300 0 0 0
MDSA 5000 50 50 50 0 0 0 0
MDYN 1 0 1 0 1 9999 300 0
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Appendix 3: Parameters added to the GLYCAM parameter file [344] to perform simulations with 
“modified” carbohydrates. 
 
# ADDITIONS TO THE GLYCAM PARAMETER SET  
BOND 
CA-OS    364.00     1.380      from gaff  
CA-N     398.00     1.400      from gaff  
OG-CA    364.00     1.38       from gaff  
N*-CA    440.20     1.37       from gaff  
N*-NB    513.10     1.36       from gaff  
CA-CV    473.70     1.39       from gaff  
NB-NB    814.40     1.23       from gaff  
CA-H4    367.00     1.08       from parm99  
CV-H4    367.00     1.08       from parm99  
CM-NA    440.20     1.37       same as ca-na  
CM-HA    367.00     1.08       same as CA-HA  
 
ANGL 
CT-OG-CT     60.000   114.700   from glycam  
OG-CT-C      60.000   109.500   same as os-ct-c (gaff) 
OS-C -CA     67.662   110.765   from gaff 
CA-NC-CA     70.000   112.200   same as ca-n2-ca (gaff) 
CA-CA-NC     65.400   119.570   same as ca-ca-n2 (gaff) 
C -CA-NC     64.993   120.000   Calculated with empirical approach 
(gaff) 
CA-CA-N      66.100   120.000   from gaff  
CA-N -H      48.200   115.140   from gaff  
CA-N -C      63.400   124.520   from gaff  
N -CT-H2     50.000   109.500   same as hc-c3-n (gaff) 
N -CT-OS     70.093   112.195   Calculated with empirical approach 
(gaff) 
AC-OG-CA     61.741   117.870   gaff  
OG-CA-CA     66.100   122.030   gaff  
CA-CT-C      64.141   110.965   gaff  
CT-N*-CA     62.700   123.210   gaff  
CT-N*-NB     65.400   121.520   gaff  
N*-CA-CV     68.700   111.200   gaff  
N*-NB-NB     75.400   112.230   gaff  
CA-N*-NB     66.500   121.230   gaff  
CA-CH-H4     50.000   120.000   gaff  
CA-CV-NB     65.400   119.570   gaff  
CV-NB-NB     73.900   113.530   gaff  
N*-CA-H4     35.000   120.000   from Bio  
H4-CV-NB     35.000   120.000   from Bio  
CA-CV-H4     35.000   125.000   from Bio 
CV-CA-H4     35.000   125.000   from Bio  
N -C -CM     68.000   112.680   same as ca-c -n (gaff) 
C -CM-NA     65.774   116.660   Calculated with empirical approach 
 
DIHE                        
CA-CA-OS-CT   1           0.90         180.00           2.  from gaff 
CT-N*-CA-H4   1           0.30         180.00           2.  from gaff 
CT-N*-CA-CV   1           0.30         180.00           2.  from gaff 
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CT-N*-NB-NB   1           1.70         180.00           2.  from gaff 
H4-CA-N*-NB   1           0.30         180.00           2.  from gaff 
H4-CA-CV-H4   1           3.63         180.00           2.  from gaff 
H4-CA-CV-NB   1           3.63         180.00           2.  from gaff 
CV-CA-N*-NB   1           0.30         180.00           2   from gaff 
CA-N*-NB-NB   1           1.70         180.00           2.  from gaff 
N*-CA-CV-H4   1           3.625        180.00           2.  from gaff 
N*-CA-CV-NB   1           3.625        180.00           2.  from gaff 
N*-NB-NB-CV   1           8.00         180.00           2.  from gaff 
C -CM-NA-C    1           0.30         180.00           2.  from gaff 
C -CM-NA-H    1           0.30         180.00           2.  from gaff 
C -NA-CM-CM   1           0.30         180.00           2.  from gaff 
CM-CM-NA-H    1           0.30         180.00           2.  from gaff 
  
 
Appendix 4: getrst.in 
 
Constant Volume Minimization 
 # Control section 
 &cntrl 
  ntpr = 1, 
  ntwr = 1, 
  ntb = 1,  
  maxcyc = 1 ntr = 0,  
  imin = 1,  
 &end 
END 
END 
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Appendix 5: minres.in 
 
Constant Volume Minimization 
 # Control section 
 &cntrl 
  ntpr = 100, 
  ntb = 1,  
  maxcyc = 400,  
  ntr = 1,  
  imin = 1, 
  ntf = 2, 
  ntc = 2, 
  ncyc = 200  
 &end 
Group input for restrain  
 5.0 
 RES 1   
END 
END 
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Appendix 6: annealingNEW.in 
group info 
 5.0 
 RES 1 1 
END 
END 
 &cntrl  
    imin = 0, 
    nmropt = 1, 
    ntpr = 500, 
    ntwx = 500, 
    ntf = 2, 
    ntc = 2,  
    ntb = 1,  
    igb = 0, 
    ntr =1,  
    nstlim = 75000,  
    dt = 0.002, 
    ntt = 1, 
    tautp = 1.0 
    temp0 = 300.0, tempi = 100.0, 
 &end 
  &wt 
    type = 'TEMP0', istep1 = 0, istep2 = 25000, 
                   value1 = 100.0, value2 = 300.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 25001, istep2 = 50000, 
                   value1 = 300.0, value2 = 300.0, 
  &end 
  &wt  
   type = 'TEMP0', istep1 = 50001, istep2 = 75000, 
                   value1 = 300.0, value2 = 100.0, 
  &end 
  &wt  
   type = 'END', 
  &end 
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Appendix 7: minAN.in 
 
 &cntrl                                               
  imin=1, 
  ntc = 2, ntf = 2, 
  ntb = 1,  
  igb = 0, 
  cut = 8, nsnb = 999999, ntmin = 1, 
  maxcyc = 500, ncyc = 300,  
  ntpr = 100, 
  ntwx = 100, 
  ntwr = 100 
 &end 
 
Appendix 8: ANallinone.in 
 
 &cntrl  
    imin = 0, 
    nmropt = 1, 
    ntpr = 500, 
    ntwx = 500, 
    ntf = 2, 
    ntc = 2,  
    ntb = 1,  
    igb = 0, 
    ntr =0,  
    nstlim = 1300000,  
    dt = 0.002, 
    ntt = 1, 
    tautp = 1.0 
    temp0 = 400.0, 
    tempi = 100.0, 
 &end 
 
  &wt 
   type = 'TEMP0', istep1 = 0, istep2 = 25000, 
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                   value1 = 100.0, value2 = 400.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 25001, istep2 = 125000, 
                   value1 = 400.0, value2 = 400.0, 
  &end 
  &wt  
   type = 'TEMP0', istep1 = 125001, istep2 = 150000, 
                   value1 = 400.0, value2 = 300.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 150001, istep2 = 650000, 
                   value1 = 300.0, value2 = 300.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 650001, istep2 = 675000, 
                   value1 = 300.0, value2 = 400.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 675001, istep2 = 775000, 
                   value1 = 400.0, value2 = 400.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 775001, istep2 = 800000, 
                   value1 = 400.0, value2 = 300.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 800001, istep2 = 1300000, 
                   value1 = 300.0, value2 = 300.0, 
  &end 
  &wt  
   type = 'END', 
  &end 
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Appendix 9: Three-letter code and affinity towards the target of the ligands used for the 
development of the QSAR models are listed below. Due to patenting reasons, the structures 
cannot be shown here, but can be obtained under written request to the Institute of Molecular 
Pharmacy of the University of Basel. 
 
ligand delta G exp (kcal/mol) 
A04 -3.85 
A05 -4.00 
A06 -4.04 
A07 -4.63 
A08 -4.80 
A09 -3.58 
A10 -4.07 
A11 -2.28 
A12 -2.85 
A13 -3.87 
A14 -3.91 
A15 -3.92 
A16 -3.61 
A17 -3.87 
A18 -3.28 
A19 -2.28 
A20 -3.48 
A21 -4.74 
A22 -3.49 
A23 -3.73 
A24 -2.28 
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A25 -5.15 
A26 -3.81 
A27 -5.28 
A28 -3.32 
A29 -4.42 
A30 -4.32 
A31 -3.71 
A32 -4.78 
A33 -2.28 
A34 -2.28 
A35 -2.28 
A36 -4.07 
A37 -3.45 
A38 -5.05 
A39 -4.74 
A40 -3.99 
A41 -4.58 
A42 -5.09 
A43 -4.13 
A44 -5.25 
A45 -4.89 
A46 -4.00 
A47 -4.73 
A48 -3.58 
A49 -4.58 
A50 -4.68 
A51 -5.30 
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A52 -4.58 
A53 -5.71 
A54 -4.73 
A55 -2.28 
A56 -2.28 
A57 -3.30 
A58 -3.42 
A59 -4.16 
A60 -4.26 
A61 -2.28 
A62 -4.31 
A63 -2.28 
A64 -4.33 
A65 -4.30 
A66 -2.28 
A67 -4.84 
A68 -5.23 
A69 -4.47 
A70 -5.19 
A71 -4.41 
A72 -4.75 
A73 -4.09 
A74 -4.76 
A75 -5.91 
A76 -5.07 
A77 -5.10 
A78 -4.65 
                                                                                                                                                                                                                          
                                                                154
   
A79 -5.05 
A80 -4.35 
A81 -4.23 
A82 -3.89 
A83 -5.06 
A84 -4.18 
A85 -4.25 
A86 -4.95 
A87 -5.48 
A88 -2.28 
A89 -3.84 
A90 -2.28 
A91 -4.96 
A92 -4.55 
A93 -4.83 
A94 -2.28 
A95 -3.88 
A96 -4.80 
A97 -5.99 
A98 -6.19 
A99 -5.48 
B01 -5.40 
B02 -4.97 
B03 -6.12 
B04 -5.73 
B05 -5.92 
B06 -5.34 
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B07 -5.43 
B08 -3.95 
B09 -5.84 
B10 -4.71 
B11 -2.28 
B12 -2.28 
B13 -6.02 
B14 -4.60 
B15 -3.80 
B16 -4.48 
B17 -5.35 
B18 -4.34 
B19 -2.28 
B20 -3.98 
B21 -3.02 
B22 -4.23 
B23 -3.69 
B24 -5.12 
B25 -3.94 
B26 -2.28 
B27 -2.28 
B28 -4.23 
B29 -4.40 
B30 -5.99 
B31 -6.04 
B32 -6.04 
B33 -3.95 
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B34 -4.35 
B35 -6.43 
B36 -3.96 
B37 -4.11 
B38 -4.76 
B39 -4.00 
B40 -4.22 
B41 -6.08 
B42 -4.75 
B43 -5.54 
B44 -4.05 
B45 -5.61 
B46 -2.28 
B47 -3.26 
B48 -5.27 
B49 -2.28 
B50 -3.05 
B51 -3.24 
B52 -2.28 
B53 -5.82 
B54 -5.97 
B55 -5.18 
B56 -3.30 
B57 -5.49 
B58 -4.03 
B59 -5.51 
B60 -3.57 
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B61 -3.88 
B62 -5.70 
B63 -3.70 
B64 -6.27 
B65 -5.92 
B66 -5.73 
B67 -6.02 
B68 -5.91 
B69 -3.61 
B70 -2.28 
B71 -6.17 
B72 -4.59 
B73 -5.40 
B74 -3.70 
B75 -5.94 
B76 -5.50 
B77 -4.72 
B78 -5.68 
B79 -6.02 
B80 -4.38 
B81 -5.72 
B82 -6.76 
B83 -2.28 
B84 -2.28 
B85 -5.32 
B86 -2.28 
B87 -4.33 
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B88 -3.62 
B89 -3.29 
B90 -3.92 
B91 -4.69 
B92 -2.28 
B93 -3.51 
B94 -4.95 
B95 -3.32 
B96 -2.28 
B97 -5.19 
B98 -4.60 
B99 -2.28 
C01 -2.28 
C02 -3.06 
C03 -2.28 
C04 -5.42 
C05 -5.18 
C06 -3.41 
C07 -2.95 
C08 -3.10 
C09 -2.94 
C10 -2.28 
C11 -3.56 
C12 -3.27 
C13 -3.89 
C14 -6.19 
C15 -2.28 
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C16 -5.03 
C17 -4.78 
C18 -3.99 
C19 -3.70 
C20 -3.81 
C21 -5.12 
C22 -4.11 
C23 -6.64 
C24 -4.97 
C25 -6.70 
C26 -6.46 
C27 -4.96 
C28 -5.42 
C29 -5.85 
C30 -2.85 
C31 -4.99 
C32 -2.85 
C33 -6.46 
C34 -6.64 
C35 -6.19 
C36 -5.72 
C37 -5.91 
C38 -4.71 
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Appendix 10: List of the new torsions defined in the parameter file of Yeti [248,352]. 
 
Atom types Barrier height 
[kcal/mol] 
Periodicity Phase shift [°] 
CA CA N ON 12.0 2 180.0 
CT OX C CT 6.0 2 180.0 
C CT SH HS 1.5 3 0.0 
CT OX C N 6.0 2 180.0 
HC CT OX C 0.0 3 0.0 
HC C C CT 12.0 2 180.0 
CA C N CT 20.0 2 180.0 
OE CT C O2 0.0 3 180.0 
O C N CT 20.0 2 180.0 
CT N SS CT 0.0 3 0.0 
CT CT SS N 0.0 3 0.0 
CA CT OH HO 1.0 3 0.0 
C N* CT CT 0.0 6 0.0 
C N* C CB 5.8 4 180.0 
CA CB C O 12.0 4 180.0 
HC CT OH HO 1.0 3 0.0 
CT OE SS O 0.0 3 0.0 
CT CT OE SS 0.0 3 0.0 
CT OX C CA 6.0 2 180.0 
CT OE CT C 4.0 3 0.0 
CT OE CT CT 4.0 3 0.0 
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Appendix 11: constraints used during the minimization step in the docking protocol (cf. Chapter 
3.2.5.1). 
 
Atoms / Group Distance [Å] Parabolic force constant [kcal/(mol.Å2)] 
Gal-6OH / Glu92 2.0 20.0 
Fuc-3OH / Ca2+
 
2.5 20.0 
COOH / Arg97 2.2 20.0 
Gal-4OH / Tyr94 2.0 20.0 
 
 
Appendix 12: settings adopted during the MC-protocol (cf. Chapter 3.2.5.1). 
 
Metal center settings comment 
octahedron geometric property for metal center 
LFSE = 0.0 ligand field stabilization: not used 
deltaH = 0.0 not used 
w(r) = 1.0 symmetry neglected, distance dependent selection 
select alternate ligand set Fuc–4OH selected 
Minimizer settings comment 
Center of rotation = Fuc-4OH Rotational center for MC trials 
Weighting comment 
HB = 1.2, Met = 1.2 energy weights for E[lig*] contributions in the selection process 
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Appendix 13: Listing of the 12 ligands carrying CM-1 charges [326,327]  used to test the 
influence of the solvent on the docking mode. 
 
A02 A06 A22 A68 B17 B37 
A05 A16 A57 A95 B34 B44 
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Appendix 14: minresCPL.in  
 
Constant Volume Minimization 
 # Control section 
 &cntrl 
  ntpr = 100, 
  ntb = 1,  
  maxcyc = 500,  
  ntr = 1,  
  imin = 1, 
  ntf = 2, 
  ntc = 2, 
  ncyc = 10  
 &end 
Group input for restrain  
 5.00 
 RES 1 159   
END 
END 
 
                                                                                                                                                                                                                          
                                                                164
   
Appendix 15: md.in 
 
 &cntrl  
    imin = 0, 
    nmropt = 1, 
    ntpr = 500, 
    ntwx = 500, 
    ntf = 2, 
    ntc = 2,  
    ntb = 1,  
    igb = 0, 
    ntr =0,  
    nstlim = 750000,  
    dt = 0.002, 
    ntt = 1, 
    tautp = 4.0 
    temp0 = 300.0, 
    tempi = 100.0, 
    lastist = 8000000, lastrst = 8000000,  
 &end 
 
  &wt 
   type = 'TEMP0', istep1 = 0, istep2 = 50000, 
                   value1 = 100.0, value2 = 300.0, 
  &end 
  &wt 
   type = 'TEMP0', istep1 = 50001, istep2 = 750000, 
                   value1 = 300.0, value2 = 300.0, 
  &end 
  &wt  
   type = 'END', 
  &end 
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Appendix 16: Listing of the 16 ligands used for testing the influence of the two partial-charge 
models on the docking mode. 
 
A04 A13 A16 A25 A44 A67 A95 B17 
A09 A14 A20 A29 A45 A91 B07 B22 
 
 
Appendix 17: Ligands used to study the reverse docking mode. 
 
3 36 66 67 68g 68j 90 B45 
B68 B82       
 
 
Appendix 18: Ligands submitted to a MD simulation in the presence of the protein. 
 
3 26 36 66 67 74 A41 A57 
B02 B31 B45 B57 B68 B71   
 
 
                                                                                                                                                                                                                          
                                                                166
   
Appendix 19: Desolvation energies calculated by AMSOL [326] for ligand carrying CM-1 charges 
[327] and by the module Prepare of Quasar [270–272,351] for the ligand carrying ESP-MNDO 
[331].  
 
Ligand  dG(slv) CM-1  dG(slv) ESP-MNDO      
---------------------------------------------------------   
 
* A61 :   -72.905    -72.670 
* A81 :   -75.739    -76.792 
* A15 :   -72.423    -73.552 
* A06 :   -79.438    -81.070 
* A10 :   -72.347    -76.058 
* A23 :   -70.169    -73.031 
* C06 :   -94.893    -90.114 
* B98 :   -92.699    -90.427 
* B93 :   -82.528    -81.758 
* B91 :   -85.612    -81.696 
* C31 :   -59.627    -63.514 
* C02 :   -89.867    -88.626 
* C03 :   -93.386    -91.609 
* A60 :   -83.492    -83.695 
* A93 :   -65.991    -73.902 
* C28 :   -72.793    -74.116 
* C36 :   -70.363    -75.508 
* A13 :   -67.844    -70.974 
* C22 :   -65.353    -66.777 
* A38 :   -65.792    -67.466 
* C32 :   -61.335    -67.109 
* C12 :   -89.390    -84.623 
* B17 :   -79.202    -84.178 
* C26 :   -65.215    -71.227 
* C30 :   -68.074    -76.235 
* B43 :   -73.555    -75.843 
* C25 :   -71.105    -73.743 
* B56 :   -73.468    -72.239 
* B06 :  -106.994    -94.304 
* B38 :   -87.248    -87.497 
* A51 :   -90.486    -91.108 
* A67 :   -87.052    -89.922 
* A70 :  -100.179    -93.814 
* B24 :   -95.451    -93.244 
* A39 :   -88.717    -87.380 
* A08 :   -89.243    -89.766 
* A04 :   -87.953    -87.899 
* B23 :  -102.763    -96.509 
* B60 :   -94.386    -92.603 
* C10 :   -89.424    -88.998 
* B88 :   -89.448    -87.151 
* A05 :   -86.406    -83.964 
* B89 :   -93.170    -88.992 
* B19 :   -87.940    -90.487 
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* B86 :   -87.949    -86.037 
* B04 :   -71.917    -72.074 
* B45 :   -74.882    -72.924 
* C14 :   -70.001    -72.438 
* B81 :   -72.108    -73.168 
* B65 :   -71.561    -72.727 
* C21 :   -72.562    -72.844 
* B85 :   -72.413    -73.578 
* A47 :   -68.133    -67.670 
* A78 :   -73.995    -74.541 
* B77 :   -68.945    -72.951 
  C34 :   -65.416    -78.895 
  B34 :   -70.843    -70.423 
  A16 :   -69.434    -71.609 
  A07 :   -66.735    -70.651 
  B37 :   -69.307    -67.568 
  B75 :   -65.866    -69.011 
  B47 :   -73.634    -73.500 
  C23 :   -82.422    -81.141 
  A17 :   -70.807    -72.181 
  A37 :   -90.249    -89.124 
  A64 :   -83.219    -82.906 
  A72 :   -85.487    -82.963 
  A98 :   -74.465    -73.521 
  B30 :   -69.367    -71.742 
  B33 :   -62.143    -65.591 
  B54 :   -72.100    -71.616 
  B64 :   -71.072    -72.677 
  B80 :   -69.166    -76.275 
  B92 :   -83.897    -82.098 
  B94 :   -88.168    -81.151 
  B97 :   -98.119    -91.664 
  C09 :   -89.461    -86.419 
  C11 :   -86.921    -82.228 
  C17 :   -63.756    -66.010 
  C19 :   -68.557    -75.824 
  C33 :   -68.247    -75.572 
  A79 :   -77.659    -80.165 
  A63 :   -72.421    -72.852 
  A73 :   -68.870    -70.590 
  A97 :   -71.260    -73.966 
  A80 :   -77.243    -76.962 
  A95 :   -77.345    -80.739 
  B36 :   -75.984    -76.050 
  B42 :   -86.510    -80.476 
  B44 :   -75.231    -75.778 
  B55 :   -78.118    -77.310 
  B62 :   -77.488    -76.592 
  C01 :   -88.315    -88.016 
  B99 :   -91.995    -89.763 
  C07 :   -90.355    -86.738 
  B25 :   -89.573    -85.250 
  A96 :   -64.976    -71.766 
  C24 :   -67.742    -74.341 
  C37 :   -65.475    -70.404 
  B26 :   -59.372    -64.925 
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  A19 :   -62.194    -68.650 
  A94 :   -66.646    -71.188 
  A11 :   -61.091    -67.718 
  A57 :   -72.113    -74.476 
  C18 :   -66.599    -72.192 
  A26 :   -76.694    -77.595 
  C04 :   -71.986    -71.418 
  A49 :   -71.471    -72.566 
  A44 :   -73.574    -79.373 
  A12 :   -69.771    -76.122 
  A88 :   -72.505    -76.973 
  C15 :   -62.632    -64.260 
  A34 :   -65.379    -70.853 
  B84 :   -64.985    -69.908 
  A24 :   -65.633    -70.149 
  B83 :   -67.031    -73.602 
  B95 :   -48.681    -78.362 
  A48 :   -74.092    -73.929 
  A14 :   -69.955    -73.985 
  C20 :   -64.665    -69.261 
  B01 :   -58.073    -63.065 
  A29 :   -69.142    -70.403 
  C38 :   -71.462    -70.171 
  A45 :   -70.970    -76.327 
  A42 :   -64.676    -67.908 
  C16 :   -67.355    -69.491 
  C13 :   -84.709    -81.067 
  A69 :   -83.742    -81.220 
  B27 :   -86.915    -78.828 
  B02 :   -81.317    -75.263 
  A27 :   -68.262    -73.130 
  B09 :   -69.965    -70.736 
  B48 :   -95.333    -94.180 
  B40 :   -88.742    -88.166 
  B07 :   -90.930    -92.590 
  A76 :   -89.151    -88.805 
  A54 :   -85.994    -87.152 
  B05 :  -100.683    -95.841 
  A87 :   -98.563    -92.077 
  A68 :   -91.230    -90.438 
  A53 :   -97.667    -93.597 
  B72 :   -94.228    -91.921 
  A52 :   -85.759    -87.235 
  B22 :   -90.686    -92.150 
  A40 :   -92.659    -87.404 
  B61 :   -92.437    -93.091 
  A20 :   -95.332    -95.552 
  A22 :   -93.082    -92.467 
  A09 :   -88.359    -87.950 
  B21 :   -99.788    -93.593 
  B51 :   -91.571    -86.405 
  B52 :   -92.931    -86.693 
  B58 :   -90.447    -89.073 
  B18 :   -87.879    -89.284 
  A59 :   -90.034    -86.686 
  B87 :   -87.166    -86.991 
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  B20 :   -91.570    -87.504 
  B39 :   -83.208    -84.053 
  A58 :   -87.740    -83.548 
  A56 :   -88.731    -85.482 
  C29 :   -72.772    -71.462 
  B57 :   -79.383    -74.659 
  B53 :   -74.806    -74.729 
  B03 :   -68.927    -70.030 
  B31 :   -68.992    -71.431 
  B67 :   -71.139    -72.211 
  B73 :   -71.105    -71.955 
  B32 :   -71.139    -72.299 
  B66 :   -74.738    -74.336 
  A91 :   -74.584    -76.287 
  A74 :   -74.451    -70.655 
  A50 :   -73.547    -73.208 
  A83 :   -75.936    -73.217 
  A46 :   -64.546    -71.521 
  B63 :   -69.927    -71.708 
  A33 :   -67.390    -76.250 
  B82 :   -72.324    -79.921 
  B74 :   -77.145    -78.633 
  B13 :   -77.959    -77.918 
  B41 :   -87.174    -81.741 
  B68 :   -81.480    -83.432 
----------------------------------------------- 
 
Min.  : -106.994    -96.509 
Max. :   -48.681    -63.065 
Rng. :    58.313     33.444 
----------------------------------------------- 
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Appendix 20: Test-/Training-set arrangement of the ligands in the different Quasar-models. 
 
Q11 Q12 
 
 
Q13 Q14 
  
training test
A07 A69 B36 C07 A06 B93
A11 A72 B42 C09 A10 B98
A12 A73 B43 C11 A13 B99
A14 A79 B44 C13 A15 C02
A17 A80 B47 C15 A16 C04
A24 A88 B54 C16 A19 C06
A26 A95 B55 C17 A23 C12
A27 A96 B62 C19 A38 C18
A29 A97 B64 C20 A44 C22
A34 A98 B80 C23 A60 C28
A37 B01 B83 C24 A61 C30
A42 B02 B84 C25 A81 C31
A45 B17 B92 C26 A93 C34
A48 B25 B94 C32 A94 C36
A49 B26 B95 C33 B34
A57 B27 B97 C37 B37
A63 B30 C01 C38 B75
A64 B33 C03 C06 B91
training test
A11 A72 B36 C06 A06 C32
A14 A73 B37 C07 A07 C34
A16 A79 B42 C09 A10 C36
A17 A80 B43 C11 A12
A19 A81 B47 C13 A13
A24 A88 B54 C15 A15
A26 A93 B55 C16 A23
A27 A94 B62 C17 A38
A29 A95 B64 C18 A60
A34 A97 B80 C19 A61
A37 A98 B83 C20 A96
A42 B01 B84 C23 B44
A44 B02 B92 C24 B75
A45 B17 B94 C25 B91
A48 B25 B95 C26 B93
A49 B26 B97 C30 B98
A57 B27 B99 C31 C02
A63 B30 C01 C33 C12
A64 B33 C03 C37 C22
A69 B34 C04 C38 C28
training test
A07 A63 B33 C04 A06 C28
A11 A64 B36 C06 A10 C30
A12 A69 B37 C07 A13 C31
A14 A72 B42 C09 A15 C32
A16 A73 B43 C11 A23 C34
A17 A79 B44 C13 A38 C36
A19 A80 B47 C15 A60
A24 A81 B54 C16 A61
A26 A88 B55 C17 A93
A27 A94 B62 C18 B34
A29 A95 B64 C19 B75
A34 A96 B80 C20 B91
A37 A97 B83 C23 B93
A42 A98 B84 C24 B97
A44 B01 B92 C25 B98
A45 B17 B94 C26 C02
A48 B25 B95 C33 C03
A49 B26 B99 C37 C12
A57 B30 C01 C38 C22
training test
A07 A63 B33 B99 A06 C22
A11 A64 B34 C01 A10 C25
A12 A69 B36 C04 A13 C26
A14 A72 B37 C07 A15 C28
A16 A73 B42 C09 A23 C30
A17 A79 B44 C11 A38 C31
A19 A80 B47 C13 A60 C32
A24 A88 B54 C15 A61 C36
A26 A94 B55 C16 A81
A27 A95 B62 C17 A93
A29 A96 B64 C18 B17
A34 A97 B75 C19 B43
A37 A98 B80 C20 B91
A42 B01 B83 C23 B93
A44 B02 B84 C24 B98
A45 B25 B92 C33 C02
A48 B26 B94 C34 C03
A49 B27 B95 C37 C06
A57 B30 B97 C38 C12
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Q15–Q17 Q18–Q20 
  
 
 
 
 
 
 
 
 
training test
A07 A68 B30 B80 A04 B45
A09 A69 B31 B82 A05 B60
A11 A72 B32 B83 A06 B65
A12 A73 B33 B84 A08 B75
A14 A74 B36 B87 A10 B77
A17 A76 B39 B92 A13 B81
A20 A79 B40 B94 A15 B85
A22 A80 B41 B95 A16 B86
A24 A83 B42 B97 A19 B88
A26 A87 B43 C01 A23 B89
A27 A88 B44 C03 A38 B91
A29 A91 B47 C07 A39 B93
A33 A95 B48 C09 A44 B98
A34 A96 B51 C11 A47 B99
A37 A97 B52 C13 A51 C02
A40 A98 B53 C15 A60 C04
A42 B01 B54 C16 A61 C06
A45 B02 B55 C17 A67 C10
A46 B03 B56 C19 A70 C12
A48 B05 B57 C20 A78 C14
A49 B06 B58 C23 A81 C18
A50 B07 B61 C24 A93 C21
A52 B13 B62 C25 A94 C22
A53 B17 B63 C26 B04 C28
A54 B18 B64 C29 B09 C30
A56 B20 B66 C32 B19 C31
A57 B21 B67 C33 B23 C34
A58 B22 B68 C37 B24 C36
A59 B25 B72 C38 B34
A63 B26 B73 B37
A64 B27 B74 B38
training test
A07 A63 B27 B75 A04 B81
A09 A64 B30 B80 A05 B85
A11 A68 B31 B82 A06 B86
A12 A69 B32 B83 A08 B88
A14 A72 B33 B84 A10 B89
A16 A73 B34 B87 A13 B91
A17 A74 B36 B92 A15 B93
A19 A76 B37 B94 A23 B98
A20 A79 B39 B95 A38 C02
A22 A80 B40 B97 A39 C03
A24 A83 B41 B99 A47 C06
A26 A87 B42 C01 A51 C10
A27 A88 B44 C04 A60 C12
A29 A91 B47 C07 A61 C14
A33 A94 B48 C09 A67 C21
A34 A95 B51 C11 A70 C22
A37 A96 B52 C13 A78 C25
A40 A97 B53 C15 A81 C26
A42 A98 B54 C16 A93 C28
A44 B01 B55 C17 B04 C30
A45 B02 B57 C18 B06 C31
A46 B03 B58 C19 B17 C32
A48 B05 B61 C20 B19 C36
A49 B07 B62 C23 B23
A50 B09 B63 C24 B24
A52 B13 B64 C29 B38
A53 B18 B66 C33 B43
A54 B20 B67 C34 B45
A56 B21 B68 C37 B56
A57 B22 B72 C38 B60
A58 B25 B73 B65
A59 B26 B74 B77
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Q21–Q23 Q24–Q26 
 
 
 
training test
A07 A63 B25 B73 A04 B85
A09 A64 B26 B74 A05 B86
A11 A68 B27 B80 A06 B88
A12 A69 B30 B82 A08 B89
A14 A72 B31 B83 A10 B91
A16 A73 B32 B84 A13 B93
A17 A74 B33 B87 A15 B97
A19 A76 B36 B92 A23 B98
A20 A79 B37 B94 A38 C02
A22 A80 B39 B95 A39 C03
A24 A81 B40 B99 A47 C10
A26 A83 B41 C01 A51 C12
A27 A87 B42 C04 A60 C14
A29 A88 B43 C06 A61 C21
A33 A91 B44 C07 A67 C22
A34 A94 B47 C09 A70 C28
A37 A95 B48 C11 A78 C30
A40 A96 B51 C13 A93 C31
A42 A97 B52 C15 B04 C32
A44 A98 B53 C16 B09 C34
A45 B01 B54 C17 B19 C36
A46 B02 B55 C18 B23
A48 B03 B57 C19 B24
A49 B05 B58 C20 B34
A50 B06 B61 C23 B38
A52 B07 B62 C24 B45
A53 B13 B63 C25 B56
A54 B17 B64 C26 B60
A56 B18 B66 C29 B65
A57 B20 B67 C33 B75
A58 B21 B68 C37 B77
A59 B22 B72 C38 B81
training test
A07 A63 B27 B75 A04 B81
A09 A64 B30 B80 A05 B85
A11 A68 B31 B82 A06 B86
A12 A69 B32 B83 A08 B88
A14 A72 B33 B84 A10 B89
A16 A73 B34 B87 A13 B91
A17 A74 B36 B92 A15 B93
A19 A76 B37 B94 A23 B98
A20 A79 B39 B95 A38 C02
A22 A80 B40 B97 A39 C03
A24 A83 B41 B99 A47 C06
A26 A87 B42 C01 A51 C10
A27 A88 B44 C04 A60 C12
A29 A91 B47 C07 A61 C14
A33 A94 B48 C09 A67 C21
A34 A95 B51 C11 A70 C22
A37 A96 B52 C13 A78 C25
A40 A97 B53 C15 A81 C26
A42 A98 B54 C16 A93 C28
A44 B01 B55 C17 B04 C30
A45 B02 B57 C18 B06 C31
A46 B03 B58 C19 B17 C32
A48 B05 B61 C20 B19 C36
A49 B07 B62 C23 B23
A50 B09 B63 C24 B24
A52 B13 B64 C29 B38
A53 B18 B66 C33 B43
A54 B20 B67 C34 B45
A56 B21 B68 C37 B56
A57 B22 B72 C38 B60
A58 B25 B73 B65
A59 B26 B74 B77
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